Document:

EX-10.6

 Exhibit 10.6 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED 
 BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 406 
 OF THE SECURITIES ACT OF 1933,
AS AMENDED. 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

BY AND BETWEEN 
 PFIZER
INC. 
 AND 

CELLECTIS SA 

JUNE 17, 2014 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
	 1.
	 	DEFINITIONS	  	 	1	 
			
	 2.
	 	RESEARCH PROGRAM	  	 	16	 
				
		 	2.1.	  	Selection of Research Project Targets	  	 	16	 
				
		 	2.2.	  	Scope and Conduct of the Research Program	  	 	16	 
				
		 	2.3.	  	Research Plans	  	 	17	 
				
		 	2.4.	  	Governance of the Research Program	  	 	17	 
				
		 	2.5.	  	Alliance Managers	  	 	18	 
				
		 	2.6.	  	Conformance with Law	  	 	18	 
				
		 	2.7.	  	Cellectis Personnel Matters	  	 	19	 
				
		 	2.8.	  	Debarment Certification	  	 	21	 
				
		 	2.9.	  	Subcontractors	  	 	21	 
				
		 	2.10.	  	Inspections	  	 	21	 
				
		 	2.11.	  	Records	  	 	21	 
			
	 3.
	 	PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS	  	 	23	 
				
		 	3.1.	  	General	  	 	23	 
				
		 	3.2.	  	Diligence	  	 	23	 
				
		 	3.3.	  	Regulatory Approvals	  	 	25	 
				
		 	3.4.	  	Control of Commercialization Activities	  	 	25	 
				
		 	3.5.	  	Manufacturing	  	 	26	 
				
		 	3.6.	  	Progress Reporting	  	 	26	 
			
	 4.
	 	LICENSES AND RELATED GRANTS OF RIGHTS	  	 	27	 
				
		 	4.1.	  	Grants to Pfizer	  	 	27	 

  
 i 

									
				
		 	4.2.	  	Grants to Cellectis	  	 	29	 
				
		 	4.3.	  	Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information	  	 	30	 
				
		 	4.4.	  	Retained Rights	  	 	30	 
				
		 	4.6.	  	Section 365(n) of Bankruptcy Code	  	 	30	 
				
		 	4.7.	  	No Implied Rights	  	 	31	 
			
	 5.
	 	PAYMENTS TO CELLECTIS	  	 	31	 
				
		 	5.1.	  	Upfront and Option Fee	  	 	31	 
				
		 	5.3.	  	Research Support Funding	  	 	31	 
				
		 	5.4.	  	Milestones	  	 	32	 
				
		 	5.5.	  	Royalties	  	 	34	 
				
		 	5.6.	  	Reports and Payments.	  	 	36	 
				
		 	5.7.	  	Maintenance of Records; Audits	  	 	36	 
			
	 6.
	 	INTELLECTUAL PROPERTY	  	 	39	 
				
		 	6.1.	  	Inventions	  	 	39	 
				
		 	6.2.	  	Patent Rights	  	 	41	 
				
		 	6.3.	  	Interference, Opposition, Revocation and Declaratory Judgment Actions	  	 	47	 
			
	 7.
	 	CONFIDENTIALITY	  	 	47	 
				
		 	7.1.	  	Confidentiality	  	 	47	 
				
		 	7.2.	  	Authorized Disclosure	  	 	48	 
				
		 	7.3.	  	Public Announcements; Publications	  	 	49	 
				
		 	7.4.	  	Obligations in Connection with Change of Control	  	 	50	 
			
	 8.
	 	REPRESENTATIONS AND WARRANTIES	  	 	51	 
				
		 	8.1.	  	Mutual Representations and Warranties	  	 	51	 
				
		 	8.2.	  	Representations and Warranties of Cellectis	  	 	51	 
				
		 	8.3.	  	Cellectis Covenants	  	 	53	 

  
 ii 

									
				
		 	8.4.	  	Representation by Legal Counsel	  	 	54	 
				
		 	8.5.	  	Disclaimer	  	 	54	 
			
	 9.
	 	GOVERNMENT APPROVALS; TERM AND TERMINATION	  	 	55	 
				
		 	9.1.	  	Government Approvals	  	 	55	 
				
		 	9.2.	  	Term	  	 	55	 
				
		 	9.3.	  	Termination by Either Party for Cause	  	 	55	 
				
		 	9.4.	  	Termination by Pfizer for Convenience	  	 	55	 
				
		 	9.5.	  	Termination on Insolvency of Cellectis	  	 	55	 
				
		 	9.6.	  	Effects of Termination	  	 	56	 
				
		 	9.7.	  	Disposition of Inventories of Products	  	 	56	 
				
		 	9.8.	  	Survival of Certain Obligations	  	 	59	 
				
		 	9.9.	  	Right to Termination of Research Project(s) or Research Program by Pfizer upon Change of Control of Cellectis	  	 	59	 
			
	 10.
	 	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE	  	 	61	 
				
		 	10.1.	  	No Consequential Damages	  	 	61	 
				
		 	10.2.	  	Indemnification by Pfizer	  	 	61	 
				
		 	10.3.	  	Indemnification by Cellectis	  	 	62	 
				
		 	10.4.	  	Procedure	  	 	62	 
				
		 	10.5.	  	Insurance	  	 	64	 
			
	 11.
	 	MISCELLANEOUS	  	 	64	 
				
		 	11.1.	  	Assignment	  	 	64	 
				
		 	11.2.	  	Further Actions	  	 	64	 
				
		 	11.3.	  	Force Majeure	  	 	64	 
				
		 	11.4.	  	Notices	  	 	64	 
				
		 	11.5.	  	Amendment	  	 	64	 
				
		 	11.6.	  	Waiver	  	 	66	 

  
 iii 

									
				
		 	11.7.	  	Severability	  	 	66	 
				
		 	11.8.	  	Descriptive Headings	  	 	66	 
				
		 	11.9.	  	Dispute Resolution	  	 	66	 
				
		 	11.10.	  	Governing Law	  	 	66	 
				
		 	11.11.	  	Consent to Jurisdiction	  	 	67	 
				
		 	11.12.	  	Entire Agreement	  	 	67	 
				
		 	11.13.	  	Independent Contractors	  	 	68	 
				
		 	11.14.	  	Counterparts	  	 	68	 
				
		 	11.15.	  	No Third Party Rights or Obligations	  	 	69	 

  
 iv 

 EXHIBITS 
  

					
	 Exhibit 1: Pfizer anti-bribery and anti-corruption principles
	  			
		
	 SCHEDULES
	  			
		
	 Schedule 1.52: Expected Subcontractors
	  			
	 Schedule 2.6.1: Research Plan
	  			
		
	 Schedule 8.2.1: In-Licensed Patent Right comprised in
the Cellectis Technology
	  			
	 Schedule 8.2.3: Cellectis Patent Rights
	  			
	 Schedule 8.2.4
	  			
	 Schedule 8.2.8
	  			
	 Schedule 8.2.9
	  			
	 Schedule 8.2.10 Disclosed Third Party Agreement
	  			

  

  
 v 

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (the “Agreement”) is entered into as of June 17, 2014 (the
“Effective Date”), by and among Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States
(“Pfizer”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Pfizer and Cellectis may each
be referred to herein individually as a “Party” and collectively as the “Parties.” 
 WHEREAS, Pfizer is
engaged in the research, development and commercialization of pharmaceutical and health care products and has developed and owns proprietary rights to certain technology related to protein engineering and target validation; 

WHEREAS, Cellectis has developed and controls proprietary rights to certain technology relating to adoptive immunotherapy CAR T-cell and genome engineering technologies; and 
 WHEREAS, Pfizer and Cellectis desire to collaborate to
discover and research novel CAR-Ts active against certain designated targets and to provide for Pfizer to further research, develop, manufacture and commercialize such
CAR-Ts and products containing such CAR-Ts, as provided for herein. 

NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS. 

When used in this Agreement, the following capitalized terms will have the meanings set forth in this Article 1. Any terms defined elsewhere in
this Agreement will be given equal weight and importance as though set forth in Article 1. 
 1.1. “Additional Third Party
Licenses” is defined in Section 5.4.2(b). 
 1.2. “Affiliate” means, with respect to any Person, any other
Person that controls, is controlled by or is under common control with such Person. A Person will be regarded as in control of another entity if it owns or controls at least fifty percent (50%) of the equity securities of the subject entity entitled
to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term “Affiliate” will not include subsidiaries or
other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or
otherwise, until such time as such restrictions are no longer in effect. 
 1.3. “Agreement” is defined in the introduction
to this Agreement. 

 1.4. “Agreement CAR-T” means any CAR-T utilizing the Cellectis Technology that is identified, created or developed Targeting a Pfizer Target. 

1.5. “Alliance Manager” is defined in Section 2.8. 

1.6. “Annual Net Sales” means, with respect to any Pfizer Licensed Product in a Pfizer Year during the applicable Royalty Term
for such Pfizer Licensed Product, the aggregate Net Sales by Pfizer, its Affiliates and its Sublicensees from the sale of such Pfizer Licensed Product in the Territory during such Pfizer Year. 

1.7. “Applicable Law” means the laws, statutes, rules, regulations, guidelines, or other requirements that may be in effect
from time to time and apply to a Party’s activities to be performed under this Agreement, including any such laws, statutes, rules, regulations, guidelines, or other requirements of the FDA or the EMA. 

1.8. “Applicable Pfizer Technology” means any (a) Know-How Controlled by Pfizer
or its Affiliates that was invented, discovered or developed during the Term and in connection with Pfizer’s or its Affiliates’ activities under the Agreement and (b) Patent Rights Controlled by Pfizer or its Affiliates as of the date
of Termination, to the extent that such Patent Right claims any Know-How described in clause (a) above, to the extent that such Know-How and Patent Rights are
necessary for the further development, manufacture and commercialization of Continuation Products 
 1.9. [***] 

1.10. “Binding Obligation” means, with respect to a Party (a) any oral or written agreement or arrangement that binds or
affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement; (b) the provisions of such Party’s charter, bylaws or other organizational documents or
(c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party’s operations or property are bound. 

1.11. “Biosimilar Biologic Product” is defined in Section 5.4.2(a). 

1.12. “Biosimilar Notice” means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. § 262(k)
of the PHS Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biological product, which application identifies a Pfizer Licensed Product as the reference product with respect
to such product, and other information that describes the process or processes used to manufacture the biological product. 
 1.13.
“BLA” means a Biologics License Application filed with the FDA in the United States with respect to a Licensed Product, as defined in Title 21 of the U.S. Code of Federal Regulations, Section 601.2 et. seq. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 2 

 1.14. “Business Day” means a day other than a Saturday, a Sunday or a day
that is a national holiday in the United States. 
 1.15. “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.16. “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending
on December 31. 
 1.17. “CAR” means a chimeric antigen receptor expressed from an experimentally validated Cellectis viral
construct with specific molecular architecture and signaling domain sequences. 
 1.18.
“CAR-T” means a population of T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct produced using
Cellectis Technology. 
 1.19. [***] 

1.20. [***] 
 1.21.
“Cellectis CAR-T Developed IP” means Developed IP directed to the manufacture, composition or use of CAR-Ts Targeting a Cellectis Program Target. 

1.22. “Cellectis Diligence Obligation” is defined in Section 3.2.4. 

1.23. “Cellectis Improvement” [***] 

1.24. “Cellectis Indemnified Party” is defined in Section 10.2. 

1.25. “Cellectis Insolvency Event” means the occurrence of any of the following: (a) a case is commenced by or against
Cellectis under applicable bankruptcy, insolvency or similar laws, (b) Cellectis files for or is subject to the institution of bankruptcy, reorganization, liquidation, receivership or similar proceedings, (c) Cellectis assigns all or a
substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for Cellectis’ business, (e) a substantial portion of Cellectis’ business is 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 3 

 subject to attachment or similar process, (f) Cellectis suspends or threatens to
suspend making payments with respect to all or any class of its debts or (g) anything analogous to any of the events described in the foregoing clauses (a) through (f) occurs under the laws of any applicable jurisdiction. 

1.26. “Cellectis Know-How” means any Know-How
comprised in the Cellectis Technology that is introduced into the Research Program by Cellectis pursuant to the applicable Research Plan. 

1.27. “Cellectis Non-Compete Period” is defined in Section 2.1.4. 

1.28. “Cellectis Patent Right” means any Patent Right comprised in the Cellectis Technology. The Cellectis Patent Rights
existing as of the Effective Date include those set forth on Schedule 8.2.3 attached hereto. 
 1.29. “Cellectis Product”
means any product incorporating a CAR-T Targeting a Cellectis Program Target which would infringe a Valid Claim of any Licensed Pfizer Intellectual Property in the absence of the Licenses from Pfizer pursuant
to Section 4.2 or that is claimed or covered by, or was made using or otherwise incorporates, any Pfizer Intellectual Property or Developed IP. 

1.30. “Cellectis Program Target” means [***], plus any additional Cellectis Program Targets added to the Agreement pursuant to
Section 2.2. 
 1.31. “Cellectis Technology” [***] 

1.32. “Cellectis Third Party Agreement” means any agreement between Cellectis and any Third Party under which Cellectis
obtains rights in or to any Cellectis Licensed Intellectual Property. 
 1.33. “Change of Control” means, with respect to a
Party, (a) a merger, reorganization or consolidation of such Party with a Third Party which results in the voting securities of such Party outstanding immediately prior thereto ceasing to represent at least fifty (50%) of the combined voting
power of the surviving entity immediately after such merger, reorganization or consolidation, (b) a Third Party becoming the beneficial owner of fifty (50%) or more of the combined voting power of the outstanding securities of such Party or
(c) the sale or other transfer to a Third Party of all or substantially all of such Party’s business or assets to which this Agreement relates. 

1.34. “Change Order” is defined in Section 2.6.3. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 4 

 1.35. “Combination Product” means a Pfizer Licensed Product containing an
Agreement CAR-T and one or more other therapeutically active ingredients. 
 1.36.
“Commercialization” or “Commercialize” means activities directed to marketing, promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold a Pfizer Licensed Product.
Commercialization will not include any activities related to Manufacturing or Development. 
 1.37. “Commercially Reasonable
Efforts” means [***] 
 1.38. “Confidential Information” of a Party means all
Know-How or other information, including proprietary information and materials (whether or not patentable) regarding such Party’s technology, products, business or objectives, that is communicated in any
way or form by the Disclosing Party to the Receiving Party, either prior to or after the Effective Date of this Agreement (including any information disclosed pursuant to the Confidentiality Agreement), and whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms and conditions of this Agreement will be deemed to be the Confidential Information of each Party. Cellectis
Improvements will be deemed to be the Confidential Information of Cellectis. Pfizer Improvements will be deemed to be the Confidential Information of Pfizer. Developed IP will be deemed to be the Confidential Information of each Party, except that CAR-T Developed IP, upon assignment thereof to Pfizer pursuant to Section 6.1.1(d), will be deemed to be the Confidential Information solely of Pfizer. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 5 

 1.39. “Confidentiality Agreement” means that certain Confidentiality
Agreement between the Parties dated March 31, 2014. 
 1.40. “Continuation Product” is defined in
Section 9.7.4(c). 
 1.41. “Control” or “Controlled” means, with respect to any (a) item of
information, including Know-How, or (b) intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this Agreement) by a Party of the ability to grant to
the other Party access to or a license under such item or right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party. 

1.42. “Develop” or “Development” means to discover, research or otherwise develop a product, including
conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology, pharmacology and other
similar efforts, test method development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies
(including pre- and post-approval studies), development of diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing,
pricing or reimbursement approval. 
 1.43. “Developed IP” [***] 

1.44. “Development Milestone” is defined in Section 5.3.1. 

1.45. “Development Milestone Payment” is defined in Section 5.3.1. 

1.46. “Diligence Issue” is defined in Section 3.2.5. 

1.47. “Disclosed Third Party Agreement” is defined in Section 8.2.10(a). 

1.48. “Disclosing Party” is defined in Section 7.1. 

1.49. “Effective Date” is defined in the introduction to this Agreement. 

1.50. [***] 
 1.51.
“EMA” means the European Medicines Agency, or any successor agency thereto. 
 [***] = CONFIDENTIAL
TREATMENT REQUESTED 

  
 6 

 1.52. “Expected Subcontractors” means the subcontractor or contractors
listed in Schedule 1.52, that Cellectis is using, or intends to use, as of the Effective Date, to engage for the performance any Research Plan Services or Research Program activities 

1.53. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.), as amended,
and the rules and regulations promulgated thereunder. 
 1.54. “FDA” means the United States Food and Drug Administration or
any successor agency thereto. 
 1.55. “Field” means human oncologic therapeutic, diagnostic, prophylactic and prognostic
purposes. 
 1.56. “First Commercial Sale” means, with respect to any Pfizer Licensed Product and any country of the world,
the first sale of such Pfizer Licensed Product under this Agreement by Pfizer, its Affiliates or its Sublicensees to a Third Party in such country, after such Pfizer Licensed Product has been granted Regulatory Approval by the competent Regulatory
Authorities in such country. 
 1.57. [***] 

1.58. “FTE” means a full time equivalent scientific person (with B.S., M.S. or Ph.D. level or equivalent degrees, including
laboratory technicians with exams recognized according to European standards) year, consisting of a minimum of a total of [***] of scientific work directly related to and in support of the Research Program by an employee of Cellectis or any of its
Affiliates. 
 1.59. “FTE Rate” means [***] per FTE. 

1.60. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.61. “Generic Competition” is defined in Section 5.4.2(a). 

1.62. “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state,
county, city or other political subdivision. 
 1.63. “IND” means an Investigational New Drug Application, as defined in the
FD&C Act, that is required to be filed with the FDA before beginning clinical testing of a Pfizer Licensed Product or Cellectis Product, as applicable, in human subjects, or an equivalent foreign filing. 

1.64. “Indemnified Party” is defined in Section 10.4.1. 

1.65. “Indemnifying Party” is defined in Section 10.4.1. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 7 

 1.66. “Joint Developed IP” is defined in Section 6.1.1(c). 

1.67. “Joint Patent Right” is defined in Section 6.2.1(d). 

1.68. “Joint Research Committee” or “JRC” is defined in Section 2.7.1. 

1.69. “Know-How” means any proprietary invention, discovery, data, information,
process, method, technique, material, technology, result or other know-how, whether or not patentable. 

1.70. “Law” means any law, statute, rule, regulation, order, judgment or ordinance of any Governmental Authority. 

1.71. “Liability” is defined in Section 10.2. 

1.72. “License” is defined in Section 4.1.1. 

1.73. “Licensed Cellectis Intellectual Property” means any and all intellectual property (including Patent Rights and Know-How) Controlled by Cellectis, including the Cellectis Technology, the Cellectis Improvements and Cellectis’ interest in the Developed IP, for Pfizer to make, have made, use, have used, sell, have sold,
offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Pfizer Licensed Products. 
 1.74.
“Licensed Pfizer Intellectual Property” means any and all Pfizer Technology, Pfizer Improvement, and Pfizer’s interest in the Developed IP, for Cellectis to make, have made, use, have used, sell, have sold, offer for sale, have
offered for sale, import, have imported and otherwise exploit and Commercialize Cellectis Products. 
 1.75. “Litigation
Conditions” is defined in Section 10.4.2. 
 1.76. “MAA” means an application with the EMA seeking Regulatory
Approval of a Licensed Product in Europe using the EMA’s centralized procedure. 
 1.77. “Major EU Market Country”
means any of [***]. 
 1.78. “Major Market Country” means any Major EU Market Country [***]. 

1.79. “Manufacturing” or “Manufacture” means activities directed to making, producing, manufacturing,
processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. 
 1.80.
“Marginal Royalty Rates” is defined in Section 5.4. 
 [***] = CONFIDENTIAL TREATMENT
REQUESTED 

  
 8 

 1.81. [***] 

1.82. “Misuse” means any use of Cellectis Confidential Information or Know-How by
Pfizer in violation of Pfizer’s non-use obligations pursuant to this Agreement or outside the scope of the licenses granted hereunder. For the avoidance of doubt, “Misuse” will not
include Pfizer’s disclosure of Cellectis Confidential Information to any Third Party in violation of Section 7. 
 1.83.
“Necessary” is defined in Section 5.4.2(b). 
 1.84. “Net Sales” means, [***] 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 9 

 [***] 

1.85. “Non-Disclosing Party” is defined in Section 7.3.2. 

1.86. “Notice of Dispute” is defined in Section 11.10.1. 

1.87. “Other Cellectis Target” means [***], plus any additional Other Cellectis Targets added to the Agreement pursuant to
Section 2.3. 
 1.88. “Party” and “Parties” is defined in the introduction to this Agreement. 

1.89. “Patent Rights” means any and all (a) patents, (b) pending patent applications, including all provisional
applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) all
patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term extensions,
supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) any other form of government-issued right substantially similar to any of the foregoing and (f) all United States and foreign
counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such Party pursuant to the provisions of this Agreement. 

1.90. “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.

 1.91. “Pfizer” is defined in the introduction to this Agreement. 

1.92. “Pfizer CAR-T Developed IP” [***] 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 10 

 1.93. “Pfizer Diligence Obligation” is defined in Section 3.2.4. 

1.94. “Pfizer Improvements” [***] 

1.95. “Pfizer Indemnified Party” is defined in Section 10.3. 

1.96. “Pfizer Know-How” means any Know-How
comprised in the Pfizer Technology. 
 1.97. “Pfizer Licensed Product” means any product containing an Agreement CAR-T that is claimed or covered by, or was made using or otherwise incorporates, any Licensed Cellectis Intellectual Property. 

1.98. “Pfizer Patent Right” means any Patent Right comprised in the Pfizer Technology. 

1.99. “Pfizer Proprietary Materials” means any and all biological (including any Antibodies) and other materials Controlled by
Pfizer and provided by Pfizer to Cellectis under this Agreement. 
 1.100. “Pfizer Quarter” means each of the four thirteen
week periods (a) with respect to the United States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. 

1.101. “Pfizer Target” means [***], plus any additional Pfizer Targets added to the Agreement pursuant to Section 2.1. 

1.102. “Pfizer Technology” means [***] 

1.103. “Pfizer Year” means the 12 month fiscal periods observed by Pfizer (a) commencing on January 1 with respect
to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 11 

 1.104. “Phase I Clinical Trial” means a study of a Pfizer Licensed Product
in human subjects or patients with the endpoint of determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. §
312.21(a), or its successor regulation, or the equivalent regulation in any other country. A so-called Phase I/II Clinical Trial will be deemed to be a Phase I Clinical Trial unless such study, when completed,
allows Pfizer to proceed directly to a Phase III Clinical Trial. 
 1.105. “Phase II Clinical Trial” means a study of a
Pfizer Licensed Product in human patients to determine the safe and effective dose range in a proposed therapeutic indication as and to the extent defined for the United Sates in 21 C.F.R. § 312.21(b), or its successor regulation, or the
equivalent regulation in any other country. 
 1.106. “Phase III Clinical Trial” means a study of a Pfizer Licensed Product
in human patients with a defined dose or a set of defined doses of a Pfizer Licensed Product designed to (a) ascertain efficacy and safety of such Pfizer Licensed Product for its intended use; (b) define warnings, precautions and adverse
reactions that are associated with the Pfizer Licensed Product in the dosage range to be prescribed; and (c) support preparing and submitting applications for Regulatory Approval to the competent Regulatory Authorities in a country of the
world, as and to the extent defined for the United States in 21 C.F.R.§ 312.21(c), or its successor regulation, or the equivalent regulation in any other country. 

1.107. “PHS Act” means the United States Public Health Service Act, as amended, and the rules and regulations promulgated
thereunder. 
 1.108. “Price Approval” means, in any country where a Governmental Authority authorizes reimbursement for, or
approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case
may be) 
 1.109. “Receiving Party” is defined in Section 7.1. 

1.110. “Regulatory Approval” means all technical, medical and scientific licenses, registrations, authorizations and approvals
(including approvals of BLAs, MAAs, supplements and amendments, pre- and post- approvals, pricing and Third Party reimbursement approvals, and labeling approvals) of any Regulatory Authority, necessary for the
use, Development, Manufacture and Commercialization of a pharmaceutical product in a regulatory jurisdiction. For the sake of clarity, Regulatory Approval will not be achieved for a Pfizer Licensed Product in a country until all applicable Price
Approvals have also been obtained by Pfizer, its Affiliates, sublicensees or distributors, where applicable, for such Pfizer Licensed Product in such country. 

1.111. “Regulatory Approval Application” means any application submitted to an appropriate Regulatory Authority seeking any
Regulatory Approval. 

  
 12 

 1.112. “Regulatory Authority” means, with respect to any national,
supra-national, regional, state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. 

1.113. “Representative” is defined in Section 7.2.1. 

1.114. “Research Plan” is defined in Section 2.6.1. 

1.115. “Research Plan Services” is defined in Section 2.6.2. 

1.116. “Research Program” is defined in Section 2.5. 

1.117. “Research Project” is defined in Section 2.6.1. 

1.118. “Research Term” means four (4) years from the Effective Date. 

1.119. “Royalty Term” means, on a Pfizer Licensed
Product-by-Pfizer Licensed Product and country-by-country basis, the period of time from
the First Commercial Sale of such Pfizer Licensed Product in such country until the later of (i) the expiration of the last Valid Claim that would, but for the license to or ownership by Pfizer hereunder, be infringed by the sale of such Pfizer
Licensed Product in such country; (ii) the loss of regulatory exclusivity for the Pfizer Licensed Product in such country or (iii) the tenth (10th) anniversary of the date of the First Commercial Sale of such Pfizer Licensed Product in
such country, but in no event later than the twentieth (20th) anniversary of the date of the First Commercial Sale in any country. 
 1.120.
“Sales Milestone” is defined in Section 5.3.2. 
 1.121. “Sales Milestone Payment” is defined in
Section 5.3.2. 
 1.122. “Sales Threshold” is defined in Section 5.3.2. 

1.123. “SEC” means the United States Securities and Exchange Commission. 

1.124. “Servier Agreement” means that certain Research, Product Development, Option, License and Commercialization Agreement
by and between Servier and Cellectis dated February 17, 2014. 
 1.125. “Servier Targets” means [***], and the five
other targets set forth in the Servier Agreement. 
 1.126. “Subcontractors” is defined in Section 2.13. 

1.127. “Sublicensee” means any Person to whom Pfizer grants or has granted, directly or indirectly, a sublicense of rights
licensed by Cellectis to Pfizer under this Agreement, in accordance with the provisions of this Agreement. 
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

  
 13 

 1.128. “[***] Patent Rights” means the Patent Rights set forth on Schedule
8.23 under the headings: CELLECTIS Patent Portfolio on [***], In-licensed Patent applications from [***], In-Licensed patent applications from [***], In-Licensed Patent applications from [***] and In-Licensed from [***]. The value attributed to the [***] Patent Rights corresponds to [***] of the total value of the Cellectis
Technology. 
 1.129. “Target” means (a) a specific biological molecule that is identified by a GenBank accession
number or similar information, or by its amino acid or nucleic acid sequence, and (b) any biological molecule substantially similar in amino acid or nucleic acid sequence that has substantially the same biological function as a molecule
disclosed in clause (a), including any naturally occurring mutant or allelic variant of a molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and post-transcriptional isoforms (e.g., alternative splice
variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have a biological function substantially similar to that of
any biological molecules disclosed in clause (a) or clause (b). 
 1.130. “Target Designation Date” means, with respect
to the original Cellectis Program Target, Other Cellectis Targets and Pfizer Targets, the Effective Date, and with respect to additional Pfizer Targets, Cellectis Program Targets and Other Cellectis Target designated pursuant to Section 2.4,
such date as provided in Section 2.4. 
 1.131. “Targeting” means, when used to describe the relationship between a
molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part through binding to such Target (or such portion thereof).

 1.132. “Term” is defined in Section 9.2. 

1.133. “Terminated Pfizer Licensed Product” is defined in Section 9.7.2(b). 

1.134. “Terminated Target” is defined in Section 9.7.2. 

1.135. “Territory” means the entire world. 

1.136. “Third Party” means any Person other than Pfizer, Cellectis or their respective Affiliates. 

1.137. “Third Party Claim” is defined in Section 10.4.1. 

1.138. “Trademark” means any trademark, trade dress, design, logo, slogan, house mark or name used in connection with the
Commercialization of any Pfizer Licensed Product by Pfizer or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the foregoing. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 14 

 1.139. “Useful” is defined in Section 5.4.2(b). 

1.140. “Valid Claim” means, with respect to a particular country, a claim of an issued and unexpired patent right included
within the Licensed Intellectual Property or Developed IP that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental authority of competent jurisdiction, which decision is unappealed
or unappealable within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. A Pfizer Licensed Product is
“Covered” by a Valid Claim if its referenced activity by Pfizer or its Sublicensees would, but for the licenses granted by Cellectis under this Agreement, infringe such Valid Claim. 

1.141. [***] 
 1.142.
Construction. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and
vice versa), (b) the words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation,” (c) the word “will” will be construed to have the same meaning and
effect as the word “shall,” (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented
or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words
“herein”, “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to sections or
exhibits will be construed to refer to sections or exhibits of this Agreement, and references to this Agreement include all exhibits hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and will
include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or
“approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and
instant messaging), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof,
(k) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to
any restrictions on such amendments, supplements or modifications set forth herein), and (l) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or.” 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 15 

	2.	 RESEARCH PROGRAM. 

 

	 	2.1	 Selection of Pfizer Targets. 

2.1.1 Pfizer Targets. Pfizer hereby designates [***] as the initial Pfizer Targets for the first six Pfizer Research Projects. 

2.1.2 Additional Pfizer Target Right. Pfizer will have the right following each anniversary of the Effective Date during the Research
Term to add up to three additional Pfizer Targets under this Agreement, subject to availability of such Target, as set forth in Section 2.4 below. 

2.1.3 Exclusivity of Pfizer Targets. Subject to Sections 3.2.6 and 4.5, during the Term of this Agreement, for each Pfizer Target,
except as set forth in a Research Plan, neither Cellectis nor any of its Affiliates will (a) grant, or seek to grant, any right under any Cellectis Technology, Cellectis Improvements, Pfizer Improvements licensed to Cellectis pursuant to
Section 4.2.3 or Developed IP to any Third Party with respect to such Pfizer Target or (b) use any Cellectis Technology, Cellectis Improvements, Pfizer Improvements licensed to Cellectis pursuant to Section 4.2.3 or Developed IP to
Develop (itself or through or with a Third Party) or Commercialize CAR-Ts Targeting such Pfizer Target. 

2.1.4 CAR-T Exclusivity. Except to the extent required of Cellectis pursuant to the Servier
Agreement, until the earlier of (i) completion or termination of the Research Term or (ii) the filing by Cellectis of an IND for a Cellectis Program Target or Other Cellectis Target (together the “Cellectis Non-Compete Period”), neither Cellectis nor any of its Affiliates will grant, or seek to grant, any right under any Cellectis Technology, Cellectis Improvements, Pfizer Improvements licensed to Cellectis
pursuant to Section 4.2.3 or Developed IP to any Third Party to Develop or Commercialize CAR-Ts in the Field, other than academic institutions solely for internal academic
non-profit research, non-commercial research collaborations, and subcontractors of Cellectis and its Affiliates. For clarity, in the event that Cellectis files an IND
for a product for a Cellectis Program Target or Other Cellectis Target the Cellectis Non-Compete Period will terminate at such time for such Cellectis Program Target or Other Cellectis Target, but will remain
in effect for all other Targets, including the remaining Cellectis Program Target or Other Cellectis Target, pursuant to terms of this Section 2.1.4. 
  

	 	2.2	 Selection of Cellectis Program Targets. 

2.2.1 Cellectis Program Targets. Cellectis hereby designates [***] as the initial Cellectis Program Target for the first Cellectis
Research Project. 
 2.2.2 Additional Cellectis Program Target Right. Cellectis will have the right following each anniversary of the
Effective Date during the Research Term to add 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 16 

 an additional Cellectis Program Target under this Agreement, subject to availability of such
Target, as set forth in Section 2.4 below. 
 2.2.3 Exclusivity of Cellectis Program Targets. During the Research Term, until the
earlier of (i) completion or termination of the Research Term or (ii) the filing by Cellectis of an IND for a Cellectis Program Target (together the “Cellectis Program Target Non-Compete
Period”), neither Pfizer nor any of its Affiliates will (a) grant, or seek to grant, any right under any Pfizer Technology, Pfizer Improvements, Cellectis Improvements licensed to Pfizer pursuant to Section 4.1.2 or Developed IP
Controlled by Pfizer to any Third Party with respect to such Cellectis Program Target in the Field or (b) use any Pfizer Technology, Pfizer Improvements, Cellectis Improvements licensed to Pfizer pursuant to Section 4.1.2 or Developed IP
Controlled by Pfizer to Develop (itself or through or with a Third Party) or Commercialize T-cells expressing a chimeric antigen receptor construct Targeting such Cellectis Program Target in the Field. For
clarity, in the event that Cellectis files an IND for a product for a Cellectis Program Target or enters into an agreement with a Third Party related to such Cellectis Program Target, other than academic institutions solely for internal academic non-profit research, non-commercial research collaborations, or subcontractors for a Cellectis Program Target then the Cellectis Program Target
Non-Compete Period will terminate at such time for such Cellectis Program Target, but will remain in effect for all other Cellectis Program Targets, pursuant to terms of this Section 2.2.3. 

 

	 	2.3	 Selection of Other Cellectis Targets. 

2.3.1 Other Cellectis Targets. Cellectis hereby designates [***] as the initial Other Cellectis Targets. 

2.3.2 Additional Other Cellectis Target Right. Cellectis will have the right following each anniversary of the Effective Date during the
Research Term to add up to two additional Other Cellectis Targets under this Agreement, subject to availability of such Target, as set forth in Section 2.4 below. 

2.4 Target Selection Process. On or within 10 days of each anniversary of the Effective Date during the Research Term (including the 3rd
anniversary of the Effective Date), Pfizer and Cellectis will meet, either in person or by phone, to designate additional Targets as either Pfizer Targets, Cellectis Program Targets, or Other Cellectis Targets (“each such date a
“Target Designation Date”). The order of designation will be, subject to the limitations set forth in Sections 2.2.2 and 2.3.2: (i) Pfizer designates a Pfizer Target, (ii) Cellectis designates a Cellectis Target (either a
Cellectis Program Target or an Other Cellectis Target) (iii) Pfizer designates a Pfizer Target, (iv) Cellectis designates a Cellectis Target (either a Cellectis Program Target or an Other Cellectis Target), (v) Pfizer designates a Pfizer
Target and (vi) Cellectis designates a Cellectis Target (either a Cellectis Program Target or an Other Cellectis Target). The Parties hereby acknowledge and agree that neither Party will be able to designate a Target as a Pfizer Target,
Cellectis Program Target or Other Cellectis Target, as applicable, if such 
 [***] = CONFIDENTIAL TREATMENT
REQUESTED 

  
 17 

 Target has previously been designated a Pfizer Target, Cellectis Program Target, Other
Cellectis Target, or Servier Target. Following the 3rd anniversary of the Effective Date, Cellectis will have the right, but not the obligation, to nominate any additional Targets as Other
Cellectis Targets. 
 2.5 Scope and Conduct of the Research Program. Under the terms and conditions set forth herein, Cellectis and
Pfizer will collaborate to conduct discovery and pre-clinical Development activities to generate and validate Agreement CAR-Ts to the Pfizer Targets and Cellectis
Program Targets (the “Research Program”). The Research Program will be conducted in accordance with the Research Plan for each Research Project (as more fully provided in Section 2.6 below), and each Party will use its
Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all of its obligations under each Research Plan in accordance with the timelines and budgets set forth in the applicable Research Plan. In addition, each Party will
conduct its activities under the Research Plan(s) in accordance with Applicable Law. 
 2.6 Research Plans. 

2.6.1 Adoption of Research Plans. The Parties will adopt a research plan (the “Research Plan”) for the Pfizer Targets
and Cellectis Program Target;s a “Research Project” will mean the work to be performed pursuant to such a Research Plan. The initial Research Plan for [***] is attached as Schedule 2.6.1. The Research Plan for any other Pfizer
Target or Cellectis Program Target will be prepared by the JRC and adopted within [***] of the Target Designation Date for such Pfizer Target or Cellectis Program Target by the JRC. Each Research Plan will reference this Agreement and will be
subject to all of the provisions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent any provisions of a Research Plan conflict or are inconsistent with the provisions of this Agreement, the
provisions of this Agreement will control. Unless otherwise expressly stated in a Research Plan, the provisions of each Research Plan will be independent of and will not affect the provisions of any other Research Plan. If the Parties are unable to
agree on a Research Plan within the specified time period, the JRC may specify the Research Plan, and all disputes regarding the preparation or modification of any Research Plan (including the approval of any Change Order) will be resolved by the
JRC pursuant to the procedures set forth in Section 2.7.5. 
 2.6.2 Responsibilities. Each Research Plan will set forth the
services and the obligations and responsibilities assigned to each Party under the corresponding Research Project (collectively the “Research Plan Services”), and will include the following minimum terms: 

 

	 	(a)	 [***] 

  

	 	(b)	 [***] 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 18 

	 	(c)	 Payment obligations of each Party. 

2.6.3 Changes in Research Plans. A Research Plan may be amended by a written amendment (a “Change Order”) to such
Research Plan. Proposed Change Orders will be prepared in writing by the JRC and will be subject to review and written approval by each of the Parties. Each Change Order will set forth the agreed changes to the applicable task, protocol,
specifications, responsibility, budget, timeline or other matter. As used in this Agreement, a Research Plan will be deemed to include any Change Orders with respect thereto. Each Change Order will reference this Agreement and the Research Plan it
relates to and will be subject to the provisions of this Agreement. To the extent any provisions of a Change Order conflict or are inconsistent with the provisions of this Agreement, the provisions of this Agreement will control. All Change Orders
will be incorporated herein by reference and form a part hereof. 
 2.7 Governance of the Research Program. 

2.7.1 Formation of the Joint Research Committee. Cellectis and Pfizer will establish a “Joint Research Committee” (or
“JRC”) to oversee and coordinate the activities of the Parties under this Agreement in regard to the Research Program. The JRC will also serve as a forum to facilitate communications between the Parties regarding the Research
Program. The JRC will be comprised of three (3) representatives from each Party as appointed by such Party, with such representatives possessing appropriate expertise and seniority to carry out the Research Projects. The JRC may change its size
from time to time by mutual consent of its members. A Party may replace one or more of its representatives from time to time upon written notice to the other Party. Each Party, respectively, will designate its initial members of the JRC within
thirty (30) days after the Effective Date. The JRC will exist until expiration of the Research Term, unless the Parties otherwise agree in writing. 

2.7.2 Co-Chairpersons and Secretary of the Joint Research Committee. Each Party will designate a
co-chairperson of the JRC and a secretary of the JRC will be designated in accordance with Section 2.8 below. A Party may change the designation of its
co-chairperson from time to time upon written notice to the other Party. The co-chairpersons will be responsible for scheduling meetings of the JRC, preparing agendas
for meetings and sending to all JRC members notices of all regular meetings and agendas for such meetings at least five (5) Business Days before such meetings. The co-chairpersons will solicit input from both Parties regarding matters to be
included on the agenda, and any matter either Party desires to have included on the agenda will be included for discussion. Nothing herein will be construed to prohibit the JRC from discussing or acting on matters not included on the applicable
agenda. The secretary will record the minutes of the meeting, circulate copies of meeting minutes to the Parties and each JRC member promptly following the meeting for review, comment and approval by the JRC members and finalize approved meeting
minutes. The co- 

  
 19 

 chairpersons will be members of the JRC but the secretary need not be a member of the JRC.

 2.7.3 Meetings. The JRC will meet at least once each Calendar Quarter until it has been terminated in accordance with
Section 2.7.1 at dates and times mutually agreed by the JRC, unless otherwise mutually agreed by the Parties. The initial meeting of the JRC will be held within thirty (30) days after the Effective Date. Either Party may call a special
meeting of the JRC on fifteen (15) days written notice to the other Party’s members of the JRC (or upon such shorter notice as exigent circumstances may require). Such written notice will include an agenda for the special meeting. In-person meetings, including special meetings, of the JRC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the JRC. Meetings of the JRC may be held telephonically or
by video conference; provided, however, that at least [***] will be held in-person. Meetings of the JRC will be effective only if at least one (1) representative of each Party is in attendance or
participating in the meeting. Members of the JRC will have the right to participate in and vote at meetings held by telephone or video conference. In addition, the JRC may act on any matter or issue without a meeting if it is documented in a written
consent signed by each member of the JRC. 
 2.7.4 Responsibilities of the Joint Research Committee. The JRC will be responsible for
(a) planning and supervising research and development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b) receiving and reviewing all data and other information
obtained by either Party in connection with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c) documenting and approving initiation and completion of each Research
Project; (d) evaluating FTE requirements for the performance of the Research Plans; and (e) such other functions as expressly specified hereunder or as agreed by the Parties. 

2.7.5 Decisions. The JRC members will use good faith efforts to reach agreement on any and all matters properly brought before them
related to the Research Program. In the event that, despite such good faith efforts, agreement on a particular matter cannot be reached by the JRC within ten days after the JRC first meets to consider such matter, or such later date as may be
mutually acceptable to the parties (each such matter, a “Disputed Matter”), then either party may refer that Disputed Matter for resolution by their respective senior executives, and such senior executives would promptly initiate
discussions in good faith to resolve such Disputed Matter. If the senior executives are unable to resolve the Disputed Matter within thirty (30) days of it being referred to them, then Cellectis will have the final decision making authority
with respect to all Disputed Matters related to Cellectis Program Targets and Pfizer will have final decision making authority with respect to all other Disputed Matters; provided that neither Party will have the authority to obligate the other
Party to perform 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 20 

 Research Plan Services that are substantially greater than the those set forth in the
Research Plan attached hereto as Schedule 2.6.1. 
 2.8 Alliance Managers. In addition to the foregoing governance provisions, each of
the Parties will appoint a single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to facilitate the relationship between the Parties as established by this
Agreement. The Alliance Managers will attend meetings of the JRC and support the respective co-chairpersons of such committee in the discharge of their responsibilities. Unless otherwise determined by the JRC,
Pfizer’s Alliance Manager will serve as secretary at each meeting of the JRC. Alliance Managers will be non-voting participants in such committee meetings. A Party may replace its Alliance Manager from
time to time upon written notice to the other Party. 
 2.9 Conformance with Law. Each Party will perform and discharge its
obligations under this Agreement and the Research Program in conformance with (a) professional standards and practices, (b) this Agreement and the Research Plan(s) and (c) all Applicable Laws. Without limiting the generality of the
foregoing, each Party will retain all records relating to its performance of this Agreement and the Research Plan(s) for the time periods required by Applicable Laws. 

2.10 Cellectis Personnel Matters. Cellectis acknowledges and agrees that it is solely responsible for the compensation of the personnel
assigned to the Research Plan Services, and as employer will be responsible for withholding all national, state, local or other applicable taxes and similar items. Cellectis also will be responsible for all other employer related obligations,
including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each employee. Cellectis personnel assigned to the Research Plan Services are not nor will they be
deemed to be employees of Pfizer. 
 2.11 Non-Solicit. 

2.11.1 Cellectis Employees. Pfizer hereby undertakes, on behalf of itself and its Affiliates, that prior to any Change of Control of
Cellectis and during the period of time from the Effective Date until [***], neither Rinat nor Pfizer’s oncology research unit (or the immumo-oncology or oncology research unit of a Third Party acquired by Pfizer) nor any person acting on their
behalf will, without the prior written consent of Cellectis, directly or indirectly, encourage to quit, or attempt to encourage to quit any director or officer, executive or scientific research employee (project leader level or higher) of any of
Cellectis and its Affiliates with whom Pfizer had contact during the Research Term, provided however, that Pfizer may engage in general solicitations such as through a search firm, newspaper or other media advertisement. In the event that Pfizer is
alleged to have breached this Section 2.11.1 and Cellectis provides written notification to Pfizer of its objection to such alleged breach within 2 months of such alleged breach, the Parties will use reasonable efforts to resolve such alleged
breach. In no event will a breach of this Section 2.11.1 be deemed a material breach of this Agreement for the purposes of Section 9.4 below. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 21 

 2.11.2 Pfizer Employees. Cellectis hereby undertakes, on behalf of itself and its
Affiliates, that prior to any Change of Control of Pfizer and during the period of time from the Effective Date [***], neither Cellectis nor any of its Affiliates nor any person acting on their behalf will, without the prior written consent of
Pfizer, directly or indirectly, encourage to quit, or attempt to encourage to quit any director or officer, executive or scientific research employee (director level or higher) of any of Pfizer and its Affiliates with whom Cellectis had contact
during the Research Term, provided however, that Cellectis may engage in general solicitations such as through a search firm, newspaper or other media advertisement. In the event that Cellectis is alleged to have breached this Section 2.11.2
and Pfizer provides written notification to Cellectis of its objection to such alleged breach within 2 months of such alleged breach, the Parties will use reasonable efforts to resolve such alleged breach. In no event will a breach of this
Section 2.11.2 be deemed a material breach of this Agreement for the purposes of Section 9.4 below. 
 2.12 Debarment
Certification. Neither Party nor any Person employed or retained to perform services by either Party has been debarred under Section 306(a) or (b) of the FD&C Act or any comparable provision of foreign law and no debarred Person
will in the future be employed or retained to perform services by either Party in connection with any work to be performed for or on behalf of the other Party. If, at any time after execution of this Agreement, either Party becomes aware that such
Party or any Person employed or retained to perform services by such Party in connection with any work performed for or on behalf of such Party is, or is in the process of being, debarred, such Party will so notify the other Party immediately. 

2.13 Subcontractors. Except for Expected Subcontractors that are hereby accepted by Pfizer, Cellectis may not engage any contractor, or
subcontractor (a “Subcontractor”) to perform any Research Plan Services or Research Program activities without Pfizer’s prior written consent, provided that such decision will be determined and communicated in a timely manner
and any consent will not be unreasonably withheld. Cellectis will be responsible for the management of all permitted Subcontractors. The engagement by Cellectis of any Subcontractor in compliance with this Section 2.13 will not relieve
Cellectis of its obligations under this Agreement or any applicable Research Plan. Any agreement between Cellectis and a permitted Subcontractor pertaining to the Research Plan Services will be consistent with the provisions of this Agreement.
Furthermore, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any Subcontractor to perform any obligations hereunder, Cellectis will cause such Subcontractor to agree in writing to be bound by terms providing
for Pfizer rights no less favorable to Pfizer than the rights granted to Pfizer in this Agreement. 
 2.14 Inspections. Each
Party’s authorized representative(s), and Regulatory Authorities to the extent required by law and applicable to the scope of the Research Plan Services performed, may, during regular business hours and, to the extent legally possible, at times
arranged in advance with the other Party, audit, inspect and copy all data, records and work products, and audit and inspect all facilities, relating to the Research Plan Services and such other Party’s performance under this Agreement and the
applicable 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 22 

 Research Plan(s) (including all data, records, work products and facilities of
subcontractors). 
 2.15 Records. Each Party will prepare, maintain and retain complete and accurate written records, accounts, notes,
reports and data of the Research Plan Services and its performance under this Agreement and the Research Plan(s), in a form and of quality reasonably acceptable to both Parties. All such information will be treated as Confidential Information of
Pfizer for the purpose of this Agreement. 
  

	3.	 PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. 

3.1 General. Except as expressly set forth in Article 2, Pfizer will have sole authority over and control of the Development,
Manufacture and Commercialization of Pfizer Licensed Products Targeting such Pfizer Target. 
 3.2 Diligence. 

3.2.1 Pfizer Development Diligence. Pfizer will use Commercially Reasonable Efforts to Develop [***] for [***] during the Term. For
avoidance of doubt, any actions taken by Pfizer’s Affiliates or Sublicensees under this Agreement will be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.1. Additionally, during the
Research Term, Pfizer, or its Affiliates or Sublicensees will: 
 (a) Initiate Development for [***] within [***] from the Target
Designation Date [***]; 
 (b) Develop [***] during the Research Term; provided that if there are [***] designated [***], such Development
will apply to the remaining [***]; and 
 (c) Not stop Development for [***] for [***] during the Research Term. For clarity, if Pfizer
stops Development of a [***] for [***], but re-initiates Development activities prior to [***], Pfizer will be deemed to have satisfied its obligation with respect to this Section 3.2.1(c). 

3.2.2 Cellectis Development Diligence. Cellectis will use Commercially Reasonable Efforts to Develop at least one Cellectis Product for
each Cellectis Program Target during the Research Term. For avoidance of doubt, any actions taken by Cellectis’ Affiliates or Sublicensees under this Agreement will be treated as actions taken by Cellectis in regard to satisfaction of the
requirements of this Section 3.2.2. Additionally, Cellectis or its Affiliates or Sublicensees will, during the Research Term,: 
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

  
 23 

 (a) Initiate Development for [***] within [***] from the Target Designation Date for [***];
and 
 (b) Not stop Development for [***] for [***] during the Research Term. For clarity, if Cellectis stops Development of a Cellectis
Program Target for [***], but re-initiates Development activities prior to [***], Cellectis will be deemed to have satisfied its obligation with respect to this Section 3.2.2(b). 

3.2.3 Commercial Diligence. Pfizer will use Commercially Reasonable Efforts to Commercialize [***] where Pfizer has received Regulatory
Approval for [***] in such country. Pfizer will have no other diligence obligations with respect to the Commercialization of Pfizer Licensed Products under this Agreement. For avoidance of doubt, any actions taken by Pfizer’s Affiliates or
Sublicensees under this Agreement will be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2.2. 

3.2.4 Exceptions to Diligence Obligations. Notwithstanding any provision of this Agreement to the contrary, each Party will be relieved
from and will have no obligation to undertake any efforts with respect to any diligence obligation under each of the Pfizer Targets or Cellectis Program Targets, as applicable, pursuant to Section 3.2.1 or Section 3.2.3 (each, a
“Pfizer Diligence Obligation”) or Section (a “Cellectis Diligence Obligation”) in the event that: 
 (a)
Pfizer or Cellectis receives or generates any safety, tolerability or other data reasonably indicating or signaling, as measured by Pfizer’s safety and efficacy evaluation criteria and methodology, that such Pfizer Licensed Product has or would
have an unacceptable risk-benefit profile or is otherwise not reasonably suitable for initiation or continuation of clinical trials in humans; 

(b) Pfizer or Cellectis receive any notice, information or correspondence from any applicable Regulatory Authority, or any applicable
Regulatory Authority takes any action, that reasonably indicates that such Pfizer Licensed Product is unlikely to receive Regulatory Approval; or 

(c) the Pfizer Diligence Obligation breach or Cellectis Diligence Obligation breach, as applicable, related to such Pfizer Target or Cellectis
Program Target, as applicable, is caused by the negligence, recklessness or intentional acts of the other Party. 
 3.2.5 Assertion of
Diligence Obligation Claims. If a Party is, becomes, or reasonably should be aware of facts that might form a reasonable basis that the 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 24 

 Other Party has failed to meet any Pfizer Diligence Obligation or Cellectis Diligence
Obligation, as applicable, then Cellectis or Pfizer, as applicable, will promptly notify Pfizer or Cellectis, as applicable, in writing of such potential alleged performance failure (each such potential alleged performance failure, a
“Diligence Issue”). Promptly upon Pfizer’s or Cellectis’, as applicable, receipt of any notice of a Diligence Issue pursuant to this Section 3.2.4, the Pfizer Alliance Manager and Cellectis Alliance Manager will meet
to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [***] after receipt of such a notice, (a) the Parties have not reached consensus regarding whether Pfizer
has failed to satisfy the Pfizer Diligence Obligations or Cellectis has failed to satisfy the Cellectis Diligence Obligations and (b) the Parties’ respective Alliance Managers have not agreed upon an appropriate corrective course of action
for such Diligence Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.10. If Cellectis or Pfizer, as applicable, fails to notify Pfizer or Cellectis, as
applicable, of a Diligence Issue pursuant to this Section 3.2.5 [***] the date that Cellectis or Pfizer, as applicable, first discovers or reasonably should have discovered such Diligence Issue, then Pfizer or Cellectis, as applicable, will be
deemed to have satisfied its Pfizer Diligence Obligations or Cellectis Diligence Obligations, as applicable, with respect to such Diligence Issue. 

3.2.6 Remedies for Breach of Pfizer Diligence Obligations. If Pfizer materially breaches any Pfizer Diligence Obligation and fails to
remedy such breach within [***] of Pfizer’s receipt of notice of such breach from Cellectis, then, with respect to Pfizer Targets [***], the applicable Pfizer Target, [***]will cease to be a Pfizer Target and will become a Cellectis Program
Target and with respect to any Pfizer Targets other than [***], the applicable Pfizer Target(s) will no longer be subject to the exclusivity provisions set forth in Section 2.1.3 above. 

3.3 Remedies for Breach of Cellectis Diligence Obligations. If Cellectis materially breaches any Cellectis Diligence Obligation and
fails to remedy such breach within [***] of Cellectis’ receipt of notice of such breach from Pfizer, then the Pfizer Non-Compete Period with respect to such Cellectis Program Target(s) as set forth in
Sections 2.2.3 will terminate. 
 3.4 Regulatory Approvals. Pfizer or its designated Affiliate(s) will file, in its own name, all
Regulatory Approval applications for Pfizer Licensed Products Targeting such Pfizer Target where Pfizer, in its sole discretion, determines it is commercially advantageous to do so. Pfizer, or its designated Affiliate(s), will have the sole
responsibility for, and sole authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval Application or any Regulatory Approval for a Pfizer Licensed Product once granted. Except to the extent necessary
to fulfill its obligations under Section 3.2.1, neither Pfizer nor any of its Affiliates will have any obligation to seek Regulatory Approval for any Pfizer Licensed Product. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 25 

	 	3.5	 Control of Commercialization Activities. 

3.5.1 General. Pfizer will have sole and exclusive control over all matters relating to the Commercialization of Pfizer Licensed
Products Targeting such Pfizer Target; and 
 3.5.2 Trademarks. Pfizer will select and own all Trademarks used in connection with the
Commercialization of any such Pfizer Licensed Products, including all goodwill associated therewith. Neither Cellectis nor its Affiliates will use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any
Trademarks used by or on behalf of Pfizer, its Affiliates or Sublicensees in connection with any Pfizer Licensed Product. Nothing in this Section 3.5.2 will be construed to prevent Cellectis from granting Pfizer any license or right in and to
any trademark, trade dress, design, logo, slogan, house mark or name Controlled by Cellectis. 
 3.6 Manufacturing. Pfizer will have
the exclusive right (subject to Sections 3.2.5 and 4.5) to Manufacture Pfizer Licensed Products Targeting such Pfizer Target itself or through one or more Affiliates or Third Parties selected by Pfizer. Pfizer will have no diligence obligations with
respect to the Manufacture of Pfizer Licensed Products except to the extent necessary to fulfill the Pfizer Diligence Obligations. Pfizer will be responsible for 100% of the associated costs for the manufacturing of Pfizer Licensed Products. 

3.7 Pfizer Progress Reporting. Commencing upon the Effective Date and until delivery of the first royalty report pursuant to
Section 5.6.2, Pfizer will provide Cellectis with annual written reports on Pfizer’s activities to Develop and Commercialize Pfizer Licensed Products Targeting such Pfizer Target. Any information or written report provided by Pfizer to
Cellectis pursuant to this Section 3 will be deemed to be Pfizer’s Confidential Information subject to the provisions of Article 7. 

3.8 Cellectis Progress Reporting. Commencing upon the Effective Date and until the end of the Pfizer
Non-Compete Period, Cellectis will provide Pfizer with annual written reports on Cellectis’ activities to Develop and Commercialize products or compounds to a Cellectis Program Target. Any information or
written report provided by Cellectis to Pfizer pursuant to this Section 3.8 will be deemed to be Cellectis’ Confidential Information subject to the provisions of Article 7. 

3.9 Right of First Refusal. 

In the event that Cellectis proposes to enter into any Third Party agreement related to the Development or Commercialization of any CAR
Targeting a Cellectis Program Target (each a “Cellectis Target Product”) in the Field, Cellectis will first provide Pfizer with written notice of such proposal, including all material terms and conditions thereof (each a
“Cellectis Target Product Notice”). For [***] following receipt of the Cellectis Target Product Notice, Pfizer will have the option to purchase or license from Cellectis the Cellectis Target Product upon the terms and conditions set
forth in the 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 26 

 Cellectis Target Product Notice. In the event Pfizer elects to purchase or license the
Cellectis Target Product from Cellectis, Pfizer will give written notice of its election to Cellectis within such [***] and the Parties will negotiate a mutually agreeable agreement for the purchase or license of the Cellectis Target Product within
[***]; provided that the timeline for completing the agreement is not delayed by the actions or inactions of Cellectis. If Pfizer does not elect to purchase or license the Cellectis Target Product, Cellectis may, within [***] following the
expiration of the option right granted to Pfizer, transfer or license the Cellectis Target Product to the proposed transferee or any other transferee, provided that this transfer will not be on terms and conditions more favorable to the transferee
than those contained in the Cellectis Target Product Notice. In the event that Cellectis does not enter into the Third Party agreement to which the Cellectis Target Product Notice relates, this Section 3.9 will continue to apply with respect to
the Cellectis Product Target. This Section 3.9 will be applicable to any potential Third Party agreement that Cellectis proposes entering into during the Term related to the Development or Commercialization of any CAR Targeting a Cellectis
Program Target in the Field. 
 3.10 Right of Negotiation. In the event that Cellectis proposes to enter into any Third Party
agreement related to the Development or Commercialization of any product Targeting an Other Cellectis Target, Cellectis will provide Pfizer with written notice of such intent and will negotiate in good faith with Pfizer regarding Pfizer’s
purchase or license of such product Targeting an Other Cellectis Target. 
  

	4.	 LICENSES AND RELATED GRANTS OF RIGHTS. 

 

	 	4.1	 Grants to Pfizer. 

4.1.1 Exclusive License. Subject to the terms and conditions of this Agreement, on a Pfizer Target-by-Pfizer Target basis and effective on the Target Designation Date for such Pfizer Target, Cellectis hereby grants to Pfizer and its Affiliates an exclusive (even as to Cellectis, except to the extent
necessary for Cellectis to perform its obligations under the Research Program) license under the Licensed Cellectis Intellectual Property (excluding [***] Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have
offered for sale, import, have imported and otherwise exploit and Commercialize Pfizer Licensed Products in the Field in the Territory, with the right to sublicense as provided in Section 4.1.4 (the “License”). 

4.1.2 [***]Patent Rights. 

(a) Subject to the terms and conditions of this Agreement on a Pfizer Target by Pfizer Target basis and effective on the Target Designation
Date for such Pfizer Target, Cellectis hereby grants to Pfizer and its Affiliates the right to use the [***] engineered by Cellectis pursuant to this Agreement to Develop Pfizer Licensed Products until the filing of an IND for each Pfizer Licensed
Product, in the Field. 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 27 

 (b) Exclusive License. Subject to the terms and conditions of this Agreement, on a
Pfizer Target-by-Pfizer Target basis and effective upon the filing of an IND for each individual Pfizer Licensed Product developed under 4.1.2(a), Cellectis hereby
grants to Pfizer and its Affiliates an exclusive (even as to Cellectis) license under the [***] Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit
and Commercialize such Pfizer Licensed Product in the Field in the Territory, with the right to sublicense as provided in Section 4.1.3. For the sake of clarity, the license granted to Pfizer by Cellectis herein does not give Pfizer the right
to [***]. 
 4.1.3 License to Cellectis Improvements. Subject to the terms and conditions of this Agreement, Cellectis hereby grants
to Pfizer and its Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Cellectis Improvements that were solely or jointly invented by the employees,
agents or independent contractors of Pfizer or its Affiliates to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize any products and processes. 

4.1.4 Right to Sublicense. Pfizer will have the right to grant sublicenses to its Affiliates and Third Parties of any and all licenses
granted to Pfizer under this Agreement by Cellectis, provided that (a) Pfizer will be jointly and severally responsible with its Sublicensees to Cellectis for failure by its Sublicensees to comply with the terms and conditions of this
Agreement; (b) each sublicense will include obligations on the Sublicensee that are consistent with the terms of this Agreement,; and (c) Pfizer will remain responsible for the payment to Cellectis of all Milestone Payments and royalties
payable with respect to the activities and Net Sales of any Sublicensee. 
 4.1.5 Direct License to Affiliates. Pfizer may at any time
request and authorize Cellectis to grant licenses directly to Affiliates of Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, Cellectis will enter into and sign a
separate direct license agreement with such designated Affiliate of Pfizer. All such direct license agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and
regulations in the country in which the direct license will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the
terms of this Agreement as set forth on the Effective Date. In countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements will not become binding between the
parties thereto until such approval or registration is granted, which approval or registration will be obtained by Pfizer. All costs of making such direct license agreement(s), including Cellectis’ reasonable attorneys’ fees, under this
Section 4.1.4 will be borne by Pfizer. 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 28 

 4.1.6 Right of Reference. Cellectis hereby grants to Pfizer a “Right of
Reference,” as that term is defined in 21 C.F.R. § 314.3(b), to any data Controlled by Cellectis or its Affiliates (a) that relates to the Licensed Cellectis Intellectual Property, the Agreement
CAR-Ts, the Pfizer Licensed Products or preclinical studies with respect to the Pfizer Licensed Products and (b) that Pfizer reasonably believes may be necessary or useful to the Development,
Manufacturing or Commercialization of any Agreement CAR-T or any Pfizer Licensed Product pursuant to this Agreement, and Cellectis will provide a signed statement to the foregoing effect, if so requested by
Pfizer in accordance with 21 C.F.R. § 314.50(g)(3). 
 4.1.7 Technology Transfer Assistance to Pfizer. Cellectis will provide
reasonable assistance, at no additional cost to Pfizer, to affect the timely and orderly transfer to Pfizer of the Know-How included in the Licensed Cellectis Intellectual Property necessary for Pfizer’s
use in performing its responsibilities under the Research Plans, and for the Development, Manufacturing and Commercialization of Pfizer Licensed Products pursuant to the License. 

 

	 	4.2	 Grants to Cellectis. 

4.2.1 Research License. Subject to the terms and conditions of this Agreement and during the Research Term with respect to each Pfizer
Target, Pfizer hereby grants to Cellectis a non-exclusive, worldwide, royalty-free license, with no right to grant sublicenses, under the Pfizer Technology to perform the activities assigned to Cellectis under
the applicable Research Plan. 
 4.2.2 Non-Exclusive License. Subject to the terms and
conditions of this Agreement, Pfizer hereby grants to Cellectis and its Affiliates a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under the Pfizer Licensed Pfizer Intellectual
Property Controlled by Pfizer solely to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Cellectis Products Targeting Cellectis Program Targets.
Cellectis will have the right to grant sublicenses of the foregoing license to Third Party collaborators following the Cellectis Non-Compete Period only if Cellectis has entered into a written agreement with
such Third Party collaborator (i) obtaining a covenant not to sue or (ii) granting Pfizer a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under improvements to the
Cellectis Technology developed in the framework of the collaboration between Cellectis and such Third Party that are Controlled by such Third Party. 

4.2.3 License to Pfizer Improvements. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to Cellectis and its
Affiliates a non-exclusive, worldwide, sublicensable, royalty-free, perpetual and irrevocable license under any Pfizer Improvements that were solely or jointly invented by the employees, agents or independent
contractors of Cellectis or its Affiliates to make, have made, 

  
 29 

 use, have used, sell, have sold, offer for sale, have offered for sale, import, have
imported and otherwise exploit and Commercialize any products and processes. 
 4.2.4 Technology Transfer Assistance to Cellectis.
Pfizer will provide reasonable assistance, at no additional cost to Cellectis, to affect the timely and orderly transfer to Cellectis of the Know-How included in the Pfizer Technology, Pfizer Improvements,
Developed IP solely owned by Pfizer, and CAR-T Developed IP (if applicable) necessary for Cellectis’ use in performing its responsibilities under the Research Plans, and for the Development, Manufacturing
and Commercialization of Cellectis Products Targeting Cellectis Programs Targets pursuant to the License under Sections 4.2.1 and 4.2.2 above. 

4.3 Reciprocal Non-Exclusive Research License for Disclosed
Know-How and Confidential Information. Without limiting any other license granted to either Party under this Agreement and subject to the terms of Section 7: 

4.3.1 Cellectis hereby grants to Pfizer and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable, royalty-free, fully paid-up, worldwide license to use any and all Cellectis Know-How included in the Licensed
Cellectis Intellectual Property and Cellectis Confidential Information disclosed to Pfizer during the Term of this Agreement solely for internal research purposes. 

4.3.2 Pfizer hereby grants to Cellectis and its Affiliates a non-exclusive, irrevocable, perpetual, non-transferable, royalty-free, fully paid-up, worldwide license to use any and all Pfizer Know-How and Pfizer Confidential Information
(other than any information regarding the identity of or Pfizer’s reasons for selecting any Pfizer Target or Additional Pfizer Target, which will only be disclosed by Cellectis to its Representatives as necessary to comply with the terms of
this Agreement) disclosed to Cellectis during the Term of this Agreement solely for internal research purposes. 
 4.3.3 Notwithstanding the
foregoing, neither Pfizer nor Cellectis will have any right under this Section 4.3 to make or use any physical material supplied by the other Party for use in the Research Program other than for use in the Research Program. 

4.4 Retained Rights. For the avoidance of doubt, except as expressly provided in regard to the licenses contained in this Article 4 or
in the provisions of Section 6.1.1, each Party will retain ownership of all of its Pfizer Technology or Cellectis Technology, as applicable. 

4.5 Other Pfizer Programs. Cellectis understands and acknowledges that Pfizer may have present or future initiatives or opportunities,
including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or that may compete with a product, program, technology or process covered by this
Agreement. Cellectis acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that 

  
 30 

 Pfizer will not itself Develop, Manufacture or Commercialize or enter into business
relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that may compete with any product, program, technology or process covered
by this Agreement. Notwithstanding the foregoing, if Pfizer or its Affiliates, other than pursuant to this Agreement, themselves Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third
Parties to Develop, Manufacture or Commercialize T-cells expressing a chimeric antigen receptor construct other than a CAR-T, with respect to a particular Pfizer Target
in the Field, then any exclusive licenses granted to Pfizer under this Agreement with respect to a Pfizer Licensed Product Targeting such Pfizer Target will be automatically converted into non-exclusive
licenses, and Cellectis’ exclusivity obligation under Sections 2.1.3 and 2.1.4 will not apply with respect to such Pfizer Target. 
 4.6
No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed, by estoppel, implication or otherwise, to have granted the other Party any license or other right with respect to any intellectual property of
such Party. 
  

	5.	 PAYMENTS TO CELLECTIS. 

5.1 Upfront Fee. Within [***] the Effective Date [***], unless this Agreement is terminated by Pfizer pursuant to Section 9.3
below, Pfizer will pay to Cellectis, concurrent with the purchase by Pfizer of the Cellectis securities pursuant to the Subscription Agreement, the non-creditable,
non-refundable amount of Eighty Million Dollars ($80,000,000). 
 5.2 Research Support
Funding. 
 5.2.1 Research Program Payments. Each Party will pay the other Party for the costs and expenses as set forth in each
Research Plan, provided that Pfizer will bear the costs associated with Research Plan Services performed by Cellectis related to Pfizer Targets, as set forth in the Research Plan, at the FTE Rate. During the Research Term, Pfizer will provide [***]
Pfizer FTEs [***] for Research Plan Services related to Cellectis Program Targets utilizing Pfizer infrastructure and technology as set forth in the Research Plan. Subject to the foregoing, the JRC shall determine the specific number of FTEs that
shall perform Research Plan Services for Cellectis from time to time. Notwithstanding the foregoing, Pfizer shall only be obligated to reimburse Cellectis for the number of FTEs actually incurred and reported pursuant to Section 5.2.3 in the
performance of its Research Plan Services. 
 5.2.2 Other Expenses. Except as expressly set forth in Section 5.2.1, each Party
will be solely responsible for all costs and expenses it incurs in performing its obligations under the Research Program. Pfizer will be funding capital equipment required at Pfizer sites and Cellectis will be funding capital equipment required at
Cellectis sites. Pfizer will be funding capital equipment required at Cellectis sites 
 [***] = CONFIDENTIAL
TREATMENT REQUESTED 

  
 31 

 that will at a later time be transferred to Pfizer and Cellectis will be funding capital
equipment required at Pfizer sites that will at a later time transferred to Cellectis. 
 5.2.3 Reports and Reimbursement Payments.
Within thirty (30) days after the end of each Calendar Quarter of the Research Term, Cellectis will provide Pfizer with a quarterly report containing a detailed account of activities performed together with an invoice for amounts payable under
Section 5.2.1, with respect to such Calendar Quarter. Each report must be accompanied by a certificate executed by a duly appointed officer of Cellectis confirming the actual total number of FTE hours supplied by Cellectis during such Calendar
Quarter and the identity of, and number of FTE hours performed by, each individual performing Research Plan Services during such Calendar Quarter. Payment shall be due within [***] after Pfizer receives such an invoice from Cellectis. 

5.2.4 Audit Rights. During the Research Term and for a period of [***], Cellectis shall keep and maintain accurate and complete records
showing the time devoted and activities performed by each FTE in performing Cellectis’ obligations under the Research Program. Upon [***] prior written notice from Pfizer, Cellectis shall permit an independent certified public accounting firm
of nationally recognized standing selected by Pfizer and reasonably acceptable to Cellectis to examine, at Pfizer’s sole expense, the relevant books and records of Cellectis as may be reasonably necessary to verify the accuracy of the invoices
submitted to Pfizer under Section 5.2.3 for the number of FTEs applied to the performance of Cellectis’ obligations under the Research Program. An examination by Pfizer under this Section 5.2.4 shall occur not more than [***] and
shall be limited to the pertinent books and records for [***] before the date of the request. Such examination shall be conducted during Cellectis’ normal business hours at Cellectis’ facility(ies) where such books and records are normally
kept. Cellectis may require the accounting firm to sign a reasonable and customary non-disclosure agreement. The accounting firm shall provide both Cellectis and Pfizer a written report disclosing whether the
invoices submitted by Cellectis are correct or incorrect and the specific details concerning any discrepancies. If the accounting firm determines the number of FTEs actually utilized by Cellectis was less than the number funded by Pfizer during the
period covered by the audit, Cellectis shall, at Pfizer’s sole discretion, either (a) refund the excess payments to Pfizer within [***] of its receipt of the auditor’s report so concluding or (b) immediately offset all such
excess payments against any outstanding or future amounts payable by Pfizer to Cellectis under this Agreement until Pfizer has received full credit for all such overpayments. Additionally, if the amount to be refunded exceeds [***] of the amount
that was properly payable, Cellectis shall reimburse Pfizer for the cost of the audit. 
  

	 	5.3	 Milestones 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 32 

 5.3.1 Development Milestones. Pfizer will pay to Cellectis the amount set forth below
within [***] of receipt of Cellectis’ invoice following the first occurrence of each event (each, a “Development Milestone”) described below for each Pfizer Licensed Product for each Pfizer Target (each such amount, a
“Development Milestone Payment”) to be payable only once with respect to each Pfizer Licensed Product Targeting a Pfizer Target. For the avoidance of doubt, if any Development Milestone Payment is paid for an Agreement CAR-T or Pfizer Licensed Product Targeting a Pfizer Target and the Development or Commercialization of such Agreement CAR-T or Pfizer Licensed Product is terminated and such
Agreement CAR-T or Pfizer Licensed Product is replaced with another Agreement CAR-T or Pfizer Licensed Product Targeting the same Pfizer Target, such Development
Milestone Payment will not be owed by Pfizer if such Agreement CAR-T or Pfizer Licensed Product later achieves the same Development Milestone. 

 

			
	 Development Milestone
	  	 Development Milestone

Payments

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 If any Development Milestone described above occurs before a previous Development Milestone occurs, then any
Development Milestone that has not yet 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 33 

 been paid for achievement of any previous Development Milestone shall become due upon the
achievement of the subsequent Development Milestone and payable together with the payment due upon achievement of such subsequent Development Milestone. For clarity, the achievement of a Development Milestone related to [***] will not result in the
payment of any other Development Milestone related to [***]. 
 5.3.2 Sales Milestones. Pfizer will pay to Cellectis the following one-time payments (each, a “Sales Milestone Payment”) within [***] of the last day of the Pfizer Year when aggregate Annual Net Sales of a Pfizer Licensed Product in a Pfizer Year first reach the
respective threshold (a “Sales Threshold”) indicated below (each, a “Sales Milestone”); provided that such Sales Threshold with respect to a Pfizer Licensed Product must be reached within [***] following the First
Commercial Sale of such Pfizer Licensed Product in the Territory. 
  

			
	 Total Annual Net Sales
	  	 Sales Milestone Payments

	[***]	  	[***]
	[***]	  	[***]

 5.4 Royalties. With respect to each Pfizer Licensed Product and subject to the provisions of
Section 5.4.2, Pfizer will pay Cellectis royalties in the amount of the applicable rates (“Marginal Royalty Rates”) set forth below of Annual Net Sales of any Pfizer Licensed Product Targeting such Pfizer Target during the
Royalty Term: 
  

			
	 Annual Net Sales
	  	 Marginal Royalty Rates

(% of the Annual Net Sales)

	[***]	  	[***]
	[***]	  	[***]

 5.4.1 Marginal Royalty Rate Application. Each Marginal Royalty Rate set forth in the table above will
apply only to that portion of the Annual Net Sales of a given Pfizer Licensed Product in the Territory during a given Pfizer Year that falls within the indicated range. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 34 

 5.4.2 Royalty Adjustments. The following adjustments will be made, on a Pfizer
Licensed Product-by-Pfizer Licensed Product and country-by-country basis, to the
royalties payable pursuant to this Section 5.4: 
 (a) Generic Competition. Royalties payable following establishment of Generic
Competition with respect to the sale by a Third Party of a product that is a Biosimilar Biologic Product to such Pfizer Licensed Product in such country will be payable at [***] of the otherwise applicable rate prior to application of this
Section 5.4.2(a). “Generic Competition” means, with respect to a given Calendar Year with respect to a Pfizer Licensed Product in any country, that during such Calendar Year, one (1) or more Third Parties have received
Regulatory Approval to sell in such country a Biosimilar Biologic Product, such Biosimilar Biologic Product(s) will be commercially available in such country and such Biosimilar Biologic Product(s) will have, in the aggregate. A product will be a
“Biosimilar Biologic Product” with respect to a Pfizer Licensed Product if such product (1) has been licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of the Public Health Service Act
(42 U.S.C. 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation, (2) has been licensed as a similar biological medicinal product by EMA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or
superseding law, statute or regulation, or (3) has otherwise achieved analogous Regulatory Approval from another applicable Regulatory Authority. 

(b) Third Party Patents. If, after the Effective Date, it is Necessary or Useful for Pfizer to license one or more Patent Rights from
one or more Third Parties in order to Develop, Manufacture, Commercialize or use any Pfizer Licensed Product, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its sole discretion, negotiate and obtain a license
under such Patent Right(s) (each such Third Party license referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to Cellectis under this Agreement with respect to Net Sales of any Pfizer Licensed
Product by Pfizer, its Affiliates or Sublicensees will be reduced by [***] of the amounts payable to Third Parties pursuant to any Additional Third Party Licenses, such reduction to continue until all such amounts have been expended, provided that
in no event will the total royalty payable to Cellectis for any Pfizer Licensed Product be less than [***] of the royalty amounts otherwise payable for such Pfizer Licensed Product and in no event will the royalty payable to Cellectis for any Pfizer
Licensed Product be reduced below [***] (in each case, other than in the case of Cellectis’ breach of any representation, warranty or covenant hereunder). For purposes of this Section 5.4.2(b), (i) “Necessary” means that,
without a license to use the Third Party’s Patent Right, the Development, Manufacture, Commercialization or use of any Pfizer 
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

  
 35 

 Licensed Product in the form such Pfizer Licensed Product exists at the time that the
Additional Third Party License is executed would, in Pfizer’s opinion, infringe such Third Party’s Patent Right and (ii) “Useful” means that Pfizer has determined in its discretion that use of such Third Party’s
Patent Right would enhance the commercial potential of such Pfizer Licensed Product. For the avoidance of doubt, the Parties agree and acknowledge that this Section 5.4.2(b) will not apply with respect to royalties payable by Pfizer to any
Third Party under any agreement in existence as of the Effective Date. Neither Party will intentionally negotiate with a Third Party an exclusive license that excludes sublicense rights to the other Party, in the event such Third Party rights are
necessary, as determined by the negotiating Party, to Develop and Commercialize Licensed Pfizer Products and Cellectis Products in connection with the Research Program in the Field. 

(c) Cellectis Third Party Agreements. Cellectis will be solely responsible for all obligations, including royalty obligations, that are
due and owing or may become due and owing with respect to any Cellectis Third Party Agreements that are in effect as of the Effective Date or that Cellectis or any of its Affiliates enters into during the Term of this Agreement. 

5.4.3 Fully Paid-Up, Royalty Free License. After expiration of the Royalty Term for any Pfizer
Licensed Product in a country in the Territory, no further royalties will be payable in respect of sales of such Pfizer Licensed Product in such country and thereafter the License with respect to such Pfizer Licensed Product in such country will be
a fully paid-up, perpetual, exclusive, irrevocable, royalty-free license. 
 5.5 Diagnostic and
Prognostic Products. In no event will any milestone, net sales or royalty payments become due or owing pursuant to Sections 5.3 or 5.4 above with respect to any Pfizer Licensed Product Developed or Commercialized for diagnostic or prognostic
purposes. 
 5.6 Reports and Payments. 

5.6.1 Cumulative Royalties. The obligation to pay royalties under Section 5.4 will be imposed only once with respect to a single
unit of a Pfizer Licensed Product regardless of how many Valid Claims in Patent Rights included within the Licensed Cellectis Intellectual Property would, but for this Agreement, be infringed by the use or sale of such Pfizer Licensed Product in the
country in which such Pfizer Licensed Product is used or sold. 
 5.6.2 Royalty Statements and Payments. Within [***] after the end of
each Pfizer Quarter, Pfizer will deliver to Cellectis a report setting forth for such Pfizer Quarter the following information, on a Pfizer Licensed Product-by-Pfizer
Licensed Product basis: (a) the Net Sales of each Pfizer Licensed Product, 
 [***] = CONFIDENTIAL
TREATMENT REQUESTED 

  
 36 

 (b) the basis for any adjustments to the royalty payable for the sale of each Pfizer
Licensed Product and (c) the royalty due hereunder for the sale of each Pfizer Licensed Product. No such reports will be due for any Pfizer Licensed Product before the First Commercial Sale of such Pfizer Licensed Product in the Territory. The
total royalty due for the sale of Pfizer Licensed Products during such Pfizer Quarter will be remitted at the time such report is delivered to Cellectis. 

5.6.3 Taxes and Withholding. It is understood and agreed between the Parties that any payments made under this Agreement are exclusive
of any value added or similar tax (“VAT”), which will be added thereon as applicable. Where VAT is properly added to a payment made under this Agreement, the party making the payment will pay the amount of VAT only on receipt of a
valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT is chargeable. In addition, in the event any of the payments made by Pfizer pursuant to this Agreement become subject to withholding taxes under the
Laws of any jurisdiction, Pfizer will deduct and withhold the amount of such taxes for the account of Cellectis, to the extent required by Law, such amounts payable to Cellectis will be reduced by the amount of taxes deducted and withheld, and
Pfizer will pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Cellectis an official tax certificate or other evidence of such tax obligations together with proof of payment from the
relevant Governmental Authority of all amounts deducted and withheld sufficient to enable Cellectis to claim such payment of taxes. Any such withholding taxes required under applicable Law to be paid or withheld will be an expense of, and borne
solely by, Cellectis. Pfizer will provide Cellectis with reasonable assistance to enable Cellectis to recover such taxes as permitted by Law. 

5.6.4 Currency. All amounts payable and calculations hereunder will be in United States dollars. As applicable, Net Sales and any
royalty deductions will be converted into United States dollars in accordance with Pfizer’s customary and usual conversion procedures, consistently applied. 

5.6.5 Method of Payment. Except as permitted pursuant to Section 5.6.4, each payment hereunder will be made by electronic transfer
in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer’s election, to such bank account as the Cellectis will designate in writing
to Pfizer at least forty-five (45) days before the payment is due. 
 5.6.6 Additional Provisions Relating to Payments. Cellectis
acknowledges and agrees that nothing in this Agreement (including any schedules and exhibits hereto) will be construed as representing an estimate or projection of either (a) the number of Pfizer Licensed Products that will or may be
successfully Developed or Commercialized or (b) anticipated sales or the actual value of any Pfizer Licensed Product. PFIZER MAKES NO REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT WILL BE ABLE TO SUCCESSFULLY DEVELOP OR
COMMERCIALIZE ANY PRODUCT OR, IF 

  
 37 

 COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT(S), PROVIDED
THAT THE FOREGOING WILL NOT LIMIT PFIZER’S OBLIGATIONS UNDER THIS AGREEMENT. 
 5.7 Maintenance of Records; Audits. 

5.7.1 Record Keeping. Pfizer will keep, and cause its Affiliates and Sublicensees to keep, accurate books of account and records in
connection with the sale of Pfizer Licensed Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Pfizer will maintain, and cause its Affiliates and Sublicensees
to maintain, such records for a period of at least [***] after the end of the Calendar Year in which they were generated. 
 5.7.2
Audits. Upon thirty (30) days prior written notice from Cellectis, Pfizer will permit an independent certified public accounting firm of internationally recognized standing selected by Cellectis and reasonably acceptable to Pfizer to
examine, at Cellectis’ sole expense, the relevant books and records of Pfizer during the period covered by such examination, as may be reasonably necessary to verify the accuracy of the reports submitted by Pfizer in accordance with
Section 5.6 and the payment of royalties hereunder. An examination by Cellectis under this Section 5.7.2 will occur not more than [***] and will be limited to the pertinent books and records for any Calendar Year ending not more than [***]
before the date of the request. The accounting firm will be provided access to such books and records at Pfizer’s or its Affiliates’ facilities where such books and records are kept and such examination will be conducted during
Pfizer’s normal business hours. Pfizer may require the accounting firm to sign a reasonable and customary non-disclosure agreement before providing the accounting firm access to Pfizer’s facilities
or records. Upon completion of the audit, the accounting firm will provide both Pfizer and Cellectis a written report disclosing whether the reports submitted by Pfizer are correct or incorrect, whether the royalties paid are correct or incorrect
and, in each case, the specific details concerning any discrepancies. No other information will be provided to Cellectis. 
 5.7.3
Underpayments/Overpayments. If such accounting firm concludes that additional royalties were due to Cellectis, Pfizer will pay to Cellectis the additional royalties within thirty (30) days of the date Pfizer receives such
accountant’s written report so concluding. If such underpayment exceeds [***] of the royalties that were to be paid to Cellectis, Pfizer also will reimburse Cellectis for all reasonable charges of such accountants for conducting the audit. If
such accounting firm concludes that Pfizer overpaid royalties to Cellectis, Cellectis will repay such amount to Pfizer in full within thirty (30) days of the receipt of such accountant’s report, or, at Pfizer’s option, Pfizer will be
entitled to offset all such overpayments against any outstanding or future amounts payable to Cellectis hereunder until Pfizer has received full credit for such overpayments. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 38 

 5.7.4 Confidentiality. All financial information of Pfizer which is subject to review
under this Section 5.7 will be deemed to be Pfizer’s Confidential Information subject to the provisions of Article 7 hereof, and Cellectis will not disclose such Confidential Information to any Third Party or use such Confidential
Information for any purpose other than verifying payments to be made by Pfizer to Cellectis hereunder. 
 5.7.5 Costs. Cellectis shall
pay the full cost of the audit unless the discrepancy is to the Cellectis’ detriment and is greater than [***] of all amounts due in such calendar year, in which cases Pfizer shall pay the reasonable cost charged by such accountant for such
inspection. 
 5.8 No Guarantee of Success. Pfizer and Cellectis acknowledge and agree that payments to Cellectis pursuant to
Section 5.2, Section 5.3 and Section 5.4: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if a Pfizer Licensed Product is successfully Developed or Commercialized, as applicable;
(b) are solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of a Pfizer Licensed Product between Pfizer (who will receive all Pfizer Licensed Product sales revenues) and Cellectis;
(c) are not intended to be used and will not be used as a measure of damages if this Agreement is terminated for any reason, including pursuant to Pfizer’s right to terminate at for convenience, before any such success is achieved and such
amounts become due; and (d) will only be triggered, and will only be relevant as provided, in accordance with the terms and conditions of such provisions. Pfizer and Cellectis further acknowledge and agree that nothing in this Agreement will be
construed as representing any estimate or projection of (i) the successful Development or Commercialization of any Pfizer Licensed Product under this Agreement, (ii) the number of Pfizer Licensed Products that will or may be successfully
Developed or Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Pfizer Licensed Products that may be successfully Developed or Commercialized under this Agreement or (iv) the damages, if any, that may
be payable if this Agreement is terminated for any reason. Pfizer makes no representation, warranty or covenant, either express or implied, that (A) it will successfully Develop, Manufacture, Commercialize or continue to Develop, Manufacture or
Commercialize any Pfizer Licensed Product in any country, (B) if Commercialized, that any Pfizer Licensed Product will achieve any particular sales level, whether in any individual country or cumulatively throughout the Territory or
(C) Pfizer will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Pfizer Licensed Product in any country, or in the Territory in general, other than is expressly required under
Section 3.2. 
  

	6.	 INTELLECTUAL PROPERTY. 

6.1 Inventions. 
 6.1.1
Ownership. All determinations of inventorship under this Agreement will be made in accordance with the laws of the United States. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 39 

 (a) Pfizer Improvements. Pfizer will own [***]. 

(b) Cellectis Improvements. Cellectis will own [***]. 

(c) Developed IP. Except as provided in Section 6.1.1(d), [***]. 

(d) Assignment of Pfizer CAR-T Developed IP. [***]. 

(e) Assignment of Cellectis CAR-T Developed IP. [***]. 

(f) Implementation. Each Party will assign, and does hereby assign, to the other Party such Patent Rights, Know-How or other intellectual property rights as necessary to achieve ownership as provided in this Section 6.1.1. Each assigning Party will execute and deliver all documents and instruments reasonably
requested by the other Party to evidence or record such assignment or to file for, perfect or enforce the assigned rights. Each assigning Party will make its relevant employees, agents and independent contractors (and their assignments and
signatures on such documents and instruments) reasonably available to the other Party for assistance in accordance with this Section 6.1.1 at no charge. 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

40 

 6.1.2 Disclosure. Each Party will promptly (and in no event less than [***] before
filing any initial Patent Right disclosing such intellectual property) disclose to the other Party any Developed IP, Cellectis Improvement and Pfizer Improvement, including all invention disclosures or other similar documents submitted to such Party
by its, or its Affiliates’, employees, agents or independent contractors describing such Developed IP, Cellectis Improvement or Pfizer Improvement, and the proposed inventorship of any new Patent Rights intended to be filed. The other Party
will promptly raise any issue regarding inventorship. Any inventorship issue raised more than [***] after notice of the filing of an initial Patent Rights and the content thereof, or the subsequent filing of new patent claims in a Patent Right
directed to substantially different inventions, will not affect ownership of the Patent Right as determined in accordance with the initial inventorship determination. 

6.2 Patent Rights. 
 6.2.1
Filing, Prosecution and Maintenance of Patent Rights. 
 (a) Cooperation. Without limiting any other rights and obligations of
the Parties under this Agreement, the Parties will cooperate with respect to the timing, scope and filing of patent applications and patent claims relating to any Cellectis Improvements, Pfizer Improvements and Developed IP to preserve and enhance
the patent protection for Agreement CAR-Ts, including the manufacture and use thereof. If the ownership rights in any Patent Rights included in Cellectis Improvements or Developed IP are substantially impeding
or would substantially impede Pfizer’s prosecution of CAR-T Developed IP assigned to Pfizer pursuant to Section 6.1.1(d), or Cellectis’s prosecution of Cellectis
CAR-T Developed IP assigned to Cellectis pursuant 6.1.1(e), the Parties will negotiate in good faith an amendment of the ownership of such Patent Rights included in Cellectis Improvements or Developed IP while
preserving for each Party substantially the same rights, including all Milestone Payments and royalty payments, as are afforded in this Agreement. 

(b) Pfizer Patent Rights. Pfizer, at its own expense, will have the sole right, but not the obligation, to prepare, file, prosecute and
maintain, throughout the world, any Patent Rights that it solely owns, including Pfizer Patent Rights and Patent Rights comprised in the Pfizer Improvements and CAR-T Developed IP (to the extent assigned to
Pfizer pursuant to Section 6.1.1(d)). Pfizer will keep Cellectis informed regarding the status of any Patent Right comprised in any such CAR-T Developed IP at Cellectis’ reasonable request. To the
extent Pfizer wishes not to file, prosecute or maintain any such Patent Right, Pfizer will provide Cellectis with thirty (30) days prior written notice to such effect, in which event Cellectis may elect to continue filing, prosecution or
maintenance of such Patent Right, and Pfizer, upon Cellectis’ written 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

41 

 request received within such thirty (30) day period, will execute such documents and
perform such acts, at Cellectis’ expense, as may be reasonably necessary to permit Cellectis to file, prosecute and maintain such Patent Right. Any such Patent Right that is prosecuted or maintained by Cellectis pursuant to this
Section 6.2.1(c)(i) will continue to be owned by Pfizer, and (ii) subject to the Parties’ other rights and obligations under this Agreement, may be licensed by Pfizer to one or more Third Parties. 

(c) Cellectis Patent Rights. Cellectis, at its own expense, will have the sole right, but not the obligation, to prepare, file,
prosecute and maintain, throughout the world, any Patent Rights included in Licensed Intellectual Property that it solely owns or has in-licensed from Third Parties, including Cellectis Patent Rights and
Patent Rights comprised in the Cellectis Improvements. Cellectis will not disclose any Pfizer Confidential Information in any Patent Rights that it files, or in connection with the prosecution of any such Patent Rights, without Pfizer’s prior
written consent. Cellectis will notify Pfizer promptly upon filing or otherwise obtaining rights in any Patent Right after the Effective Date that covers or may cover the Development, Manufacture, Commercialization or use of any Pfizer Licensed
Product. In the absence of such prompt notification, any such Patent Rights will be excluded from the Valid Claim definition. Cellectis will keep Pfizer informed regarding each Patent Right included in the Licensed Intellectual Property that
Cellectis or any Third Party licensor is prosecuting and will consider in good faith any recommendations made by Pfizer in regard to the filing, prosecution or maintenance of any such Patent Right. To the extent Cellectis wishes not to file,
prosecute or maintain any such Patent Right (other than any such Patent Right owned or co-owned by a Third Party licensor), Cellectis will provide Pfizer with thirty (30) days prior written notice to such
effect, in which event Pfizer may elect to continue filing, prosecution or maintenance of such Patent Right, and Cellectis, upon Pfizer’s written request received within such thirty (30) day period, will execute such documents and perform
such acts, at Pfizer’s expense, as may be reasonably necessary to permit Pfizer to file, prosecute and maintain, at its own discretion, such Patent Right. Any such Patent Rights that are prosecuted or maintained by Pfizer pursuant to this
Section 6.2.1(c) will continue to be owned by Cellectis, and will be excluded from the Valid Claim definition; and, in addition to the exclusive licenses granted to Pfizer under Section 4, Cellectis will and does hereby grant to Pfizer
(subject to any existing Third Party rights) a non-exclusive, sublicensable, perpetual, irrevocable, royalty-free, fully paid-up, worldwide license to practice and
exploit such Patent Rights for any and all purposes. Cellectis will not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under any Cellectis Third Party Agreement that is included in the Licensed
Intellectual Property without Pfizer’s prior written consent. 

  
 42 

 (d) Joint Patent Rights. In the event the Parties conceive or generate any Joint
Developed IP, other than any Joint Developed IP that constitutes CAR-T Developed IP and is assigned to Pfizer pursuant to Section 6.1.1(c), or Cellectis CAR-T
Developed IP and is assigned to Cellectis pursuant to Section 6.1.1(d), the Parties will promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Patent Right
covering or claiming any such Joint Developed IP (a “Joint Patent Right”) Pfizer will have the first right to file on and control prosecution of any Patent Right covering or claiming any Joint Developed IP used in the development,
manufacture, composition or use of any CAR-T Targeting such Pfizer Target in accordance with Section 6.2.1(b). For avoidance of doubt, “prosecution” as used in this Section 6.2.1
includes oppositions, nullity or revocation actions, post-grant reviews and other patent office proceedings involving the referenced Patent Rights. 

(e) Liability. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right included in the Licensed Intellectual
Property or Developed IP (including CAR-T Developed IP) or otherwise exercising its rights under this Section 6.2.1, such Party, and its Affiliates, employees, agents or representatives, will not be
liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. 

(f) Extensions. The decision to file for a patent term extension and particulars thereof (including which patent(s) to extend) will be
made with the goal of obtaining the optimal patent term and scope of protection for Pfizer Licensed Products. Pfizer will have the sole right but not the obligation to apply for and obtain any patent term extension or related extension of rights,
including supplementary protection certificates and similar rights, for any patent relating to a Pfizer Licensed Product (including the choice of which patent(s) to extend), provided that it will consult with Cellectis before applying for or
obtaining any such extensions or rights for any patents included in the Licensed Cellectis Intellectual Property. The Parties will provide reasonable assistance to each other in connection with obtaining any such extensions for any patent included
in the Licensed Cellectis Intellectual Property. To the extent reasonably and legally required in order to obtain any such extension in a particular country, each Party will make available to the other a copy of the necessary documentation to enable
such other Party to use the same for the purpose of obtaining the extension in such country. 
 (g) Joint Research Agreement. This
Agreement will be understood to be a joint research agreement under 35 U.S.C. § 103(c)(3) entered into for the purpose of researching, identifying and Developing Agreement CAR-Ts and Pfizer Licensed
Products. 

  
 43 

 (h) Recording. If a Party deems it necessary or desirable to register or record this
Agreement or evidence of this Agreement with any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then the Parties will agree on a proposed evidence of such recording and the Parties will
comply with the terms of Section 7.2.3 in respect of such filing. Each Party will execute and deliver to the other Party any documents necessary or desirable to complete such registration or recordation in accordance with the terms of
Section 7.2.3. 
 6.2.2 Enforcement of Patent Rights. 

(a) Notice. If either Pfizer or Cellectis becomes aware of any infringement that may affect competition of either Party within the
Field, anywhere in the world, of any issued Patent Right within the Licensed Intellectual Property or Developed IP, such Party will promptly notify the other Party in writing to that effect. 

(b) Infringement of Certain Patent Rights. 

(i) Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, if any infringement of a Patent Right included in
the Licensed Intellectual Property by a Third Party arises from the Development, Manufacture or Commercialization of a product that does, or may, compete with a Pfizer Licensed Product Targeting such Pfizer Target, Pfizer will have the first right,
but not the obligation, to take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Patent Right within six (6) months from the date of notice and to join Cellectis as a party plaintiff in
each of the following circumstances: (x) where the Pfizer Licensed Product with which the Third Party’s infringement will compete has been [***] or is the subject of [***] and no Cellectis Product or
CAR-T product of another Cellectis licensee has begun or completed [***], or (y) where such Patent Right is directed exclusively to a Pfizer Target or a Pfizer Licensed Product Targeting such Pfizer
Target; in all other circumstances, Pfizer may, with prior written consent of Cellectis (not to be unreasonably withheld), have the right to take action against such Third Party infringer. 

(ii) Pfizer will bear all the expenses of any suit brought by it claiming infringement of any such Patent Right. Cellectis will cooperate with
Pfizer in any such suit and will have the right to consult with Pfizer and to participate in and be represented by independent counsel in such litigation at its own expense. Pfizer will incur no liability to Cellectis as a consequence of such 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

44 

 litigation or any unfavorable decision resulting therefrom, including any decision holding
any such Patent Right invalid or unenforceable, and Pfizer will not, without Cellectis’ prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Cellectis or
admits the invalidity or unenforceability of any such Patent Right. 
 (iii) If Pfizer has not obtained a discontinuance of infringement by,
or filed suit against, any such Third Party infringer within the six (6) month period set forth in subsection (i) above, then Cellectis will have the right, but not the obligation, to bring suit against such Third Party infringer, at
Cellectis’ sole expense; provided, however, that Cellectis will only have the foregoing right if Pfizer would not be required (by Applicable Law or otherwise) to join such suit as a party and such suit would not involve a Patent Right covering
a then-existing Agreement CAR-T or Pfizer Licensed Product. Pfizer will have no obligation to cooperate with Cellectis in any such litigation, provided that Pfizer may, at its sole discretion, elect to consult
with Cellectis and to participate in and be represented by independent counsel in such litigation at its own expense. Cellectis will incur no liability to Pfizer as a consequence of such litigation or any unfavorable decision resulting therefrom,
including any decision holding any such Cellectis Patent Right or Joint Patent Right invalid or unenforceable; and Cellectis will not, without Pfizer’s prior written consent, enter into any settlement or consent decree that requires any payment
by or admits or imparts any other liability to Pfizer or admits the invalidity or unenforceability of any such Patent Right. 
 (iv) The
enforcing Party will keep the other Party reasonably informed of all material developments in connection with any such suit. Subject to the terms and conditions of any applicable Cellectis Third Party Agreements, any recoveries obtained by either
Party as a result of any proceeding against such a Third Party infringer will be allocated as follows: 
 (A) Such recovery will first be
used to reimburse each Party for all out-of-pocket litigation costs in connection with such litigation paid by that Party; and 

(B) With respect to any remaining portion of such recovery, if Pfizer was the enforcing Party, Cellectis will receive an amount equal to the
royalty that would be payable, pursuant to Section 5.4, on an amount of Net Sales of the relevant Pfizer Licensed Product(s) in the country(ies) where such infringement occurred equal to such remaining

  
 45 

 
portion of such recovery, and Pfizer will receive any remaining portion of such recovery; or 

(C) With respect to any remaining portion of such recovery, if Cellectis was the enforcing Party, Cellectis will receive any remaining portion
of such recovery, except to the extent such recovery was calculated based on lost sales of Pfizer, in which case the allocation of such remaining portion will be made as provided in Section 6.2.2(b)(iv)(B). 

(c) Other Infringement of Joint Patent Rights. With respect to any notice of a Third Party infringer of any Joint Patent Right other
than in the case of a Joint Patent Right subject to Section 6.2.2(b), the Parties will meet as soon as reasonably practicable to discuss such infringement and determine an appropriate course of action and the Parties’ respective rights and
responsibilities with respect to any enforcement thereof. 
 6.2.3 Biosimilar Notices. 

(a) Upon Pfizer’s request any time after completion of the first Phase II Clinical Trial for any Pfizer Licensed Product, Cellectis will
use reasonable efforts to assist and cooperate with Pfizer in establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and preparing submissions responsive to any Biosimilar Notices
received by Pfizer; provided that Pfizer will make the final decisions with respect to such strategy and any such responses. 
 (b)
Biosimilar Notices. Pfizer will comply with the applicable provisions of 42 U.S.C. § 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in
the United States, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received by Pfizer from any
Third Party regarding any Pfizer Licensed Product that is being Commercialized in the applicable jurisdiction, and the exchange of information between any Third Party and Pfizer pursuant to such requirements; provided that, prior to any submission
of information by Pfizer to a Third Party, Cellectis will have the right to review the patent information included in such proposed submission, solely with respect to Patent Rights Controlled by Cellectis, and to make suggestions as to any changes
to such patent information that Cellectis reasonably believes to be necessary; provided further that Pfizer will determine the final content of any such submission. In the case of a Pfizer Licensed Product approved in the United States under the PHS
Act (or, in the case of a country in the Territory other than the United States, any similar law), to the extent permitted by Applicable Law, Pfizer, as the 

  
 46 

 sponsor of the application for the Pfizer Licensed Product, will be the “reference
product sponsor” under the PHS Act. Pfizer will give written notice to Cellectis of receipt of a Biosimilar Notice received by Pfizer with respect to a Pfizer Licensed Product, and Pfizer will consult with Cellectis with respect to the
selection of the Patent Rights to be submitted pursuant to 42 U.S.C. § 262(l) (or any similar law in any country of the Territory outside the United States); provided that Pfizer will have final say on such selection of Patent Rights. Cellectis
agrees to be bound by the confidentiality provisions of 42 U.S.C. § 262(l)(1)(B)(iii). In order to establish standing in connection with any action brought by Pfizer under this Section 6.2.3, Cellectis, upon Pfizer’s request, will
reasonably cooperate with Pfizer in any such action, including timely commencing or joining in any action brought by Pfizer under this Section 6.2.3 solely to the extent any Patent Rights Controlled by Cellectis are involved in any such action,
and the Parties rights and responsibilities regarding any action will be determined in accordance with Section 6.2.2(b). 
 6.3
Interference, Opposition, Revocation and Declaratory Judgment Actions. If the Parties mutually determine that, based upon the review of a Third Party’s patent or patent application or other intellectual property rights, it may be
desirable in connection with any Agreement CAR-T or Pfizer Licensed Product to provoke or institute an interference, opposition, revocation, post-grant review or other patent office proceedings or declaratory
judgment action with respect thereto, then the Parties will consult with one another and will [***] in connection with such an action. Unless otherwise mutually determined by the Parties, if (i) such impasse exists during the Research Term then
Cellectis will control such action and will select counsel for such action and (ii) such impasse exists following the Research Term then Pfizer will control such action and will select counsel for such action. The rights and obligations of the
Parties under Section 6.4 are expressly subject to this Section 6.3. 
 6.4 Infringement of Third Party Patent Rights. If
the Development, Manufacture or Commercialization of any Pfizer Licensed Product is alleged by a Third Party to infringe a Third Party’s patent or other intellectual property rights, the Party becoming aware of such allegation will promptly
notify the other Party. The Party that is alleged to infringe the Third Party’s patent or intellectual property rights will have the right to take such action as it deems appropriate in response to such allegation, and will be solely
responsible for all damages, costs and expenses in connection therewith, subject to Section 10.1. 
 7. CONFIDENTIALITY 

7.1 Confidentiality. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and [***],
each Party (the “Receiving Party”) receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will: (a) keep the Disclosing Party’s Confidential Information confidential;
(b) not disclose, or permit the disclosure of, the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

47 

 Party’s Confidential Information for any purpose, provided, however, that a Receiving
Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information (i) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the
time of disclosure by the Disclosing Party; (ii) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (iii) became generally available to the public or otherwise
part of the public domain after its disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement; (iv) was disclosed to the Receiving Party, other than under
an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party; or (v) was independently discovered or developed by or on behalf of the Receiving Party
without the use of any Confidential Information of the Disclosing Party. 
 7.2 Authorized Disclosure. 

7.2.1 Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 7.1, the Receiving Party may
disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s, its Affiliates’ and its Sublicensees’ officers, directors, employees, consultants, contractors, licensors and agents (collectively,
“Representatives”) who (a) have a need to know such Confidential Information in connection with the performance of the Receiving Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement
and (b) have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set
forth in this Article 7. 
 7.2.2 Disclosure to Third Parties. 

(a) Notwithstanding the foregoing provisions of Section 7.1, the Parties may disclose Confidential Information belonging to the other
Party: 
 (i) to Governmental Authorities (A) to the extent reasonably necessary to obtain or maintain INDs or Regulatory Approvals for
any Agreement CAR-T or Pfizer Licensed Product Targeting such Pfizer Target, or any Cellectis Target or Cellectis Product Targeting such Cellectis Target, within the Territory, and (B) in order to respond
to inquiries, requests, investigations, orders or subpoenas relating to this Agreement; 
 (ii) to outside consultants, contractors,
advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent reasonably necessary for the performance of this Agreement and under reasonable obligations
of confidentiality; 

  
 48 

 (iii) to the extent reasonably necessary, in connection with filing or prosecuting Patent
Rights or Trademark rights as permitted by this Agreement; 
 (iv) to the extent reasonably necessary, in connection with prosecuting or
defending litigation as permitted by this Agreement; 
 (v) subject to Section 7.3.2, in connection with or included in scientific
presentations and publications relating to Agreement CAR-Ts or Pfizer Licensed Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical
trials to clincialtrials.gov or PhRMA websites; and 
 (vi) to the extent necessary in order to enforce its rights under this Agreement and
as permitted in the Agreement. 
 (b) In the event a Party deems it reasonably necessary to disclose Confidential Information belonging to
the other Party pursuant to Section 7.2.2(a)(i)(B), the Disclosing Party will to the extent possible give reasonable advance written notice of such disclosure to the other Party and take all reasonable measures to ensure confidential treatment
of such information. 
 7.2.3 SEC Filings and Other Disclosures. Notwithstanding any provision of this Agreement to the contrary,
either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with applicable Law, including the rules and regulations promulgated by the United States
Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties
will consult with one another on the terms of this Agreement to be redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.2.3, such Party will, at its
own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party. 

7.3 Public Announcements; Publications. 

7.3.1 Announcements. Except as may be expressly permitted under Section 7.2.3, neither Party will make any public announcement
regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement will prevent (a) either Party from making any public disclosure relating to this Agreement if the contents of
such public disclosure have previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; (b) Pfizer from making any 

  
 49 

 scientific publication or public announcement with respect to any Pfizer Licensed Product
Targeting such Pfizer Target under this Agreement; provided, however, that, except as permitted under Section 7.2, Pfizer will not disclose any of Cellectis’ Confidential Information in any such publication or announcement without
obtaining Cellectis’ prior written consent to do so and (c) Cellectis from making any scientific publication or public announcement with respect to any Cellectis Licensed Product Targeting such Cellectis Program Target under this
Agreement; provided, however, that, except as permitted under Section 7.2, Cellectis will not disclose any of Pfizer’s Confidential Information in any such publication or announcement without obtaining Pfizer’s prior written consent
to do so. The Parties agree that they will release the announcement attached hereto as Schedule 7.3.1 regarding the signing of this Agreement following the Effective Date. 

7.3.2 Publications. During the Term, each Party will submit to the other Party (the
“Non-Disclosing Party”) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the
Non-Disclosing Party’s Confidential Information. In addition, each Party will submit to the other Party for its review and approval any proposed publication or public presentation relating to the Research
Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the Licensed Intellectual Property, Cellectis CAR-T Developed IP and Pfizer CAR-T Developed IP and the rights granted to each Party hereunder and determining whether any portion of the proposed publication or presentation containing the Non-Disclosing
Party’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted to the Non-Disclosing Party
no later than thirty (30) days before submission for publication or presentation (the “Review Period”). The Non-Disclosing Party will provide its comments with respect to such
publications and presentations within twenty (20) days after its receipt of such written copy, and the other Party will delete any Confidential Information of the Non-Disclosing Party upon request. The
Review Period may be extended for an additional sixty (60) days in the event the Non-Disclosing Party can, within fifteen (15) days of receipt of the written copy, demonstrate reasonable need for
such extension, including for the preparation and filing of patent applications. Cellectis and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties
in any publication governed by this Section 7.3.2. 
 7.4 Obligations in Connection with Change of Control. If Cellectis is
subject to a Change of Control, Cellectis will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Pfizer is released to (a) any Affiliate of Cellectis that becomes an Affiliate as a result of
the Change of Control or (b) any Representatives of Cellectis (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the Change of Control, unless such Representatives have signed individual
confidentiality agreements which include equivalent obligations to those set out in this Article 7. If any Change of Control of 

  
 50 

 Cellectis occurs, Cellectis will promptly notify Pfizer, share with Pfizer the policies and
procedures it plans to implement in order to protect the confidentiality of Pfizer’s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are reasonably requested by Pfizer. 

8. REPRESENTATIONS AND WARRANTIES. 
 8.1
Mutual Representations and Warranties. Each of Cellectis and Pfizer hereby represents and warrants to the other Party that: 
 8.1.1
it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization; 
 8.1.2 the execution,
delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its
shareholders or other holders of its voting securities or voting interests; 
 8.1.3 it has the power and authority to execute and deliver
this Agreement and to perform its obligations hereunder; 
 8.1.4 this Agreement has been duly executed and is a legal, valid and Binding
Obligation on each Party, enforceable against such Party in accordance with its terms; and 
 8.1.5 the execution, delivery and performance
by such Party of this Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. 

8.2 Representations and Warranties of Cellectis. Cellectis hereby represents and warrants to Pfizer that: 

8.2.1 except as expressly disclosed in Schedule 8.2.1, Cellectis is the sole and exclusive owner of the Cellectis Technology existing as of the
Effective Date, all of which is free and clear of any claims, liens, charges or encumbrances; 
 8.2.2 it has and will have the full right,
power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer or Pfizer’s Affiliates under this Agreement; 

8.2.3 as of the Effective Date (a) Schedule 8.2.3 sets forth a true and complete list of all Cellectis Patent Rights, (b) each such
Patent Right is in full force and effect and (c) Cellectis or its Affiliates or their licensors have timely paid all filing and renewal fees payable with respect to such Patent Rights; 

  
 51 

 8.2.4 to its knowledge: (i) the Cellectis Patent Rights existing as of the Effective
Date, are, or, upon issuance, will be, valid and enforceable patents and (ii) as of the Effective Date, except as set forth in Schedule 8.2.4, no Third Party (a) is infringing any Cellectis Patent Right for use in CARs in the Field or
(b) has challenged or threatened to challenge the extent, validity or enforceability of any Cellectis Patent Right (including, by way of example, through the institution or threat of institution of interference, nullity or similar invalidity
proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 
 8.2.5 it and its
counsel, and, to its knowledge, [***], have complied with all Applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Cellectis Patent Rights existing as of the Effective Date; 

8.2.6 except as expressly disclosed in Schedule 8.2.6, Cellectis has independently developed all Cellectis
Know-How existing as of the Effective Date or otherwise has a valid right to use, and to permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, such Cellectis Know-How for all permitted purposes under this Agreement; 
 8.2.7 it [***] has obtained from all inventors
of Cellectis Technology existing as of the Effective Date, valid and enforceable agreements assigning to Cellectis [***] each such inventor’s entire right, title and interest in and to all such Cellectis Technology; 

8.2.8 except as expressly disclosed in Schedule 8.2.8, no Cellectis Technology existing as of the Effective Date is subject to any funding
agreement with any Governmental Authority; 
 8.2.9 except as expressly disclosed in Schedule 8.2.9, neither Cellectis nor any of its
Affiliates are subject to any agreement or obligation that limits any ownership or license right granted to Pfizer or its Affiliates under this Agreement, including any right granted to Pfizer or its Affiliates to access, practice, grant any
licenses or sublicenses under, or provide Pfizer’s Sublicensees with access to any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each
case, that would, but for such agreement or obligation, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

52 

 8.2.10 (a) there are no Cellectis Third Party Agreements existing as of the Effective Date,
other than the Cellectis Third Party Agreements expressly disclosed in Schedule 8.2.10 (each, a “Disclosed Third Party Agreement”), true and complete redacted copies of which have been provided to Pfizer, (b) except as provided
in the Disclosed Third Party Agreements and except for the Servier Agreement, no Third Party has any right, title or interest in or to, or any license under, any Cellectis Technology for use of CAR-Ts in the
Field, (c) no rights granted by or to Cellectis or its Affiliates under any Disclosed Third Party Agreement conflict with any right or license granted to Pfizer or its Affiliates hereunder and (d) Cellectis and its Affiliates are in
compliance in all respects with all Disclosed Third Party Agreements, including all due diligence obligations of Cellectis under the Disclosed Third Party Agreements; 

8.2.11 there is no (a) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil,
criminal, regulatory or otherwise, pending or, to the knowledge of Cellectis, threatened against Cellectis or any of its Affiliates or (b) judgment or settlement against or owed by Cellectis or any of its Affiliates, in each case in connection
with the Cellectis Technology or relating to the transactions contemplated by this Agreement. 
 8.3 Representations and Warranties of
Pfizer. Pfizer hereby represents and warrants to Cellectis that it has and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to Cellectis or
Cellectis’s Affiliates under this Agreement. 
 8.4 Cellectis Covenants. In addition to the covenants made by the Parties
elsewhere in this Agreement, Cellectis hereby covenants to the other that: 
 8.4.1 Cellectis will use its reasonable efforts to obtain,
[***] of the Effective Date or as soon thereafter as practicable, an executed confirmatory letter agreement [***] substantially in the form as provided by Pfizer prior to the Effective Date or as otherwise acceptable to Pfizer. 

8.5 Mutual Covenants. In addition to the covenants made by the Parties elsewhere in this Agreement, each Party hereby covenants to the
other that, from the Effective Date until expiration or termination of this Agreement: 
 8.5.1 it will not (a) take any action that
diminishes the rights under the Licensed Cellectis Intellectual Property or Licensed Pfizer Intellectual Property or Developed IP granted or assigned under this Agreement or (b) fail to take any action that is reasonably necessary to avoid
diminishing the rights under the Licensed Cellectis Intellectual Property, Licensed Pfizer Intellectual Property or Developed IP granted or assigned to Pfizer or Pfizer’s Affiliates under this Agreement; 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

53 

 8.5.2 it will (a) not enter into any Third Party Agreement that adversely affects
(i) the rights granted to the other Party hereunder or (ii) its ability to fully perform its obligations hereunder; (b) not amend, terminate or otherwise modify any Third Party Agreement (including for Cellectis, the Servier
Agreement) or consent or waive rights with respect thereto in any manner that (i) adversely affects the rights granted to the other Party hereunder or (ii) its ability to fully perform its obligations hereunder; (c) fulfill, and cause
its Affiliates to fulfill, all of their respective obligations under all Third Party Agreements (including for Cellectis Servier Agreements) so as not to be in breach of such agreements; (e) inform Pfizer of existence of all notices received by
Cellectis or its Affiliates relating to any alleged breach or default by Cellectis or its Affiliates under any Third Party Agreement (including Servier Agreement), and all other notices received by Cellectis or its Affiliates in connection with any
Cellectis Third Party Agreement (including any Disclosed Third Party Agreement) that pertain to the rights granted to Pfizer or Pfizer’s Affiliates hereunder, within [***] after receipt thereof; and (f) in the event that Cellectis does not
resolve any such alleged breach or default, notify Pfizer within [***] before the expiration of the cure period for such breach of default under such Cellectis Third Party Agreement such that Pfizer is able to cure or otherwise resolve such alleged
breach or default, and if Pfizer makes any payments to any Third Party in connection with the cure or other resolution of such alleged breach or default, then Pfizer may credit the amount of such payments against any royalties or other amounts
payable to Cellectis pursuant to this Agreement. 
 8.5.3 it will not enter into or otherwise allow itself or its Affiliates to be subject to
any agreement or arrangement which limits the ownership rights of the other Party or its Affiliates with respect to, or limits the ability of the other Party or its Affiliates to grant a license, sublicense or access, or provide or provide access or
other rights in, to or under, any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement,
be included in the rights licensed or assigned to the other Party or its Affiliates pursuant to this Agreement; and 
 8.5.4 it will maintain
valid and enforceable agreements with all Persons acting by or on behalf of itself or its Affiliates under this Agreement which require such Persons to assign to it their entire right, title and interest in and to all Patent Rights, Know-How or other intellectual property rights that are conceived or generated in the course of performing Research Plan Services. 

8.6 Representation by Legal Counsel. Each Party hereto represents that it has been represented by legal counsel in connection with this
Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party which drafted such
terms and provisions. 
 8.7 Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER
REPRESENTATIONS AND 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

54 

 WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY
IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 
 9. GOVERNMENT APPROVALS; TERM
AND TERMINATION. 
 9.1 Government Approvals. Each of Cellectis and Pfizer will cooperate with the other Party and use
Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits
and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 

9.2 Term. The term of this Agreement (the “Term”) will commence on the Effective Date and will extend, unless this
Agreement is terminated earlier in accordance with this Article 9, on a Pfizer Licensed Product-by-Pfizer Licensed Product and country-by-country basis, until such time as the Royalty Term with respect to the sale of such Pfizer Licensed Product in such country expires. 

9.3 Termination by Pfizer for Failure of Cellectis to Obtain Shareholder Approval. In the event that Cellectis is unable to obtain
approval of its shareholders by August 15, 2014 for the issuance of 2,786,924 ordinary shares of Cellectis to Pfizer pursuant to the Subscription Agreement by and between Cellectis and Pfizer OTC BV dated as of the Effective Date, then Pfizer
will have the right, at its sole discretion, to terminate this Agreement in its entirety. 
 9.4 Termination by Either Party for
Cause. Either Party may terminate this Agreement, in its entirety or, at the terminating Party’s option, on a Pfizer Target-by-Pfizer Target basis or Cellectis
Program Target-by Cellectis Program Target basis, as applicable, at any time during the Term of this Agreement by giving written notice to the other Party if the other Party commits a material breach of its
obligations under this Agreement and such breach remains uncured for ninety (90) days, measured from the date written notice of such breach is given to the breaching Party. Notwithstanding the foregoing, a Party will have the right to terminate
this Agreement pursuant to this Section 9.4 (a) in part with respect to an individual Pfizer Target or Cellectis Program Target, as applicable, only if the other Party’s material breach giving rise to such termination right relates to such
Pfizer Target or Cellectis Program Target, as applicable, or (b) in its entirety only if such material breach fundamentally frustrates the objectives or transactions contemplated by this Agreement taken as a whole or affects substantially all
of the Research Program. 
 9.5 Termination by Pfizer for Convenience. At any time after the one (1) year anniversary of the
Effective Date, Pfizer will have the right to terminate this Agreement for any or no reason, either in its entirety or on a Pfizer Target-by-Pfizer Target basis, by
providing sixty (60) days advance written notice of such termination to Cellectis. 

  
 55 

 9.6 Termination on Insolvency of Cellectis. This Agreement may be terminated upon
written notice by Pfizer at any time in the event of a Cellectis Insolvency Event. 
 9.7 Effects of Termination. 

9.7.1 Effect of Termination by Pfizer for Failure of Cellectis to Obtain Shareholder Approval. If Pfizer terminates this Agreement
pursuant to Section 9.3: 
 (a) all work under all Research Plans will cease; 

(b) all rights and licenses granted by Cellectis to Pfizer pursuant to Sections 4.1 and will terminate; 

(c) all rights and licenses granted by Pfizer to Cellectis pursuant to Sections 4.2 will terminate; and 

(d) Pfizer will be relieved of any and all payment obligations under Section 5, including the upfront payment that would become due and
payable pursuant to Section 5.1; and 
 (e) Any material or Confidential Information provided by a Party to the other Party in the
course of the performance of this Agreement will be returned or destroyed as directed in writing by the providing Party. 
 9.7.2 Effect
of Termination by Pfizer for Cause. If Pfizer terminates this Agreement with respect to any or all Pfizer Targets pursuant to Section 9.4 (each, a “Terminated Target”): 

(a) all work under the applicable Research Plan with respect to each Terminated Target will cease; 

(b) all licenses granted to Pfizer with respect to such Terminated Target and any Pfizer Licensed Product Targeting such Terminated Target
(each, a “Terminated Pfizer Licensed Product”), including under Section 4.1, will continue and become irrevocable and perpetual, and Pfizer will have no further obligations to Cellectis under this Agreement with respect to any
such Terminated Target or Terminated Pfizer Licensed Product (including no further obligation to pay Milestone Payments) other than (i) those obligations that expressly survive termination in accordance with Section 9.9 and (ii) an
obligation to pay royalties with respect to Net Sales of Terminated Pfizer Licensed Products in accordance with the terms and conditions of this Agreement, in an amount equal to [***] of the amount that would otherwise have been payable under this
Agreement; 
 (c) If Pfizer terminates this Agreement in its entirety pursuant to Section 9.4, or if Pfizer terminates this Agreement
in its entirety pursuant 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

56 

 to Section 9.5: (i) all licenses granted by Pfizer to Cellectis under Sections 4.1.1
an 4.2.2 will terminate, (ii) Pfizer will have no further obligations to Cellectis under this Agreement other than those obligations that expressly survive termination in accordance with Section 9.9, and (iii) any material or
Confidential Information provided Pfizer to Cellectis in the course of the performance of this Agreement will be returned or destroyed as directed in writing by Pfizer; 

(d) Pfizer will have the right to offset, against any payment owing to Cellectis under subparagraph (b) above, any damages found or
agreed by the Parties to be owed by Cellectis to Pfizer; 
 (e) Cellectis will remain entitled to receive payments that accrued before the
effective date of such termination; 
 (f) nothing in this Section 9.7.1 will limit any other remedy Pfizer may have for
Cellectis’ breach of this Agreement; and 
 (g) the rights and obligations of the Parties with respect to all Pfizer Targets other than
any such Terminated Target will remain in full force and effect. 
 9.7.3 Effect of Termination by Pfizer on Insolvency of Cellectis.
If Pfizer terminates this Agreement pursuant to Section 9.6: 
 (a) Cellectis will have no further obligation to perform any of its
obligations under this Agreement (including Cellectis’ obligations under the Research Program) other than those obligations that expressly survive termination of this Agreement in accordance with Sections 9.7.2(b) and 9.9; 

(b) all licenses granted to Pfizer, including under Section 4.1, will continue and become, subject only to the royalty obligation set
forth below in this Section 9.7.2(b), irrevocable and perpetual, and Pfizer will have no further obligations to Cellectis under this Agreement (including no further obligation to pay Milestone Payments) other than (i) those obligations
that expressly survive termination in accordance with Section 9.9 and (ii) an obligation to pay royalties with respect to Net Sales of Pfizer Licensed Products in accordance with the terms and conditions of this Agreement; 

(c) Cellectis will remain entitled to receive payments that accrued before the effective date of such termination; 

(d) Pfizer will have the right to offset, against any payment owing to Cellectis under subparagraph (b) above, any damages found or
agreed by the Parties to be owed by Cellectis to Pfizer; and 

  
 57 

 (e) nothing in this Section 9.7.2 will limit any other remedy Pfizer may have for
Cellectis’ breach of this Agreement. 
 9.7.4 Effect of Termination by Cellectis for Cause or by Pfizer for Convenience. 

(a) If Cellectis terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.4, or if Pfizer terminates this
Agreement with respect to any Pfizer Target pursuant to Section 9.5, then (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2 and 4.1.3 with respect to any such Pfizer Target, (ii) any Pfizer Licensed Product
Targeting such Pfizer Target will terminate, and (iii) any material or Confidential Information provided by Cellectis to Pfizer in the course of the performance of this Agreement will be returned or destroyed as directed in writing by
Cellectis. 
 (b) If Cellectis terminates this Agreement in its entirety pursuant to Section 9.4, or if Pfizer terminates this
Agreement in its entirety pursuant to Section 9.5: (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2 and 4.1.3 will terminate, (ii) Cellectis will have no further obligations to Pfizer under this Agreement other
than those obligations that expressly survive termination in accordance with Section 9.9, (iii) all rights and licenses granted by Pfizer to Cellectis pursuant to Section 4.2 will continue, (iv) Pfizer’s right of first refusal
set forth in Section 3.9 will continue to the extent that such Cellectis Product is Covered by Licensed Pfizer Intellectual Property and (v) any material or Confidential Information provided by Cellectis to Pfizer in the course of the
performance of this Agreement will be returned or destroyed as directed in writing by Cellectis. 
 (c) In the event that Cellectis
terminates this Agreement for cause pursuant to Section 9.4 or Pfizer terminates this Agreement without cause pursuant to Section 9.5 with respect to a Licensed Pfizer Product Targeting a Pfizer Target, on Cellectis’ written notice to
Pfizer, which notice may only be delivered within [***] following the effective date of such termination, unless such termination is related to material concerns regarding the safety of the Compound(s) or Product(s), the Parties will negotiate in
good faith for a period not to exceed [***] following the effective date of termination regarding: 
 (i) the grant by Pfizer to Cellectis
of a royalty-bearing, non-exclusive license under the Applicable Pfizer Technology permitting Cellectis to continue to Develop, Commercialize and Manufacture any Product under Development or Commercialization
by Pfizer under this Agreement at the time of 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

58 

 
termination, in the form in which such Product then exists (a “Continuation Product”); and 

(ii) the related transfer to Cellectis of development data and regulatory filings specifically relating to such Continuation Product or the
granting to Cellectis of rights of reference with respect to such data and filings. 
 (d) Neither Party will be obligated to enter into any
transaction described in Section 9.7.4(c) and neither Party will have any liability to the other for failure to do so. 
 (e) For the
avoidance of doubt, if Cellectis terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.4, or if Pfizer terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.5, in each case including
all Pfizer Targets in the event that this Agreement is terminated in its entirety, any such Pfizer Target will no longer be considered to be a Pfizer Target for the purpose of this Agreement. 

9.7.5 Satisfaction of Obligations During Notice Period. During the period from providing a notice of termination through the termination
of the Agreement, the Parties will continue to perform their obligations under this Agreement. 
 9.7.6 Pending Dispute Resolution. If
a Party gives notice of termination under Section 9.4 and the other Party disputes whether such notice was proper, then the issue of whether this Agreement has been terminated will be resolved in accordance with Section 11.10 and this
Agreement will remain in effect pending the resolution of such dispute. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination will be effective immediately. If as a result
of such dispute resolution process it is determined that the notice of termination was improper, then no termination will have occurred and this Agreement will remain in effect. 

9.8 Disposition of Inventories of Products. Following termination of this Agreement with respect to one or more Pfizer Targets, Pfizer,
its Affiliates and its Sublicensees will have the right to continue to sell their existing inventories of Pfizer Licensed Product(s) Targeting such Pfizer Targets that have received Regulatory Approval prior to such termination for a period not to
exceed [***] after the effective date of such termination or expiration and Pfizer will pay any royalties payable in connection with such sales in accordance with Section 5.5. 

9.9 Survival of Certain Obligations. Expiration or termination of this Agreement will not relieve the Parties of any obligation that
accrued before such expiration or termination. The following provisions will survive expiration or termination of this Agreement: Sections 1 (Definitions); 5.6.2 to 5.6.6 (Reports and Payments); 5.7 (Maintenance and Audit Rights); 7
(Confidentiality); 8 (Representations and Warranties); 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

59 

 
9.3 to 9.9 (Effect of Termination); 10 (Limitation on liabilities) and 11 (Miscellaneous) . In addition, any Section that is referred to in the above listed Sections shall survive solely for the
interpretation or enforcement of the listed Sections. 
 9.10 Right to Termination of Research Project(s) or Research Program by Pfizer
upon Change of Control of Cellectis. If a Change of Control of Cellectis is consummated during the Research Term, Pfizer will have the right to terminate any Research Project or the Research Program in its entirety, upon written notice to
Cellectis within [***] after consummation of such Change of Control of Cellectis. Such termination of any Research Project or the Research Program (a) will not constitute termination of this Agreement, (b) will not affect the Parties’
rights and obligations under this Agreement other than those relating to such Research Project or the Research Program and (c) will not relieve either Party of any obligation that arose prior to such termination. Following any such termination
of any Research Project or the Research Program, as applicable, Pfizer will have no further funding obligation under Article 2 or Section 5.3 with respect to such Research Project or the Research Program, as applicable, other than that which
may have accrued prior to such termination. In addition, if, at any time following a Change of Control of Cellectis consummated during the Research Term, Cellectis or its successor fails to perform its obligations under the Research Program in any
material respect, then, effective upon written notice to Cellectis or its successor, Pfizer will have the right to terminate any Research Project or the Research Program in its entirety pursuant to this Section 9.10, and Cellectis will promptly
transfer to Pfizer, at no additional cost to Pfizer, such Cellectis Know-How and Cellectis Improvements, including related materials, as is necessary for Pfizer to complete all activities contemplated under
such Research Project or the Research Program, as applicable. For the avoidance of doubt, in the event that Pfizer terminates a Research Project or the Research Program in accordance with this Section 9.10, such termination will not be deemed
to be a termination for cause under Section 9.4 or a termination for convenience under Section 9.5, and the only effects of such termination are as set forth in this Section 9.10. Notwithstanding any provision of this Agreement to the
contrary, nothing in this Section 9.10 will limit, or preclude Pfizer from seeking, any other remedy Pfizer may have for Cellectis’ breach of this Agreement; provided that Pfizer may not seek remedy under both this Section 9.10 and
Section 9.4 with respect to the same performance failure by Cellectis or its successor. 
 9.11 Bankruptcy. All rights and
licenses granted under or pursuant to this Agreement by Cellectis are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined
under Section 101 of the U.S. Bankruptcy Code. The Parties agree that Pfizer, as licensee of intellectual property under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The
Parties further agree that in the event of a rejection of this Agreement by Cellectis in any bankruptcy proceeding by or against Cellectis under the U.S. Bankruptcy Code, (i) Pfizer will be entitled to a complete duplicate of (or complete
access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in Pfizer’s possession, 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

60 

 will be promptly delivered to it upon Pfizer’s written request therefor, and
(ii) Cellectis will not interfere with Pfizer’s rights to intellectual property and all embodiments of intellectual property, and will assist and not interfere with Pfizer in obtaining intellectual property and all embodiments of
intellectual property from another entity. The term “embodiments” of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and products
embodying intellectual property, Pfizer Licensed Products, filings with Regulatory Authorities and related rights, and Cellectis Technology. 
 10.
LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE. 
 10.1 No Consequential Damages. Except with respect to liability arising
from a breach of Article 7, from any willful misconduct or intentionally wrongful act, or to the extent such Party may be required to provide indemnification under this Article 10, in no event will either Party, its Affiliates, its Sublicensees or
any of its, its Affiliates’ or its Sublicensees’ respective Representatives be liable under this Agreement for any special, indirect, incidental, consequential or punitive damages, whether in contract, warranty, tort, negligence, strict
liability or otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates or Representatives. Without limiting the generality of the foregoing, “consequential damages” will be deemed
to include, and neither Party will be liable to the other Party or any of such other Party’s Affiliates, Representatives or stockholders for, any damages based on or measured by loss of projected or speculative future sales of the Pfizer
Licensed Products, any Milestone Payment due upon any unachieved event under Section 5.3, any unearned royalties under Section 5.4 or any other unearned, speculative or otherwise contingent payments provided for in this Agreement. 

10.2 Indemnification by Pfizer. Pfizer will indemnify, defend and hold harmless Cellectis, its Affiliates, their sublicensees,
contractors, subcontractors and distributors and each of its and their respective employees, officers, directors and agents (each, a “Cellectis Indemnified Party”) from and against any and all liability, loss, damage, expense
(including reasonable attorneys’ fees and expenses) and cost (collectively, a “Liability”) that the Cellectis Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

61 

 10.3 Indemnification by Cellectis. Cellectis will indemnify, defend and hold harmless
Pfizer, its Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and against any and all Liabilities that the
Pfizer Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 
 [***] 

10.4 Procedure. 
 10.4.1
Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any
governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”) is entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party will promptly notify
the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party
from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby. 
 10.4.2
Control. Subject to Pfizer’s right to control any actions described in Section 6.2 (even where Cellectis is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within
ten (10) Business Days after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

62 

 sufficient financial resources, in the reasonable judgment of the Indemnified Party, to
satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the
Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the “Litigation
Conditions”). Within ten (10) Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party will give notice to the Indemnifying
Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as
such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the
Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will cooperate, and will cause its Affiliates and agents to
cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or
appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s intent to defend any
Third Party Claim within ten (10) Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party’s
expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as
the case may be, will have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that
the other Party is defending as provided in this Agreement. 
 10.4.3 Settlement. The Indemnifying Party will not, without the prior
written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole and exclusive right to settle any Third Party
Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but will not have the right to settle such Third
Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not make any admission of liability in respect of
any Third Party Claim without the prior written consent of the other Party, and the Indemnified Party 

  
 63 

 
will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

10.5 Insurance. Each Party will obtain and maintain, during the Term, commercial general liability insurance, including products
liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification obligations under Section 10.2 or
Section 10.3, as applicable, in each case with limits of not less than [***] per occurrence and in the aggregate. 
 11. MISCELLANEOUS. 

11.1 Other Cellectis Targets. For sake of clarity, except as set forth in Section 2.1.4
(CAR-T Exclusivity), 2.3 (Selection of Other Cellectis Targets), 2.4 (Targets Selection Process), and 2.8 (Right of Negotiation) Other Cellectis Targets are outside the scope of this Agreement. 

11.2 Assignment. Either Party may not assign this Agreement or any interest hereunder without the prior written consent of the other,
which consent will not be unreasonably withheld or delayed., except that this Agreement may be assigned as follows: (a) a Party may assign its rights and obligations under this Agreement by way of sale of itself or the sale of the portion of
its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest and (b) a Party may assign its rights and obligations under this Agreement to any of its Affiliates. This Agreement will be
binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of
this Agreement. Any assignment not in accordance with this Section 11.2 will be void. 
 11.3 Further Actions. Each Party agrees
to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

11.4 Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to the extent that such
performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and the
nonperforming Party takes Commercially Reasonable Efforts to resume performance. For purposes of this Agreement, “force majeure” will include conditions beyond the control of the Parties, including an act of God, voluntary or
involuntary compliance with any Applicable Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, or
destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 
 11.5 Notices. Any notice or
notification required or permitted to be provided pursuant to the terms and conditions of this Agreement (including any notice of force majeure, 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

64 

 breach, termination, change of address, etc.) will be in writing and will be deemed given
upon receipt if delivered personally or by facsimile transmission (receipt verified), five days after deposited in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by
overnight delivery using a nationally recognized express courier service and specifying next Business Day delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a
Party as will be specified by like notice, provided, however, that notices of a change of address will be effective only upon receipt thereof): 

All correspondence to Pfizer will be addressed as follows: 

Pfizer Inc. 
 Notices: R&D
Business Development 
 235 East 42nd Street 

New York, NY 10017 
 Attention:
Attn.: R&DBD Contract Notice 
 [***] 

with a copy to: 
 Pfizer Inc. 

Notices: Pfizer Legal Division 

235 East 42nd Street 
 New York,
NY 10017 
 Attn.: Chief Counsel, R&D 

[***] 
 All correspondence to
Cellectis will be addressed as follows: 
 Cellectis 

8, rue de la Croix Jarry 
 75013
Paris 
 Attn.: Chief Executive Officer 

Fax.: +33 1 81 69 16 03 
 with a
copy to: 
 Cellectis 
 8, rue
de la Croix Jarry 
 75013 Paris 

Attn.: General Counsel 
 Fax.: +33
1 81 69 16 03 
 11.6 Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or
effective unless made in writing and signed by a duly authorized officer of each Party. 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

65 

 11.7 Waiver. No provision of this Agreement will be waived by any act, omission or
knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision
hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

11.8 Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable,
the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any
such event, this Agreement will be construed as if such clause or portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as
expressed in this Agreement to the fullest extent permitted by Applicable Law. 
 11.9 Descriptive Headings. The descriptive headings
of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

11.10 Dispute Resolution. If any dispute or disagreement arises between Pfizer and Cellectis in respect of this Agreement, they will
follow the following procedures in an attempt to resolve the dispute or disagreement: 
 11.10.1 The Party claiming that such a dispute
exists will give notice in writing (a “Notice of Dispute”) to the other Party of the nature of the dispute. 
 11.10.2
Within [***] of receipt of a Notice of Dispute, the Pfizer Alliance Manager and the Cellectis Alliance Manager will meet in person or by teleconference and exchange written summaries reflecting, in reasonable detail, the nature and extent of the
dispute, and at this meeting they will use their reasonable endeavors to resolve the dispute. 
 11.10.3 If the Alliance Managers are unable
to resolve the dispute during the meeting described in Section 11.10.2 or if for any reason such meeting does not take place within the period specified in Section 11.10.2, then the dispute will be referred to the JRC which will meet no
later than [***] following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the dispute. 
 11.10.4 If
the JRC is unable to resolve the dispute during the meeting described in Section 11.10.3 or if for any reason such meeting does not take place within the period specified in Section 11.10.3, then the head of Rinat and the Chief Executive
Office of Cellectis will meet at a mutually agreed-upon time and location for the purpose of resolving such dispute. 
 11.10.5 If, within a
further period of [***], or if in any event within [***] of initial receipt of the Notice of Dispute, the dispute has 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

66 

 
not been resolved, or if, for any reason, the meeting described in Section 11.10.4 has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that,
subject to Section 11.11 below, either Party may initiate litigation to resolve the dispute. 
 11.11 Election of Resolution
Process. Notwithstanding any provision of Section 11.10 to the contrary, if (i) either Party raises any allegation or claim of Misuse (each, a “Misuse Allegation”) and (ii) the Parties are unable to resolve such
Misuse Allegation pursuant to the dispute escalation process described in Sections 11.10.1 through 11.10.5 (the “Escalation Process”), then, following completion of the Escalation Process, the Parties may mutually agree to have such
Misuse Allegation resolved pursuant to the terms of Section 11.12 (the “Arbitration Process”). If the Parties fail to agree on use of arbitration pursuant to Section 11.12 in a timely manner (not to exceed [***]), then the
Parties will be deemed to have elected to have such Misuse Allegation resolved through litigation. 
 11.12 Arbitration Process. If
the Parties mutually elect to resolve any Misuse Allegation pursuant to the Arbitration Process, then such Misuse Allegation will be referred to and finally resolved by binding arbitration in accordance with the Commercial Rules and Procedures (the
“Rules”) of the International Chamber of Commerce (“ICC”), by an arbitral tribunal composed of three arbitrators, all of whom will have relevant experience in pharmaceutical industry, appointed by agreement of the
Parties in accordance with the Rules. If, at the time of the arbitration, the Parties agree in writing to submit the dispute to a single arbitrator, said single arbitrator will (1) have relevant experience in pharmaceutical industry and
(2) be appointed by agreement of the Parties, or, failing such agreement, by ICC in accordance with the Rules. The foregoing arbitration proceedings may be commenced by either Party by written notice to the other Party. Unless otherwise agreed
by the Parties hereto, all such arbitration proceedings will be held in London, England, provided that proceedings may be conducted by telephone conference call with the consent of both Parties and the arbitrator(s). All arbitration proceedings will
be conducted in the English language. 
 11.12.1 Limited Discovery. Documentary discovery may be conducted at the discretion of the
arbitrator(s), provided that any such discovery will (a) be limited to documents directly relating to the Misuse Allegation, (b) be conducted pursuant to document discovery procedures as set forth under the laws of the State of New York,
U.S.A., (c) be conducted subject to the schedule stipulated by the Parties, or in the absence of stipulation, the schedule ordered by the arbitrator(s), and (d) not require either Party, its Affiliates or their respective employees, officers,
directors or agents to be subject to deposition. Notwithstanding any provision of this Section 11.12.1 to the contrary, all discovery must be completed within sixty (60) days of the notice of commencement of arbitration proceedings. 

11.12.2 Awards and Fees. The arbitrator(s) may only consider awards of direct monetary damages and will not under any circumstances have
the authority to grant (a) injunctive relief, (b) equitable relief, (c) orders for specific performance, (d) punitive damages or (e) consequential damages as described in 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

67 

 
Section 10.1. The allocation of expenses of the arbitration, including reasonable attorney’s fees, will be determined by the arbitrator(s), or, in the absence of such determination,
each Party will pay its own expenses. 
 11.12.3 Rulings. All arbitration proceedings must be completed within 180 days of the notice
of commencement of arbitration proceedings. The Parties hereby agree that, subject to the provisions of this Section 11.12.3, the arbitrator(s) has authority to issue rulings and orders regarding all procedural and evidentiary matters that the
arbitrator(s) deem reasonable and necessary with or without petition therefore by the Parties as well as the final ruling and judgment. Rulings will be issued by written order summarizing the arbitration proceedings no more than 30 days after the
final submissions of the Parties. All rulings by the arbitrator(s) will be final and non-appealable to any court except in circumstances where such rulings do not comply with the terms of Section 11.12.

 11.12.4 Enforcement of Rulings by Courts of Competent Jurisdiction. Any ruling issued by the arbitrator(s) pursuant to
Section 11.12 may be enforced, to the extent that such ruling complies with the provisions of Section 11.12, in any court having jurisdiction over any of the Parties or any of their respective assets. 

11.12.5 Confidentiality. All activities undertaken by the arbitrator(s) or the Parties pursuant to this Section 11.12 will be
conducted subject to obligations of confidentiality no less restrictive than those set forth in Section 7. Further, the Parties acknowledge and agree that their respective conduct during the course of the arbitration and their respective
statements and all information exchanged in connection with the arbitration is Confidential Information under this Agreement and subject to the provisions of Section 7. 

11.12.6 Unauthorized Disclosure of Confidential Information to Third Parties. Notwithstanding any provision of this Agreement to the
contrary (i) the provisions of this Section 11.12 will not apply to Pfizer’s disclosure of Cellectis Confidential Information to any Third Party in violation of Section 7 and (ii) Cellectis reserves its rights under
Section 11.10 to immediately initiate litigation seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under Section 7 with respect to any such
unauthorized disclosure. 
 11.13 Governing Law. This Agreement, and all claims arising under or in connection therewith, will be
governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof. 

11.14 Consent to Jurisdiction. Each Party to this Agreement, by its execution hereof, (a) hereby irrevocably submits to the
exclusive jurisdiction of the United Kingdom for the purpose of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof, (b) hereby
waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not 

  
 68 

 subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred to any court other than one of the above-named courts, or
should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees
not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other than one of the above-named
courts whether on the grounds of inconvenient forum or otherwise. 
 11.15 Entire Agreement. This Agreement, including its Exhibits
and Schedules, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written,
between the Parties respecting the subject matter hereof and thereof, including the Confidentiality Agreement which is hereby terminated effective as of the Effective Date, provided that such Confidentiality Agreement will continue to govern the
treatment of Confidential Information disclosed by the Parties prior to the Effective Date in accordance with its terms. 
 11.16
Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of
their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or
to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 
 11.17
Pfizer Anti-Bribery and Anti-Corruption Practices. Throughout the term of this Agreement, Cellectis, its Affiliates and Subcontractors must comply with the Anti-Bribery and Anti-Corruption provisions set forth in Attachment 11.17 hereto. 

11.18 Counterparts. This Agreement may be executed in two counterparts, each of which will be an original and both of which will
constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which will be binding when received by the applicable Party. 

11.19 No Third Party Rights or Obligations. No provision of this Agreement will be deemed or construed in any way to result in the
creation of any rights or obligation in any Person not a Party to this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer will
remain liable hereunder for the performance by any such Affiliates of any such obligations. 

  
 69 

 [The remainder of this page has been intentionally left blank. The signature page
follows.] 

  
 70 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. 
  

									
	PFIZER	  		  	CELLECTIS SA
					
	By:	 	 /s/ G.M. Dolsten
	  		  	By:	 	 /s/ Andre Choulika

	Name:	 	G.M. Dolsten	  		  	Name:	 	Andre Choulika
	Title:	 	President of RD	  		  	Title:	 	CEO

 ATTACHMENT 11.17 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRACTICES 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 EXHIBIT 1 TO ATTACHMENT 11.17 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRINCIPLES 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 1.52: Expected Subcontractors 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 2.6.1: Research Plan 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Appendix A: 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Appendix B: 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Appendix C: 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Appendix D: 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.1: In Licensed Patent Right comprised in the Cellectis Technology 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.3: Cellectis Patent Rights 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.4 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.8 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.9 

[***] 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 8.2.10: Disclosed Third Party Agreement 

[***]  

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 

 EXECUTION COPY 

AMENDMENT 
 THIS
AMENDMENT (“Amendment”) is made this 1st day of December, 2016 by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having
a place of business at 235 East 42nd Street, New York, New York 10017 United States (“Pfizer”), and Cellectis SA, a corporation organized and existing under the laws of France and
having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). 
 WHEREAS, Pfizer and Cellectis are
Parties to the Research Collaboration and License Agreement dated June 17, 2014 (as amended from time to time, the “Pfizer Collaboration Agreement”); 

WHEREAS, in furtherance of, and as part of, the transactions contemplated by the Pfizer Collaboration Agreement, subject to the terms and
conditions set forth in this Amendment, Cellectis desires to clarify the grant of certain rights to Pfizer; 
 WHEREAS, pursuant to the
Servier Agreement (as defined in the Pfizer Collaboration Agreement), Cellectis granted certain exclusive patent rights to Servier on the terms set forth therein in respect of, among other things, the Other Products in the Other Field in the Other
Territory; 
 WHEREAS, in furtherance of, and as part of, the transactions contemplated by the Servier Agreement and pursuant to the terms
set forth therein, Servier has requested that Cellectis license certain patent rights to Pfizer in respect of the Other Products in the Other Field in the Other Territory; and 

WHEREAS, the parties desire to amend the Pfizer Collaboration Agreement as set forth below. 

NOW, THEREFORE, for valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 

 

	1.	 Section 1 is amended to include the following definitions: 

1.88 “Other Field” means anti-tumor adoptive immunotherapy, together with any additional fields as amended from time to time by
Cellectis at the written direction of Servier pursuant to Section 4.3(b) of the Servier Agreement. 
 1.89 “Other Products”
means, as of the Effective Date, UCART19 [***], corresponding to an allogeneic anti-tumor adoptive T-cell expressing a single chain chimeric antigen receptor (CAR) directed against [***] target, and including
specific attributes, as initially developed by Cellectis as per the Servier Agreement, and that are initially licensed by Cellectis to Servier as per the Servier Agreement together with any additional allogeneic anti-tumor adoptive T-cell CARs that bind to [***] as may be optioned by Servier from Cellectis under the Servier Agreement, 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

 together with any additional products as amended from time to time by Cellectis at the
written direction of Servier pursuant to Section 4.3(b) of the Servier Agreement. 
 1.90 “Other Territory” means the United
States of America together with any additional territories as amended from time to time by Cellectis at the written direction of Servier pursuant to Section 4.3(b) of the Servier Agreement. 

1.123 “Servier” means Les Laboratoires Servier, a corporation organized and existing under the laws of France and having a place of
business located at 50 rue Carnot, 92150 Suresnes, France. 
 The remaining definitions will be renumbered in alphabetical order as necessary. 

 

	2.	 Section 4.1.2 of the Pfizer Collaboration Agreement is replaced in its entirety with the following:

 4.1.2 [***] Patent Rights. 

(a) Subject to the terms and conditions of this Agreement on a Pfizer
Target-by-Pfizer Target basis and effective on the Target Designation Date for such Pfizer Target, Cellectis hereby grants to Pfizer and its Affiliates the right to use
the [***] engineered by Cellectis pursuant to this Agreement to Develop Pfizer Licensed Products until the filing of an IND for each Pfizer Licensed Product, in the Field. 

(b) Subject to the terms and conditions of this Agreement on an Other
Product-by-Other Product basis and effective as of October 30, 2015 (or such later date as such Other Product is included hereunder pursuant to Section 4.3(b)
of the Servier Agreement), Cellectis hereby grants to Pfizer and its Affiliates the right to use the [***] engineered by Cellectis pursuant to the Servier Agreement to Develop Other Products, and Cellectis shall further have the obligation to grant
the rights set forth in this Section 4.l.2(b) to subcontractors as directed by Pfizer pursuant to Section 4.l.5(b) herein, until the filing of an IND for each Other Product, in the Other Field. 

(c) Subject to the terms and conditions of this Agreement, on a Pfizer
Target-by-Pfizer Target basis and effective upon the filing of an IND for each individual Pfizer Licensed Product developed under 4.1.2(a), Cellectis hereby grants to
Pfizer and its Affiliates an exclusive (even as to Cellectis) license under the [***] Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and
Commercialize such Pfizer Licensed Product in the Field in the Territory, with the right to sublicense as provided in Section 4.1.3. Notwithstanding the foregoing, Pfizer hereby acknowledges and agrees that Cellectis shall have the right and
obligation to grant licenses and rights to a Third Party as set forth in Section 4.l5(b) and Pfizer’s license and other rights under the [***] Patent Rights shall be limited accordingly so long as any such agreement remains in effect with
such Third Party. For the sake of clarity, the license granted to Pfizer by Cellectis herein does not 

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
 2 

 give Pfizer the right (i) to [***] or (ii) sublicense the [***] Patent Rights
pursuant to Section 4.1.4, provided however that Pfizer may sublicense pursuant to Section 4.1.4 solely in relation to a transaction involving, with respect to all [***] Patent Rights, only the [***] Patent Rights owned by Cellectis or
owned by University of Minnesota. 
 (d) Subject to the terms and conditions of this Agreement, on an Other Product-by-Other Product basis and effective upon the filing of an IND for each individual Other Product developed under 4.1.2(b), Cellectis hereby grants to Pfizer and its Affiliates an exclusive (even as to
Cellectis) license under the [***] Patent Rights, to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize such Other Product in the Other Field in the
Other Territory, and Cellectis shall further have the obligation to grant the licenses and rights set forth in this Section 4.1.2(d) to subcontractors as directed by Pfizer pursuant to Section 4.1.5(b) herein. For the sake of clarity, the
license granted to Pfizer by Cellectis herein does not give Pfizer the right (i) to [***] or (ii) sublicense the [***] Patent Rights pursuant to Section 4.1.4, provided however that Pfizer may sublicense pursuant to Section 4.1.4
solely in relation to a transaction involving, with respect to all [***] Patent Rights, only the [***] Patent Rights owned by Cellectis or owned by University of Minnesota. 

(e) In accordance with Section 4.l.5(b) of this Agreement, Pfizer has directed Cellectis to grant certain rights to Servier previously
granted to Pfizer pursuant to Sections 4.l.2(a) and (c) herein. Pfizer hereby consents to the license granted by Cellectis to Servier pursuant to the Servier Agreement, as amended. The parties acknowledge and agree that any rights or licenses
that have been granted to Servier at Pfizer’s request (including any expansions of such rights or licenses, pursuant to this Agreement, that Pfizer directs Cellectis in writing to grant to Servier), or that may hereafter be granted by Cellectis
to Servier, a subcontractor as directed by Servier, or a Third Party at the request of Pfizer, are rights or licenses that were provided to Pfizer pursuant to this Agreement in accordance with the broad collaboration and development activities
contemplated hereunder, and therefore Cellectis has already received (or, in the future and in accordance with the terms of this Agreement, will have the right to receive) compensation that Cellectis and Pfizer have determined is fair and equitable
and that Cellectis shall therefore not have the right to any additional payments or compensation from Servier, Pfizer or any other person or entity in connection with the foregoing. Without limiting the foregoing, the parties agree and acknowledge
that all consideration paid or to be paid, whether one-time payments, milestone payments, royalty payments or otherwise, to Cellectis under the Servier Agreement or this Agreement shall not be reduced or
otherwise modified or amended because of the license granted to Servier or other parties as contemplated hereby. 
  

	3.	 Section 4.1.5 of the Pfizer Collaboration Agreement is replaced in its entirety with the following:

  

	 	(a)	 Direct License to Affiliates. Pfizer may at any time request and authorize Cellectis

  
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
 3 

	 	
to grant licenses directly to Affiliates of Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, Cellectis will enter
into and sign a separate direct license agreement with such designated Affiliate of Pfizer. All such direct license agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by
the laws and regulations in the country in which the direct license will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this
Agreement to the terms of this Agreement as set forth on the Effective Date. In countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements will not become
binding between the parties thereto until such approval or registration is granted, which approval or registration will be obtained by Pfizer. All costs of making such direct license agreement(s), including Cellectis’ reasonable attorneys’
fees, under this Section 4.1.4 will be borne by Pfizer. Cellectis may provide a copy of any such license or similar agreements (and this Agreement) to any of its direct or indirect licensors to the extent required to comply with the terms of
any license agreement to which Cellectis is a party from time to time. 

  

	 	(b)	 Direct License to Third Parties. Pfizer may at any time request and authorize Cellectis to grant the
rights and licenses set forth in Sections 4.l.2(a), 4.1.2(b), 4.l.2(c) and 4.l.2(d) of this Agreement directly to third parties by giving written notice designating to which Third Party such direct right or license is to be granted. Upon receipt of
any such notice, Cellectis will enter into and sign a separate direct license or similar agreement with such designated Third Party, which, to the extent involving [***] Patent Rights licensed to Cellectis by Life Technologies Corporation, must
include a license in respect of all of the [***] Patent Rights. All such direct license or similar agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and
regulations in the country in which the direct license or right will be exercised. Cellectis may provide a copy of any such license or similar agreements to any of its direct or indirect licensors to the extent required to comply with the terms of
any license agreement to which Cellectis is a party from time to time. The parties further agree and acknowledge that no additional consideration would be due to Cellectis from Pfizer or such Third Party in respect of the grant of any such license
or similar right, and the grant of any such license or similar right shall limit Pfizer’s license and other rights accordingly so long as any such agreement remains in effect with such Third Party. The parties acknowledge and agree that any
rights or licenses that may hereafter be granted by Cellectis at the request of Pfizer as contemplated by the immediately preceding sentence are rights or licenses that were previously provided to Pfizer pursuant to this Agreement in accordance with
the broad collaboration and development activities contemplated by such agreement, and therefore Cellectis has already received (or, in the future and in accordance with the terms of this Agreement, will have the right to receive) compensation that
Cellectis and Pfizer have determined is fair and equitable and that Cellectis shall therefore not have the right to any additional payments or compensation from Pfizer or any other person or entity in connection with the foregoing. The parties
further 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 4 

	 	
agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license or similar agreements and this Agreement to the terms of this Agreement. In
countries where the validity of such direct license or similar agreements requires prior governmental approval or registration, such direct license or similar agreements will not become binding between the parties thereto until such approval or
registration is granted, which approval or registration will be obtained by Pfizer or the Third Party, as applicable. 

  

	4.	 Sections 9.7.4(a) and (b) of the Pfizer Collaboration Agreement are replaced in their entirety with the
following: 

  

	 	(a)	 If Cellectis terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.4, or if
Pfizer terminates this Agreement with respect to any Pfizer Target pursuant to Section 9.5, then (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2 and 4.1.3 with respect to any such Pfizer Target will terminate,
(ii) any Pfizer Licensed Product Targeting such Pfizer Target will terminate, and (iii) any material or Confidential Information provided by Cellectis to Pfizer in the course of the performance of this Agreement will be returned or
destroyed as directed by Cellectis. 

  

	 	(b)	 If Cellectis terminates this Agreement in its entirety pursuant to Section 9.4, or if Pfizer terminates
this Agreement in its entirety pursuant to Section 9.5: (i) all licenses granted by Cellectis to Pfizer under Sections 4.1.1, 4.1.2(a), 4.1.2(c) and 4.1.3 will terminate, (ii) all rights and licenses granted by Cellectis to Pfizer pursuant
to Section 4.l.2(b) and 4.1.2(d), and all obligations to which the parties are bound hereunder with relation thereto, will continue in full force and effect, to the extent such rights and licenses were not previously or concurrently terminated
(including as set forth in Section 9.7.4(a) herein) and will subsequently terminate in accordance with the terms of the Servier Agreement, wherein such rights and licenses were initially granted to Servier, (iii) Cellectis will have no
further obligations to Pfizer under this Agreement other than those obligations that expressly survive termination in accordance with Section 9.9, (iv) all rights and licenses granted by Pfizer to Cellectis pursuant to Section 4.2
will continue, (v) Pfizer’s right of first refusal set forth in Section 3.9 will continue to the extent that such Cellectis Product is Covered by Licensed Pfizer Intellectual Property and (vi) any material or Confidential
Information provided by Cellectis to Pfizer in the course of the performance of this Agreement will be returned or destroyed as directed in writing by Cellectis. For the avoidance of doubt, all rights and licenses granted by Cellectis to Pfizer
pursuant to Section 4.1.2(b) and 4.1.2(d), and all obligations to which the parties are bound hereunder with relation thereto, will terminate immediately upon the earlier to occur of (i) termination or expiration of the of the license
granted by Cellectis to Servier in respect of the [***] Patent Rights for the Other Products pursuant to the Servier Agreement, or (ii) on an Other Product-by-Other
Product basis, termination or expiration of the license granted by Servier to Pfizer in respect of an Other Product pursuant to the Exclusive License and Collaboration Agreement dated as of October 30, 2015 by and between Pfizer and Servier (as
amended from time to time). 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 5 

 Except as modified and amended herein, the terms and conditions of the Agreement shall
remain in full force and effect. The Agreement and this Amendment constitute the entire understanding between the Parties and supersedes all prior agreements, whether written or oral. No modification or amendment to the Agreement or Amendment shall
be valid unless in writing and signed by both Parties. 
 (remainder of page intentionally left blank) 

  
 6 

 IN WITNESS WHEREOF, the Parties hereby agree to the forgoing. 

 

			
	PFIZER, INC.
		
	By:	 	 /s/ John DeYoung

		 	Name: John DeYoung
		 	Title: Vice President
	
	CELLECTIS S.A.
		
	By:	 	 /s/ André Choulika

		 	Name: André Choulika
		 	Title: Chief Executive Officer

  
 7EX-10.8

 Exhibit 10.8 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED 
 BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE 

SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 406 
 OF THE SECURITIES ACT OF 1933,
AS AMENDED. 
 EXECUTION VERSION 

ASSET CONTRIBUTION AGREEMENT 

BY AND BETWEEN 
 PFIZER
INC. 
 AND 

ALLOGENE THERAPEUTICS, INC. 

Dated as of April 2, 2018 
  

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1 DEFINITIONS; CERTAIN RULES OF INTERPRETATION
	  	 	1	 
			
	 1.1
	 	 Definitions
	  	 	1	 
			
	 1.2
	 	 Rules of Interpretation
	  	 	19	 
		
	 ARTICLE 2 THE TRANSACTION AGREEMENT
	  	 	20	 
			
	 2.1
	 	 Purchased Assets
	  	 	20	 
			
	 2.2
	 	 Excluded Assets
	  	 	20	 
			
	 2.3
	 	 Assumed Liabilities
	  	 	21	 
			
	 2.4
	 	 Excluded Liabilities
	  	 	22	 
			
	 2.5
	 	 Non-Assignable Assets
	  	 	23	 
			
	 2.6
	 	 Shared Contracts
	  	 	24	 
		
	 ARTICLE 3 CONSIDERATION FOR TRANSFER
	  	 	24	 
			
	 3.1
	 	 Consideration
	  	 	24	 
			
	 3.2
	 	 Withholding Taxes
	  	 	24	 
		
	 ARTICLE 4 CLOSING AND CLOSING DELIVERIES
	  	 	25	 
			
	 4.1
	 	 Closing; Time and Place
	  	 	25	 
			
	 4.2
	 	 Deliveries by Pfizer Parties
	  	 	25	 
			
	 4.3
	 	 Deliveries by NewCo
	  	 	26	 
		
	 ARTICLE 5 MILESTONES, ROYALTIES AND OTHER FINANCIAL OBLIGATIONS
	  	 	27	 
			
	 5.1
	 	 Post-Closing Financial Obligations
	  	 	27	 
			
	 5.2
	 	 Diligence and Post-Closing Obligations
	  	 	32	 
		
	 ARTICLE 6 REPRESENTATIONS AND WARRANTIES OF PFIZER
	  	 	34	 
			
	 6.1
	 	 Organization
	  	 	34	 
			
	 6.2
	 	 Power and Authority Relative to this Agreement
	  	 	34	 
			
	 6.3
	 	 Consents; No Violation
	  	 	34	 
			
	 6.4
	 	 Permits
	  	 	35	 
			
	 6.5
	 	 Compliance with Laws
	  	 	35	 
			
	 6.6
	 	 Absence of Certain Changes
	  	 	36	 
			
	 6.7
	 	 Tax Matters
	  	 	37	 
			
	 6.8
	 	 Prospective Employees; Employee Benefits
	  	 	38	 
			
	 6.9
	 	 Intellectual Property
	  	 	40	 
			
	 6.10
	 	 Purchased Assets
	  	 	42	 

							
	 6.11
	 	 Investigations; Litigation
	  	 	43	 
			
	 6.12
	 	 Inventory
	  	 	43	 
			
	 6.13
	 	 Assigned Contracts
	  	 	43	 
			
	 6.14
	 	 Finders or Brokers
	  	 	44	 
			
	 6.15
	 	 Accredited Investor
	  	 	44	 
			
	 6.16
	 	 No Other Representations and Warranties
	  	 	44	 
		
	 ARTICLE 7 REPRESENTATIONS AND WARRANTIES OF NEWCO
	  	 	44	 
			
	 7.1
	 	 Organization
	  	 	44	 
			
	 7.2
	 	 Capitalization
	  	 	45	 
			
	 7.3
	 	 Subsidiaries
	  	 	46	 
			
	 7.4
	 	 Power and Authority Relative to this Agreement
	  	 	46	 
			
	 7.5
	 	 No Consent
	  	 	46	 
			
	 7.6
	 	 Investigations; Litigation
	  	 	47	 
			
	 7.7
	 	 Finders or Brokers
	  	 	47	 
			
	 7.8
	 	 Solvency
	  	 	47	 
			
	 7.9
	 	 Funding
	  	 	47	 
			
	 7.10
	 	 Valid Issuance of Shares
	  	 	48	 
			
	 7.11
	 	 Compliance with Other Instruments
	  	 	48	 
			
	 7.12
	 	 Agreements; Actions
	  	 	48	 
			
	 7.13
	 	 Certain Transactions
	  	 	49	 
			
	 7.14
	 	 Rights of Registration and Voting Rights
	  	 	49	 
			
	 7.15
	 	 Material Liabilities
	  	 	50	 
			
	 7.16
	 	 Changes
	  	 	50	 
			
	 7.17
	 	 Employee Matters
	  	 	51	 
			
	 7.18
	 	 Tax Returns and Payments
	  	 	52	 
			
	 7.19
	 	 Insurance
	  	 	52	 
			
	 7.20
	 	 Employee Agreements
	  	 	52	 
			
	 7.21
	 	 Permits
	  	 	53	 
			
	 7.22
	 	 Corporate Documents
	  	 	53	 
			
	 7.23
	 	 Foreign Corrupt Practices Act
	  	 	53	 
			
	 7.24
	 	 Data Privacy
	  	 	53	 
			
	 7.25
	 	 Non-Reliance
	  	 	54	 
		
	 ARTICLE 8 PRE-CLOSING COVENANTS
	  	 	54	 

  
 ii 

					
			
	 8.1
	 	 Conduct of the Purchased Programs Prior to Closing
	 	54
			
	 8.2
	 	 Access to Information
	 	56
			
	 8.3
	 	 Commercially Reasonable Efforts
	 	56
			
	 8.4
	 	 Consents
	 	57
			
	 8.5
	 	 Exclusive Dealing
	 	57
			
	 8.6
	 	 Financing
	 	58
			
	 8.7
	 	 Pre-Closing Cooperation
	 	58
			
	 8.8
	 	 Conduct of NewCo Prior to Closing
	 	58
		
	 ARTICLE 9 POST-CLOSING COVENANTS
	 	58
			
	 9.1
	 	 Cooperation
	 	58
			
	 9.2
	 	 Return of Assets; Transfer of Purchased Assets
	 	59
			
	 9.3
	 	 Records and Documents
	 	59
			
	 9.4
	 	 Bulk Sales Waiver
	 	60
			
	 9.5
	 	 Confidentiality
	 	60
			
	 9.6
	 	 Non-Solicitation of Employees
	 	60
			
	 9.7
	 	 Worker Notification Laws Matters
	 	63
			
	 9.8
	 	 [Reserved]
	 	63
			
	 9.9
	 	 Reporting of Pfizer Financial Information
	 	64
		
	 ARTICLE 10 EMPLOYEES
	 	65
			
	 10.1
	 	 Employees and Employee Benefits
	 	65
			
	 10.2
	 	 No Benefit to Employees Intended
	 	68
		
	 ARTICLE 11 CONDITIONS TO CLOSING
	 	68
			
	 11.1
	 	 Conditions to NewCo’s Obligation to Close
	 	68
			
	 11.2
	 	 Conditions to Pfizer’s Obligation to Close
	 	69
			
	 11.3
	 	 Conditions to Obligations of Each Party to Close
	 	69
		
	 ARTICLE 12 TAX MATTERS
	 	70
			
	 12.1
	 	 Allocation of Consideration
	 	70
			
	 12.2
	 	 Intended Tax Treatment; Cooperation; Allocation of Taxes
	 	70
			
	 12.3
	 	 Tax Contests
	 	72
		
	 ARTICLE 13 TERMINATION
	 	73
			
	 13.1
	 	 Termination of Agreement
	 	73
			
	 13.2
	 	 Effect of Termination
	 	73

  
 iii 

							
	 ARTICLE 14 INDEMNIFICATION
	 	 	74	 
			
	 14.1
	 	 Indemnification by Pfizer
	 	 	74	 
			
	 14.2
	 	 Indemnification by NewCo
	 	 	74	 
			
	 14.3
	 	 Time for Claims
	 	 	74	 
			
	 14.4
	 	 Procedures for Indemnification
	 	 	75	 
			
	 14.5
	 	 Limitations on Indemnification
	 	 	75	 
			
	 14.6
	 	 Third Party Contributors
	 	 	76	 
			
	 14.7
	 	 Duty to Mitigate
	 	 	76	 
			
	 14.8
	 	 Satisfaction by Equity Consideration; Set-off
	 	 	76	 
			
	 14.9
	 	 Qualifications
	 	 	77	 
			
	 14.10
	 	 Remedies Exclusive
	 	 	77	 
			
	 14.11
	 	 Remedies Cumulative
	 	 	77	 
		
	 ARTICLE 15 MISCELLANEOUS PROVISIONS
	 	 	77	 
			
	 15.1
	 	 Expenses
	 	 	78	 
			
	 15.2
	 	 Entire Agreement
	 	 	78	 
			
	 15.3
	 	 Amendment, Waivers and Consents
	 	 	78	 
			
	 15.4
	 	 Successors and Assigns
	 	 	78	 
			
	 15.5
	 	 Governing Law
	 	 	78	 
			
	 15.6
	 	 Jurisdiction; Waiver of Jury Trial
	 	 	79	 
			
	 15.7
	 	 Rules of Construction
	 	 	79	 
			
	 15.8
	 	 Severability
	 	 	79	 
			
	 15.9
	 	 Exhibits and Schedules
	 	 	79	 
			
	 15.10
	 	 Notices
	 	 	80	 
			
	 15.11
	 	 Rights of Parties
	 	 	81	 
			
	 15.12
	 	 Public Announcements
	 	 	81	 
			
	 15.13
	 	 Specific Performance
	 	 	81	 
			
	 15.14
	 	 Counterparts
	 	 	82	 

 EXHIBITS 
  

			
		
	 Exhibit A:
	  	List of Pfizer Subsidiaries
		
	 Exhibit B:
	  	General Assignment and Bill of Sale
		
	 Exhibit C:
	  	Patent Assignment
		
	 Exhibit D:
	  	Patent and Know-How License Agreement

  
 iv 

					
			
		 	Exhibit E:	  	Transition Services Agreement
			
		 	Exhibit F:	  	Investors’ Rights Agreement
			
		 	Exhibit G:	  	Equity Commitment Letters
			
		 	Exhibit H-1:	  	Preferred Stock Purchase Agreement
			
		 	Exhibit H-2:	  	Preferred Stock Purchase Agreement
			
		 	Exhibit I:	  	Right of First Refusal and Co-Sale Agreement
			
		 	Exhibit J:	  	Voting Agreement

  

  
 v 

 ASSET CONTRIBUTION AGREEMENT 

This Asset Contribution Agreement (this “Agreement”) is entered into as of April 2, 2018 (the “Effective
Date”), by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”). 

WHEREAS, Pfizer and the Pfizer Subsidiaries (the “Pfizer Parties”) are engaged in, among other things, the Purchased
Programs; 
 WHEREAS, NewCo desires to purchase from Pfizer, and Pfizer desires to sell to NewCo, certain assets related to the Purchased
Programs, and NewCo is willing to assume certain Liabilities related to the Purchased Programs, in each case upon the terms and conditions set forth herein; and 

WHEREAS, it is intended that the transactions contemplated by this Agreement, taken together with the transactions contemplated by the
Preferred Stock Purchase Agreement, shall be treated as an exchange described in Section 351 of the Internal Revenue Code of 1986, as amended (the “Code”). 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS; CERTAIN RULES OF INTERPRETATION 

1.1 Definitions. As used in this Agreement, the following terms shall have the meanings set forth or as referenced below: 

“409A Plan” shall have the meaning specified in Section 7.2(e). 

“Ablexis Agreement” shall mean that certain Consortium and License Agreement dated as of December 22, 2009, by and
between Aliva Biopharmaceuticals, Inc. and Pfizer, as amended from time to time. 
 “Ablexis Antibodies” shall mean
antibodies generated under the Ablexis Agreement in connection with any Purchased Assets. 
 “Affiliate” shall mean
(a) in the case of an individual, the individual’s spouse (or civil partner) and the members of the immediate family (which for purposes of this definition shall include only parents, siblings, children and spouses (or civil partners) of
the foregoing) of (i) the individual, (ii) the individual’s spouse (or civil partner) and (iii) any Entity that directly or indirectly, through one or more intermediaries, is controlled by, or is under common control with, any of
the foregoing individuals, or (b) in the case of an Entity, another Entity or a Person that directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, such Entity; provided
that, for the purposes of this definition, “control” 

 (including with correlative meanings, the terms “controlled by” and “under common
control with”), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such Person, whether through the ownership of voting
securities, by contract or otherwise. 
 “Agreement” shall have the meaning specified in the Preamble. 

“Allogeneic Product” shall mean a product for administration to humans, which embodies, incorporates or includes a CAR-T. 
 “Annual Net Sales” shall have the meaning specified in
Section 5.1(c)(ii). 
 “Arising Patent” shall mean: 

 

	 	(a)	 (i) any Exclusive Know-How Patent (as that term is defined in the
Patent and Know-How License Agreement), (ii) any Non-Exclusive Know-How Patent (as that term is defined in the Patent and Know-How License Agreement) and (iii) any non-provisionals, continuations, divisions, renewals, reexaminations, reissues, reexaminations, extensions, restorations, and
foreign counterparts thereof, and any and all patents granted on the Patents in clauses (i) and (ii); and 

  

	 	(b)	 any non-provisionals, continuations, divisions, renewals,
reexaminations, reissues, reexaminations, extensions, restorations, and foreign counterparts of a Transferred Pfizer Patent, and any and all patents granted thereon. 

“Assigned Contracts” shall have the meaning specified in Section 2.1(a). 

“Assigned Patent” shall mean any Patent included in the Pfizer Assigned IP Rights. 

“Assignment Consent” shall have the meaning specified in Section 2.5(a). 

“Assumed Liabilities” shall have the meaning specified in Section 2.3. 

“Books and Records” shall have the meaning specified in Section 2.1(d). 

“Business Day” shall mean any day other than (a) a Saturday or a Sunday or (b) a day on which banking institutions
are closed in New York, New York or San Francisco, California. 
 “Calendar Quarter” shall mean the respective periods of
three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
 “Calendar
Year” shall mean each twelve (12) month period commencing on January 1. 
 “Cap” shall have the meaning
specified in Section 14.5(a). 
 “CAR” shall mean a chimeric antigen receptor expressed from an
experimentally validated viral construct with specific molecular architecture and signaling domain sequences. 

  
 2 

 “CAR-T” shall mean a population of
allogeneic T-cells with a unique set of experimentally validated biologic attributes expressing a CAR construct. 

“CD19 Target” shall mean the Target corresponding to the B lymphocyte antigen Cluster of Differentiation 19. 

“CD52 Product” shall mean a product that (a) comprises an antibody that binds CD52 and has the Pfizer identifier number
of [***] and (b) incorporates, or is made, developed, or optimized, by the use of, the Transferred Pfizer Know-How. 

“Cellectis” shall mean Cellectis SA. 

“Class A Preferred Stock” shall mean, collectively, the Series A Preferred Stock and the Series A-1 Preferred Stock. 
 “Clinical Trial” shall mean a human clinical study conducted on
sufficient numbers of human subjects that is designed to (a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its intended use, and
to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such
pharmaceutical product. 
 “Closing” shall have the meaning specified in Section 4.1. 

“Closing Date” shall have the meaning specified in Section 4.1. 

“Code” shall have the meaning specified in the Preamble. 

“Combination Product” shall have the meaning specified in the definition of “Net Sales”. 

“Commercially Reasonable Efforts” shall mean, with respect to a party’s obligations or activities under this Agreement,
the carrying out of such obligations or activities with a level of effort and resources consistent with the commercially reasonable practices normally devoted by a similarly situated company, including, as applicable, [***] it being understood that
commercially reasonable efforts may not require that such party develop each and every product in its portfolio or as to which it has rights simultaneously, and it being further understood that, without limiting any obligation in this Agreement, it
is possible that the application of Commercially Reasonable Efforts as described in the foregoing definition may be consistent with the termination of the development of a product in certain circumstances. 

“Common Stock” shall mean the common stock, par value $0.001 per share of NewCo. 

“Confidential Information” shall have the meaning specified in Section 9.6(a). 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 3 

 “Confidential Disclosure Agreement” shall mean that certain confidentiality
agreement between Two River Consulting, LLC, a Delaware limited liability company, and Pfizer, dated November 8, 2017. 

“Confidential Information Agreements” shall have the meaning specified in Section 7.20. 

“Consent” shall mean any approval, consent, ratification, permission, waiver or authorization (including any Governmental
Approval). 
 “Consideration” shall have the meaning specified in Section 3.1. 

“Consolidated Return” shall mean any affiliated consolidated, combined, or unitary Tax Return filed with respect to a group
that includes a Pfizer Party (or any other Affiliate of the Pfizer Parties). 
 “Continuation Period” shall have the
meaning specified in Section 10.1(b). 
 “Contract” shall mean any written or oral agreement,
contract, obligation, promise, understanding, arrangement, license, or legally binding commitment or undertaking of any nature, other than a Pfizer Benefit Plan. 

“Copyrights” shall mean all copyrightable works of authorship and all copyrights and applications, throughout the world,
whether published or unpublished, including rights to prepare, reproduce, perform, display and distribute copyrighted works and copies, compilations and derivative works thereof. 

“Cooperation Period” shall have the meaning specified in Section 2.5(a). 

“Cover”, “Covering” and “Covered” shall mean, with respect to a Patent and an invention,
that, in the absence of ownership of or a license under such Patent, the practice of such invention (e.g., with respect to a Patent in the U.S., the manufacture, use, sale, offer for sale or importation of such invention) would infringe a Valid
Claim of such Patent (assuming, in the case of a pending patent application, that the claims of such patent application as then existing were issued). 

“Covered Benefit Plan” shall have the meaning specified in Section 6.8(d).  

“Damages” shall mean losses, damages, settlements, awards, fines, penalties, fees, liabilities, costs, including costs of
investigation, or expenses of any nature, including reasonable attorneys’ fees. 
 “Deductible” shall have the meaning
specified in Section 14.5(a) 
 “Developed Pfizer Targets” shall mean the following Targets:
BCMA, FLT3, CD33, EGFRVIII, CD70, MUC16, DLL3, Claudin18.2, and Wt1. 
 “Development Update” shall have the meaning
specified in Section 5.2(b)(iv)(A). 
 “Disclosing Party” shall have the meaning specified in
Section 9.6(a). 

  
 4 

 “Drop-Dead Date” shall have the meaning specified in
Section 13.1(d). 
 “Early Access Program” shall mean any program that provides patients with a
Product prior to Regulatory Approval in any country or region in the Territory and in which the use of such Product is not primarily intended to obtain information about the safety or effectiveness of a drug. “Early Access Programs” shall
include treatment INDs / protocols, and named patient programs. 
 “Early Stage Target” shall mean the following Targets:
[***]. 
 “Effective Date” shall have the meaning specified in the Preamble. 

“Employee Transfer Date” shall mean May 1, 2018 or such other date as is mutually agreed to between the parties. 

“Enforceability Exceptions” shall have the meaning specified in Section 6.2(b). 

“Entity” shall mean any corporation (including any non-profit corporation), general
partnership, limited partnership, limited liability partnership, joint venture, estate, trust or company (including any limited liability company or joint stock company) or other similar entity. 

“Equity Commitment Letters” shall have the meaning specified in Section 7.9. 

“Equity Consideration” shall have the meaning specified in Section 3.1. 

“Equity Consideration Cancellation” shall have the meaning specified in Section 14.8. 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended. 

“Excluded Assets” shall have the meaning specified in Section 2.2. 

“Excluded Liabilities” shall have the meaning specified in Section 2.4. 

“Excluded Taxes” shall mean, without duplication, (a) all Taxes of the Pfizer Parties or any of their Affiliates, or for
which the Pfizer Parties or any of their Affiliates is or are liable (including under any common law doctrine of de facto merger or transferee or successor liability or otherwise by operation of contract or Law), for any taxable period, (b) all
Taxes related to the Excluded Assets or Excluded Liabilities for any taxable period, (c) all Taxes relating to the Purchased Programs, the Purchased Assets, the Transferred Employees, or the Assumed Liabilities, in each case with respect to any
Pre-Closing Tax Period (including the portion of any Straddle Period through the end of the Closing Date, as determined in accordance with Section 12.2(e)) and (d) all Taxes, if any, imposed on NewCo
under Section 1445 or 1446(f) of the Code in connection with the transactions contemplated by this Agreement. 
 “Exclusive
Group 3 Know-How” shall have the meaning set forth in the Patent and Know-How License Agreement. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 5 

 “Exclusive Group 3 Patents” shall have the meaning set forth in the Patent
and Know-How License Agreement. 
 “FCPA” shall have the meaning specified in
Section 7.23. 
 “FD&C Act” shall mean the United States Federal Food, Drug, and Cosmetic
Act, as amended, and the rules and regulations promulgated thereunder. 
 “FDA” shall mean the United States Food and Drug
Administration and any successor agency. 
 “Financing” shall have the meaning specified in
Section 7.9. 
 “Financing Agreements” shall mean, collectively, the Preferred Stock Purchase
Agreement, the Investors’ Rights Agreement, the Right of First Refusal and Co-Sale Agreement and the Voting Agreement. 

“First Commercial Sale” shall mean, with respect to a given Product in a given country or region of the Territory, the first
sale of such Product by NewCo, its Affiliates or Sublicensees to a Third Party in such country after such Product has been granted Regulatory Approval by the appropriate Governmental Authority for commercial sale in such country; provided
that, any sale occurring under an Early Access Program shall be deemed a “First Commercial Sale” for purposes hereunder. 

“Founders” shall mean David D. Chang, Joshua A. Kazam, Veer Bhavnagri, David M. Tanen and Arie S. Belldegrun. 

“GAAP” shall mean United States generally accepted accounting principles in effect from time to time. 

“General Assignment and Bill of Sale” shall have the meaning specified in Section 4.2(a). 

“Governmental Approval” shall mean any: (a) permit, license, certificate, concession, Consent, clearance, confirmation,
exemption, franchise, certification, designation, rating, registration, variance, qualification or accreditation issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law;
(b) with respect to a pharmaceutical or biological product in a country or regulatory jurisdiction, the act of a Governmental Authority necessary for the testing, manufacturing, marketing, labeling, distribution, advertising, commercial sale or
use of such product in such country or regulatory jurisdiction, including the approval of an Investigational New Drug Application, Biologic License Application or New Drug Application by the FDA or any analogous approval in jurisdictions other than
the United States, but, in all cases, excluding any separate pricing or reimbursement approval, where required (“Regulatory Approval”); or (c) right under any Contract with any Governmental Authority. 

“Governmental Authority” shall mean any: (a) nation, principality, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental 

  
 6 

 
authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official,
representative, organization, unit, body or Entity and any court or other tribunal); (d) multinational organization or body; or (e) individual, Entity or body exercising, or entitled to exercise, any executive, legislative, judicial,
administrative, arbitral, regulatory, police, military or Tax Authority or power. 
 “Group 1 Pfizer IP Rights” shall mean
those Intellectual Property Rights set forth on Schedule 2.1(c)(1) under the heading “Group 1 Pfizer IP Rights”.  

“Group 2 Pfizer IP Rights” shall mean those Intellectual Property Rights set forth on Schedule 2.1(c)(2) under the
heading “Group 2 Pfizer IP Rights”. 
 “Group 3 Pfizer IP Rights” shall mean those Intellectual Property Rights
set forth on Schedule 4.2(c) under the heading “Group 3 Pfizer IP Rights” under which NewCo is granted licenses from Pfizer pursuant to the Patent and Know-How License Agreement. 

“IFRS” shall mean International Financial Reporting Standards in effect from time to time. 

“Inactive Employee” shall have the meaning specified in Section 10.1(a). 

“IND” shall mean an Investigational New Drug Application submitted under the FD&C Act, or an analogous application or
submission with any analogous agency or Governmental Authority outside of the United States for the purposes of obtaining permission to conduct Clinical Trials. 

“Indemnitee” shall have the meaning specified in Section 14.4. 

“Indemnitor” shall have the meaning specified in Section 14.4. 

“Initial NewCo Organizational Documents” shall have the meaning specified in Section 7.1(b). 

“Intellectual Property Rights” or “IP Rights” shall mean any or all rights in and to intellectual property
and intangible industrial property rights of a Pfizer Party, including Patents, Trade Secrets, Copyrights, Trademarks, Know-How, internet domain names and any rights similar, corresponding or equivalent to any
of the foregoing anywhere in the world. 
 “Investors’ Rights Agreement” shall have the meaning specified in
Section 4.2(e). 
 “IRS” shall mean the United States Internal Revenue Service. 

“Key Assigned Contract” shall mean the Pfizer-Cellectis Agreement, the Pfizer-Servier Agreement and the WuXi Agreement. 
 “Key Assigned Contract Patents” shall
mean (a) those Patents licensed to Pfizer under the Pfizer-Servier Agreement or the Pfizer-Cellectis Agreement immediately prior to the Closing Date and
(b) any Patents that, under the terms of the Pfizer-Servier Agreement or the Pfizer-Cellectis 

  
 7 

 
Agreement, would be licensed to Pfizer following the Closing if, in each case, Pfizer had remained a party thereto, in each case of clauses (a) and (b) taking into account any field or use
limitations in effect under such relevant Key Assigned Contract. 
 “Key Employee” shall mean Joshua A. Kazam, David M.
Tanen, and any other executive-level employee (including division director and vice president-level positions) as well as any employee or consultant who either alone or in concert with others develops, invents, programs or designs any of the NewCo
Intellectual Property. 
 “Know-How” shall mean any
non-public or proprietary information, inventions, discoveries, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, technology, techniques, designs, drawings,
correspondence, computer programs, documents, apparatus, results, strategies, Regulatory Filings, information and submissions pertaining to, or made in association with, filings with any Governmental Authority or patent office, data (including
pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market data, financial data or descriptions), devices, assays, chemical
formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, whether or not patentable. 

“Law” shall mean any federal, state, local, foreign and supranational or other law, statute, code, constitution, treaty,
principle of common law, directive, ordinance, rule, regulation or Order, or any similar provision or requirement having the force or effect of law, of any Governmental Authority. 

“Liability” shall mean any and all debts, liabilities and obligations, whether fixed, contingent or absolute, matured or
unmatured, accrued or not accrued, determined or determinable, secured or unsecured, disputed or undisputed, subordinated or unsubordinated, or otherwise. 

“Lien” shall mean any lien, claim, mortgage, encumbrance, pledge, license, security interest, equity or charge of any kind.

 “Material Adverse Effect” shall mean any event, change or effect that, when taken individually or together with all
other adverse events, changes and effects (a) would reasonably be expected to be materially adverse to the condition (financial or otherwise), assets, business or operations of the Purchased Programs, the Purchased Assets and the Products,
taken as a whole, or (b) would prevent or materially delay the Pfizer Parties’ consummation of the Transactions; provided, however, that any events, changes or effects will not be deemed to constitute a Material Adverse Effect to
the extent resulting from (1) general economic, political or market conditions in the pharmaceutical industry as a whole, but only to the extent that such changes or conditions do not have a materially disproportionate effect on the Purchased
Programs, taken as a whole, compared with other industry participants; (2) the impact of the Transactions, including the announcement or pendency of this Agreement or the Transactions, on relationships, contractual or otherwise, with customers,
suppliers, distributors, partners or employees; (3) any failure by any Pfizer Party or the Purchased Programs to meet internal projections or forecasts for any period (provided that the underlying causes of such failure may, to the extent
applicable, be considered in determining whether there has been a Material Adverse Effect); (4) acts of war or terrorism (or 

  
 8 

 
the escalation of the foregoing) or natural disasters or other force majeure events; (5) changes in any Law applicable to the Purchased Programs or applicable accounting regulations or
principles or the interpretation thereof; (6) compliance by Pfizer or any of its Affiliates with a request by NewCo that Pfizer or any of its Affiliates take an action (or refrain from taking an action) to the extent such action or inaction is
in compliance with such request; or (7) any action taken by Pfizer or any of its Affiliates as required by this Agreement or with NewCo’s written consent. 

“Marginal Royalty Rates” shall have the meaning specified in Section 5.1(c)(ii). 

“Milestone Event” shall have the meaning specified in Section 5.1(a) . 

“Milestone Payment” shall have the meaning specified in Section 5.1(a). 

“Net Sales” shall mean, in the case of sales of any Product(s) by or for the benefit of NewCo, its Affiliates or Sublicensees
(for the purpose of this definition only, the “Seller”) in the Royalty Territory applicable to such Product to independent, unrelated persons, including any distributor who purchases for purposes of resale to end-users (such a distributor to expressly not be deemed a Seller under this definition and, along with other such independent, unrelated persons, for the purpose of this definition only, “Buyers”)
in bona fide arm’s length transactions (except as provided below with respect to clinical trial samples), the gross amount billed or invoiced by Seller with respect to such Product during the applicable period, less the following deductions, in
each case to the extent actually paid, granted or accrued by such Seller (each as recognized by GAAP applied consistently throughout the calculation, as applicable) or allowed and taken by such Buyers and, in each case, not otherwise recovered by or
reimbursed to Seller in connection with such Product (for the purpose of this definition only, “Permitted Deductions”): [ 
  

	 	(a)	 trade, cash, promotional, prompt payment and quantity discounts; 

 

	 	(b)	 uncollectible amounts or reasonable reserves accrued therefor (it being understood that any subsequent
reductions in such accrual amounts due to collections in subsequent periods shall be included in Net Sales when such reductions occur); 

  

	 	(c)	 returns, refunds, allowances, rebates and chargebacks; 

 

	 	(d)	 customs or excise duties, excise (including, but not limited to, the amount of any annual branded prescription
drug manufacturer and importer fees attributable to the Products paid by the Seller), sales or use Taxes, consumption Tax, value added Tax or other Taxes (except income Taxes) or duties relating to sales Taxes on sales (such as excise, sales or use
Taxes or value added Tax); 

  

	 	(e)	 Taxes on sales of pharmaceutical specialties reimbursed pursuant to a government health service, health
insurance, social insurance or similar social services program; 

  

	 	(f)	 freight, insurance, packing costs and other transportation charges to the extent added to the sales price;

  

	 	(g)	 amounts repaid or credits taken by reason of rejections, defects or returns or because of retroactive price
reductions, or due to recalls or Laws requiring rebates; 

  
 9 

	 	(h)	 rebates taken by or fees paid to distributors, wholesalers, group purchasing organizations, pharmacy benefit
management companies and management care entities and charge-backs, including any discount, rebate or reimbursement program applicable to a Product under which Seller provides to low income, uninsured or other patients the opportunity to purchase
Products at discounted prices; 

  

	 	(i)	 rebates and/or discounts on sales of Products given to health insurance and other types of payers due to
specific agreements (“claw-back” type of agreements) involving the Products; and 

  

	 	(j)	 any other specifically identifiable amounts included in gross amounts invoiced for the Products, to the extent
such amounts are customary deductions from net sales calculations in the pharmaceutical or biotechnology industries in the applicable country or countries for reasons substantially equivalent to those listed above. 

“Net Sales” shall not include any consideration received with respect to a sale, use or other disposition of any Product in a country for
development purposes or as samples or for charitable purposes. Notwithstanding the foregoing, the amounts invoiced by NewCo, its Affiliates, or Sublicensees for the sale of Product among NewCo, its Affiliates, or Sublicensees for resale shall not be
included in the computation of Net Sales hereunder and Net Sales shall be the gross invoice or contract price charged to the Third Party customer for that Product, less the Permitted Deductions. All of the foregoing elements of Net Sales
calculations shall be determined in accordance with GAAP or IFRS, as applicable to the Seller. 
 Notwithstanding the foregoing, if a Product either
(i) is sold in the form of a combination product containing both the Product and one or more independently therapeutically active pharmaceutical molecules (i.e. a chemical entity performing a therapeutic or prophylactic function distinct from
the enhancement of the activity of the Product itself) that are not other Products or (ii) is sold in a form that contains (or is sold bundled with for the same price) a delivery device therefor (in either case of (i) or (ii), a
“Combination Product” and any such other independently therapeutically active pharmaceutical molecules or delivery device, an “Other Component” of such Combination Product), the Net Sales of such Product for the
purpose of calculating royalties owed under this Agreement for sales of such Product shall be determined by multiplying the actual Net Sales of the Combination Product (calculated using the above provisions) by the fraction A/(A+B), where A is the
invoice price on a country-by-country basis, during the Royalty Term in question, of the Product when sold separately and B is the invoice price on a country-by-country basis, during the Royalty Term in question, of the other active pharmaceutical molecule or delivery device when sold separately. If any other active
pharmaceutical molecule or delivery device in the combination is not sold separately in a country, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by a fraction: (A/C), where A is the invoice price of the
Product in such country if sold separately, and C is the invoice price of the Combination Product in such country. If neither the Product nor any other active pharmaceutical molecule or delivery device in the Combination Product is sold separately,
the adjustment to Net Sales shall be determined by the parties in good faith to reasonably reflect the fair market value of the contribution of the Product in the Combination Product to the total fair market value of such Combination Product;
provided that in the event the parties do not agree on such relative value contributions, either party may 

  
 10 

 
require that the matter be referred to an independent expert selected by agreement of the parties. Except in the case of fraud or manifest error on the part of such independent expert, the
decision of such independent expert as to such relative value contributions shall be binding upon the parties. The costs of the independent expert shall be borne by the non-prevailing party. 

“NewCo” shall have the meaning specified in the Preamble. 

“NewCo 401(k) Plan” shall have the meaning specified in Section 10.1(g). 

“NewCo Damages” shall have the meaning specified in Section 14.1. 

“NewCo Fundamental Representations” shall have the meaning specified in Section 11.2(a). 

“NewCo Indemnified Persons” shall have the meaning specified in Section 14.1. 

“NewCo Intellectual Property” shall mean all patents, patent disclosures and all related continuation, continuation-in-part, divisional, reissue, reexamination, utility model, renewals, extensions, certificate of invention and design patents, patent applications, registrations
and applications for registrations, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, information and
proprietary rights and processes, similar or other intellectual property rights or know-how, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any
of the foregoing, and any and all such cases that are owned or used by, or are necessary to, NewCo in the conduct of the NewCo’s business as now conducted and as presently proposed to be conducted. 

“Non-Assignable Asset” shall have the meaning specified in
Section 2.5(a). 
 “Order” shall mean any (a) temporary, preliminary or permanent order,
judgment, injunction, edict, decree, ruling, pronouncement, determination, decision, opinion, verdict, sentence, stipulation, writ or award that is or has been issued, made, entered, rendered or otherwise put into effect by or under the authority of
any court, administrative agency or other Governmental Authority or any arbitrator or arbitration panel; or (b) settlement or conciliation agreement with any Governmental Authority that is or has been entered into in connection with any
Proceeding. 
 “Organizational Documents” shall mean a certificate of incorporation, bylaws, limited partnership agreement,
limited liability company agreement or comparable constituent or organizational documents. 
 “Other Assets” shall have the
meaning specified in Section 2.1(f). 
 “Other Investors” shall mean TPG Carthage Holdings, L.P.,
a Delaware limited partnership, The Rise Fund Carthage, L.P., a Delaware limited partnership, VVAG Special Fund LLC, a Delaware limited liability company, Vida Ventures, LLC, a Delaware limited liability company, The Regents of the University of
California, the Seaview Trust, the Belldegrun Family Trust, Franz Humer, Owen Witte, Chang 2006 Family Trust, Christine Cassiano, Joshua A. Kazam, KB/V LLC, James Economou, Allan Pantuck, Linda Barnes, Stuart Holden, Roy

  
 11 

 
Doumani, Kiernan Family Trust, Vera Kiernan Trustee, David M. Tanen, Veer Bhavnagri and, if it enters into an Equity Commitment Letter prior to the Closing, Gilead Sciences, Inc. 

“Other Royalty-Bearing Product” shall mean any Allogeneic Product that (a) Targets a Target that is not a Pfizer Target,
(b) is either (i) Covered by a Valid Claim of any Transferred Pfizer Patent, Arising Patent or Key Assigned Contract Patent or (ii) incorporates or is made, discovered, developed, or derived from the use of Transferred Pfizer Know-How and (c) for which an IND is first filed on or before the fifth (5th) anniversary of the Closing Date. 

“Patent and Know-How License Agreement” shall have the meaning specified in
Section 4.2(c). 
 “Patent Assignment” shall have the meaning specified in
Section 4.2(b). 
 “Patents” shall mean any and all (a) issued patents, (b) pending
patent applications, including all non-provisional or provisional applications, substitutions, continuations,
continuations-in-part, divisions and renewals, and all patents granted thereon,
(c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term
adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and
(f) United States and foreign counterparts of any of the foregoing. 
 “Permits” shall mean, with respect to any
Person, any license, franchise, permit, approval or other similar authorization issued by, or otherwise granted by, any Governmental Authority to which or by which such Person is subject or bound. 

“Permitted Lien” shall mean (a) any Lien for Taxes not yet due or delinquent as of the Closing Date or which are being
contested in good faith by appropriate Proceedings and for which appropriate reserves have been established under GAAP, (b) vendors’, mechanics’, materialmen’s, carriers’, workers’, landlords’, repairmen’s,
warehousemen’s, construction and other similar Liens arising or incurred in the ordinary and usual course of business and consistent with past practice or with respect to Liabilities that are not yet due and payable or, if due, are not
delinquent or are being contested in good faith by appropriate Proceedings, (c) Liens imposed or promulgated by applicable Law or any Governmental Authority with respect to real property, including zoning, building or similar restrictions,
(d) pledges or deposits in connection with workers’ compensation, unemployment insurance, and other social security legislation, (e) Liens imposed by securities Laws, (f) Liens relating to intercompany borrowings among a person
and its wholly owned subsidiaries, provided that, as to the Pfizer Parties and the Purchased Assets, the Products and/or the Purchased Programs, such Liens are released and extinguished prior to or at the Closing, (g) defects, irregularities or
imperfections of title which do not materially interfere with, or materially impair the use of, the property or assets subject thereto, or (h) Liens resulting from the action or inaction of NewCo or any of its Affiliates. 

“Person” shall mean any individual, Entity or Governmental Authority. 

“Personal Information” shall have the meaning specified in Section 7.24. 

  
 12 

 “Pfizer” shall have the meaning specified in the Preamble. 

“Pfizer Assigned IP Rights” shall mean the Group 1 Pfizer IP Rights and the Group 2 Pfizer IP Rights. 

“Pfizer Benefit Plan” shall mean each “employee benefit plan” as defined in Section 3(3) of ERISA (whether or
not subject to ERISA) and each other pension, retirement, profit-sharing, deferred compensation, change in control, retention, employment, independent contractor, consulting, equity or equity-based compensation, stock purchase, employee stock
purchase, severance or termination pay, vacation or paid time-off, bonus or other incentive, medical, health or welfare benefit, retiree medical, health or welfare benefit, life insurance, medical
reimbursement, fringe benefit or other plan, agreement, arrangement, program, policy or contract (including any related funding mechanism), in each case, whether oral or written, funded or unfunded, or insured or self-insured, that is sponsored,
maintained, contributed to or required to be contributed to by Pfizer or any of its Subsidiaries. 

“Pfizer-Cellectis Agreement” shall mean that certain Research Collaboration and
License Agreement between Pfizer, Inc. and Cellectis SA dated June 17, 2014, as amended as of the Effective Date. 
 “Pfizer
Damages” shall have the meaning specified in Section 14.2. 
 “Pfizer Damages Fraction”
shall have the meaning specified in Section 14.2. 
 “Pfizer Fundamental Representations” shall
have the meaning specified in Section 11.1(a). 
 “Pfizer Indemnified Persons” shall have the
meaning specified in Section 14.2. 
 “Pfizer Parties” shall have the meaning set forth in the
Preamble. 
 “Pfizer Savings Plan” shall mean the Pfizer Savings Plan (plan number 002). 

“Pfizer-Servier Agreement” shall mean that certain Exclusive License and
Collaboration Agreement between Servier and Pfizer, Inc. dated October 30, 2015. 
 “Pfizer Subsidiaries” shall mean
the Subsidiaries of Pfizer set forth on Exhibit A. 
 “Pfizer Target” shall mean (a) the Developed Pfizer
Targets, (b) the Early Stage Targets, and (c) the ROR1 Target and the CD19 Target. 
 “Pfizer Territory” shall,
with respect to a Product, mean the United States and any other countries included in the “Pfizer Territory” as defined for such Product in the Pfizer-Servier Agreement (including to the extent the
license conversion provisions in such agreement apply); provided that in the event NewCo, its Affiliate or Sublicensee otherwise obtains the right to sell or otherwise commercialize such Product in any country or countries other than the
United States, including by termination or amendment, in whole or in part, of the Pfizer-Servier Agreement as it may be amended from time to time, the Pfizer Territory shall include such country or countries
with respect to such Product. 

  
 13 

 “Pfizer’s knowledge” and similar phrases shall mean the actual
knowledge of the individuals listed on Schedule 1.1(a) after due and reasonable inquiry. 
 “Post-Closing NewCo Organizational
Documents” shall have the meaning specified in Section 7.1(b). 
 “Post-Closing Tax
Period” shall mean any Tax period beginning after the Closing Date and, in the case of a Straddle Period, the portion of such period beginning after the Closing Date. 

“Pre-Closing Tax Period” shall mean any Tax period ending on or before the Closing
Date and, in the case of a Straddle Period, the portion of such period ending on and including the Closing Date. 
 “Preferred Stock
Purchase Agreement” shall have the meaning specified in Section 4.2(f). 
 “Price
Approval” shall mean, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination
effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be). 

“Proceeding” shall mean any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), prosecution, hearing, inquiry, audit, examination or investigation that is, has been or may in the future be commenced, brought, conducted or heard at law or in equity or before any Governmental Authority.

 “Product” shall mean any Royalty-Bearing Product or Other Royalty-Bearing Product. 

“Prospective Employees” shall have the meaning specified in Section 6.8(a). 

“Purchased Assets” shall have the meaning specified in Section 2.1. 

“Purchased Inventory” shall have the meaning specified in Section 2.1(b). 

“Purchased Programs” shall mean the programs conducted by the Pfizer Parties as of the date hereof related to developing,
manufacturing, commercializing, distributing, promoting, packaging, importing, marketing, selling and otherwise exploiting the Products with respect to the Pfizer Targets, but for the avoidance of doubt, excluding the Excluded Assets. 

“Purchased Programs Registered Intellectual Property” shall have the meaning specified in
Section 6.9(a). 
 “Purchased Programs Permits” shall have the meaning specified in
Section 6.4. 
 “Receiving Party” shall have the meaning specified in
Section 9.6(a). 
 “Regulatory Approval” shall have the meaning specified in the definition of
“Governmental Approval”. 

  
 14 

 “Regulatory Filing” shall mean any documentation constituting or relating
to or supporting any filing or application with any Governmental Authority with respect to a Product, including any documents submitted to any Governmental Authority, including INDs, applications for Regulatory Approval, and all correspondence with
any Governmental Authority with respect to any Product (including minutes of any meetings, telephone conferences or discussions with any Governmental Authority). 

“Regulatory Laws” shall mean the following Laws: (a) the Federal Food, Drug, and Cosmetic Act, as amended, and all
regulations promulgated thereunder, (b) the federal False Claims Act (42 U.S.C. § 1320a-7b(a)), as amended, (c) the Physician Payments Sunshine Act, (d) the Patient Protection and
Affordable Care Act, (e) the federal Medicare and Medicaid statutes, (f) the federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, (g) the federal Physician Self-Referral (Stark) Law,
42 U.S.C. § 1395nn, (h) the federal Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a, (i) the Federal Trade Commission Act, (j) the Public Health Service Act and
(k) any other Laws governing research, development, clinical testing, investigational use, marketing clearance, marketing approval, manufacturing, servicing, packaging, labeling, promotion, sale, import or export of a pharmaceutical product.

 “Representatives” shall mean officers, directors, employees, agents, advisors and Affiliates. 

“Restated Bylaws” shall have the meaning specified in Section 7.1(b). 

“Restated Certificate” shall mean the Amended and Restated Certificate of Incorporation of NewCo, adopted and filed by NewCo
on or before the closing of the transaction contemplated by the Preferred Stock Purchase Agreement. 
 “Right of First Refusal and Co-Sale Agreement” shall have the meaning specified in Section 4.2(g). 

“ROR1 Target” shall mean the Target corresponding to Tyrosine-protein kinase transmembrane receptor ROR1, also known as
neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1). 
 “Royalty-Bearing Product” shall mean either (a) any CD52
Product or (b) any Allogeneic Product that Targets a Pfizer Target and: 
 (i) is, on a country-by-country basis, Covered by a Valid Claim of (A) any Transferred Pfizer Patent, (B) any Arising Patent, or (C) any Key Assigned Contract Patent; 

(ii) incorporates or is made, discovered, developed, or derived from the use of Transferred Pfizer
Know-How; or 
 (iii) meets the definition of a (A) “Pfizer Licensed Product” under the Pfizer-Cellectis Agreement, (B) “Pfizer Licensed Product” under the Pfizer-Servier Agreement or (C) “Servier Licensed Product” under the Pfizer-Servier Agreement. 

  
 15 

 “Royalty Term” shall mean, with respect to a given Product in a given
country in the Territory, the period beginning upon the First Commercial Sale of such Product in such country and ending on the later of (a) expiration of the last to expire Valid Claim of (i) any applicable Transferred Pfizer Patent,
(ii) any Arising Patent or (iii) any Key Assigned Contract Patent, in each case ((i), (ii) or (iii)) Covering such Product in such country or (b) twelve (12) years from First Commercial Sale of such Product in such country. 

“Royalty Territory” shall mean (i) for any Product Targeting the Pfizer Targets CD19 or ROR1, the Pfizer Territory and
(ii) for any other Product, all countries of the world. 
 “Sales Milestone Payment” shall have the meaning specified
in Section 5.1(b). 
 “Series A Preferred Stock” shall mean the Company’s Series A
Preferred Stock, $0.001 par value per share. 
 “Series A-1 Preferred Stock” shall
mean the Company’s Series A-1 Preferred Stock, $0.001 par value per share. 

“Servier” shall mean, collectively, Les Laboratoires Servier and Institut de Recherches Internationales Servier. 

“Servier Product” shall mean any Product Targeting the Pfizer Targets CD19, ROR1 and EGFRVIII, and as to which either
(i) Cellectis has granted Servier a license to develop and commercialize such Product in the Servier Territory, prior to the Effective Date, and which Servier has granted to Pfizer a sublicense under such rights in the United States pursuant to
the Pfizer-Servier Agreement, prior to the Effective Date, or (ii) Pfizer has granted Servier a license to develop and commercialize such Product in the Servier Territory, under the Pfizer-Servier Agreement, prior to the Effective Date; provided that a Product Targeting EGFRVIII will no longer be deemed a Servier Product under this Agreement if Servier no longer is granted such license
referred to in clause (ii) from Pfizer or its assignee under the Pfizer-Servier Agreement, as it may be amended from time to time. 

“Servier Territory” shall have the meaning as set forth in the Pfizer-Servier
Agreement. 
 “Set-off” shall have the meaning specified in
Section 14.8. 
 “Shared Contracts” shall mean all Contracts listed on Schedule 2.6, which
relate in part, but not exclusively, to the Purchased Programs. 
 “Stock Plan” shall have the meaning specified in
Section 7.2(b) 
 “Straddle Period” shall have the meaning specified in
Section 12.2(e). 
 “Sublicensee” shall mean any Person, including any assignee, transferee,
licensee or sublicensee of NewCo or its Affiliates, to whom NewCo or its Affiliate has granted, including via sale, assignment, license, sublicense or other transfer of assets, any rights (a) assigned or otherwise transferred to NewCo or its
Affiliates under this Agreement or (b) licensed or sublicensed to NewCo or its Affiliates under the Patent and Know-How License Agreement. 

  
 16 

 “Subsidiary” shall mean, with respect to any Person, any Entity in which
such Person has a fifty percent (50%) or greater interest. 
 “Target” shall mean (a) a specific biological molecule
that is identified by a GenBank accession number or similar information, or by its amino acid or nucleic acid sequence, and (b) any biological molecule substantially similar in amino acid or nucleic acid sequence that has substantially the same
biological function as a molecule disclosed in clause (a), including any naturally occurring mutant or allelic variant of a molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and post-transcriptional
isoforms (e.g., alternative splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c) truncated forms (including fragments thereof) which have a biological function
substantially similar to that of any biological molecules disclosed in clause (a) or clause (b). 
 “Targeting” shall
mean, when used to describe the relationship between a molecule and a Target, that the molecule (a) binds to the Target (or a portion thereof) and (b) is designed or being developed to exert its biological effect in whole or in part
through binding to such Target (or such portion thereof). 
 “Targets” shall mean, when used as a verb, the correlative
meaning of “Targeting.” 
 “Tax” shall mean all forms of taxation imposed by any Tax Authority, including all
national, state or local taxation (including income, value added, alternative or add-on minimum, occupation, real and personal property, escheat or unclaimed property, social security, gross receipts, sales,
use, production, transfer, registration, ad valorem, franchise, profits, license, withholding, payroll, employment, unemployment, disability, excise, severance, occupation, premium or windfall profit taxes, stamp, customs duties, capital stock, and
other import or export duties, estimated and other taxes of any kind whatsoever), together with any interest, penalties, and additions to tax, whether disputed or not. 

“Tax Authority” shall mean a Governmental Authority responsible for the imposition, assessment or collection of any Tax
(domestic or foreign). 
 “Tax Contest” shall have the meaning specified in Section 12.3(a). 

“Tax Referee” shall have the meaning specified in Section 12.2(c). 

“Tax Return” shall mean any report, return, statement, declaration, notice, claim for refund, certificate or other document
(including any related or supporting schedules, statements or information) filed or required to be filed with any Tax Authority, or required to be maintained by any Person, in connection with the determination, assessment, collection or payment of
any Tax. 
 “Term” shall mean the period of time commencing on the Effective Date and extending on a country-by-country basis until the earlier of (a) the last to expire of any Royalty Term for any Product in such country in the Territory and (b) the termination of
this Agreement in accordance with ARTICLE 13. 
 “Territory” shall have the meaning specified on Schedule
1.1(b). 

  
 17 

 “Territory Option Agreement” means that certain Option Letter, dated as of
the Effective Date, by and between Pfizer and NewCo, wherein NewCo is granted an option by Pfizer to expand the Territory under certain conditions. 

“Third Party” shall mean any Person other than Pfizer, NewCo or their respective Affiliates. 

“Total Annual Net Sales” shall have the meaning specified in Section 5.1(b). 

“Trade Secrets” shall mean all trade secrets under applicable law and other rights in
know-how and confidential or proprietary information, processing, manufacturing or marketing information, including new developments, inventions, processes, ideas or other proprietary information that provide
any Pfizer Party with advantages over potential or actual competitors who do not know or use it and documentation thereof (including related papers, invention disclosures, blueprints, drawings, research data and results, flowcharts, diagrams,
chemical compositions, formulae, diaries, notebooks, specifications, designs, methods of manufacture, processing techniques, data processing techniques, compilations of information, customer and supplier lists, pricing and cost information, and
business and marketing plans and proposals) and all claims and rights related thereto. 
 “Trademarks” shall mean any and
all trademarks, service marks, trade dress, logos, slogans, trade names, all material unregistered trademarks, together with all adaptations, derivations and combinations thereof, and all goodwill associated with any of the foregoing throughout the
world. 
 “Transaction Agreements” shall mean this Agreement and the General Assignment and Bill of Sale, the Patent
Assignment, the Patent and Know-How License Agreement, the Transition Services Agreement, the Territory Option Agreement, the Preferred Stock Purchase Agreement, the Investors’ Rights Agreement, the Right
of First Refusal and Co-Sale Agreement, the Voting Agreement and the Equity Commitment Letters. 

“Transactions” shall mean, collectively, the transactions contemplated by this Agreement. 

“Transfer Taxes” shall mean all federal, state, local or foreign sales (including bulk sales), use, VAT, transfer, real
property transfer, recording, mortgage recording, license, stamp, stamp duty, documentary, conveyance, excise, registration, or similar Taxes that may be imposed in connection with the transfer of Purchased Assets. 

“Transferred Employee” shall have the meaning specified in Section 10.1(a). 

“Transferred Pfizer Know-How” shall mean
Know-How included in the Pfizer Assigned IP Rights or the Group 3 Pfizer IP Rights licensed to NewCo pursuant to the Patent and Know-How License Agreement, including
manufacturing Know-How, in each case which is maintained as a Trade Secret as of the Closing Date. Notwithstanding the foregoing, Transferred Pfizer Know-How shall not
include any such Know-How which NewCo can demonstrate through competent, written evidence was known to NewCo or any of its Representatives (other than a Transferred Employee) prior to the Closing Date other
than (a) from a Pfizer Party, its licensor or its 

  
 18 

 
Representative or (b) from a Third Party who is, or was at the relevant time of disclosure, under an obligation of confidentiality with respect to such
Know-How. 
 “Transferred Pfizer Patents” shall mean the Assigned Patents and the
Patents included in the Group 3 Pfizer IP Rights. 
 “Transition Services Agreement” shall have the meaning specified in
Section 4.2(d). 
 “Treasury Regulations” shall mean the regulations promulgated under the Code
by the United States Treasury and IRS. 
 “Valid Claim” shall mean: (a) a claim of any issued and unexpired patent
that (i) has not been, disclaimed, revoked or held unenforceable or invalid by a decision of a Governmental Authority of competent jurisdiction from which no appeal can be taken, or by a decision of a Governmental Authority of competent
jurisdiction that can be appealed, but with respect to which an appeal has not taken within the time allowed for appeal, and (ii) has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or
(b) a claim of any pending patent application that (i) has not been cancelled, withdrawn or abandoned, without being re-filed in another application in the applicable jurisdiction, (ii) has not
been finally rejected by an administrative agency or other governmental action from which no appeal can be taken and (iii) has not been pending or filed more than [***] years from the earliest possible priority date for such patent application;
provided that if such claim is later issued, it shall from the issuance date forward be deemed to be a Valid Claim. 

“VAT” shall mean (i) value added tax goods and services tax and (ii) any other similar turnover, sales or purchase,
tax or duty, in the case of each of clause (i) and clause (ii), levied by any jurisdiction whether central, regional or local. 

“Voting Agreement” shall have the meaning specified in Section 4.2(h). 

“Worker Notification Law” shall mean the United States Worker Adjustment and Retraining Notification Act of 1988 or similar
state or local Law. 
 “WuXi Agreement” shall mean that certain Master Services Agreement between Pfizer and WuXi AppTec,
Inc., dated December 4, 2015. 
 1.2 Rules of Interpretation. Except as otherwise explicitly specified to the contrary,
(a) references to a Section, Article, Exhibit or Schedule mean a Section or Article of, or Schedule or Exhibit to, this Agreement, unless another agreement is specified, (b) the word “including” (in its various forms) means
“including without limitation,” (c) references to a particular statute or regulation include all rules and regulations thereunder and any predecessor or successor statute, rules or regulation, in each case as amended or otherwise
modified from time to time, (d) words in the singular or plural form include the plural and singular form, respectively, (e) references to a particular Person include such Person’s successors and assigns to the extent not prohibited
by this Agreement, (f) “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply “if,” (g) the headings contained in this
Agreement, in any Exhibit or Schedule hereto and in the table of contents to this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this 

  
 19 

 Agreement, (h) the words “will” and “shall” shall be interpreted to have the same
meaning, (i) unless otherwise specifically provided for herein, the term “or” shall not be deemed to be exclusive and (j) references to “$” shall mean U.S. dollars. 

ARTICLE 2 
 THE TRANSACTION
AGREEMENT 
 2.1 Purchased Assets. Subject to the terms and conditions of this Agreement, including the terms of
Section 2.2, Pfizer shall, and shall cause the other Pfizer Parties to, transfer, convey, assign and deliver to NewCo, and NewCo shall acquire and accept from the Pfizer Parties, all of their respective right, title and
interest in, to and under the following (collectively, the “Purchased Assets”), in each case free and clear of all Liens except Permitted Liens: 

(a) Contracts. All Contracts set forth on Schedule 2.1(a) or otherwise used or held for use by Pfizer exclusively
in connection with the Purchased Programs (collectively, the “Assigned Contracts”);  

(b) Inventory. The inventory of raw materials,
works-in-progress and drug substance to the extent related exclusively to the Purchased Programs and owned by the Pfizer Parties as of the Closing Date, including,
without limitation, the inventory set forth on Schedule 2.1(b) (collectively, the “Purchased Inventory”); 

(c) Intellectual Property. The Pfizer Assigned IP Rights; 

(d) Books and Records. All books and records exclusively relating to the Purchased Assets, other than Consolidated
Returns, and other than any books and records the disclosure of which would reasonably be expected to violate any Law or that relate solely to (i) personnel matters unrelated to Transferred Employees, (ii) any Excluded Asset, and
(iii) any attorney work product, attorney-client communications, and other items that are protected by attorney-client privilege (the “Books and Records”); 

(e) Goodwill. All goodwill of the Pfizer Parties related to the Purchased Programs; 

(f) Other Assets. The other assets of the Pfizer Parties identified on Schedule 2.1(f), which
includes the Transferred Pfizer Know-How (the “Other Assets”); and 

(g) Subsequently Assigned Assets. Non-Assignable Assets assigned pursuant to
Section 2.5. 
 2.2 Excluded Assets. Notwithstanding any other provision of this Agreement, the Purchased
Assets shall not include, and the Pfizer Parties and their Affiliates shall retain and shall not contribute, transfer, convey, assign or deliver to NewCo any of the following (collectively, the “Excluded Assets”): 

  
 20 

 (a) any assets of the Pfizer Parties that are not included within the
definition of Purchased Assets; 
 (b) any Contracts or intercompany payables or receivables between and among Pfizer and its
Subsidiaries; 
 (c) any cash, checks, money orders, marketable securities, short-term instruments and other cash
equivalents, funds in time and demand deposits or similar accounts, and any evidence of indebtedness issued or guaranteed by any Governmental Authority; 

(d) any Intellectual Property Rights (including retained rights under the Intellectual Property Rights owned by the Pfizer
Parties and licensed to NewCo under the Patent and Know-How License Agreement) other than the Pfizer Assigned IP Rights; 

(e) any Pfizer Benefit Plan and any assets related thereto; 

(f) all Tax losses and credits, Tax loss and credit carry forwards and other Tax attributes, all deposits or advance payments
with respect to Taxes, and any claims, rights, and interest in and to any refund, credit or reduction of Taxes, in each case relating to Excluded Taxes (regardless of when received); 

(g) all rights, claims or causes of action of a Pfizer Party against Third Parties to the extent relating to any Excluded Asset
or any Excluded Liability; 
 (h) Non-Assignable Assets, subject to
Section 2.5; 
 (i) the assets, Contracts, equipment or other property listed on Schedule
2.2(i); and 
 (j) all income Tax Returns and records and other Tax Returns to the extent not exclusively related to the
Purchased Programs or Purchased Assets. 
 For the purposes of Section 2.1 and
Section 2.2, the terms Purchased Assets and Excluded Assets, as applicable, shall not include any Tax assets. 

2.3 Assumed Liabilities. NewCo shall assume, satisfy and thereafter discharge the following Liabilities of Pfizer or its Affiliates, as
applicable (the “Assumed Liabilities”): 
 (a) all Liabilities under the Assigned Contracts arising after
the Closing, and including all unfulfilled binding commitments made prior to the Closing Date to purchase inventory that are scheduled to be delivered or provided thereafter; 

(b) all other Liabilities arising from or relating to the Purchased Assets or the conduct of the Purchased Programs after the
Closing, including all Liabilities under, and obligations to comply with, applicable Laws; provided that Assumed Liabilities shall not include any Liability for Excluded Taxes;  

  
 21 

 (c) all Liabilities arising from or relating to the practice by NewCo, its
Affiliates or Sublicensees of any Intellectual Property Rights owned by the Pfizer Parties and licensed to NewCo under the Patent and Know-How License Agreement; 

(d) all Liabilities arising from or relating to the employment or termination of employment of any Prospective Employee on or
after the Closing Date (except as provided in Section 2.4(c)(ii)); 
 (e) all Liabilities arising from any lawsuits
commenced and claims made after the Closing to the extent resulting from the conduct of the Purchased Programs or the ownership of, or license to, the Purchased Assets after the Closing, including lawsuits and claims arising from the developing,
manufacturing, commercializing, distributing, promoting, packaging, importing, marketing, selling or otherwise exploiting any Product after the Closing, including any post-Closing product liability claims, warranty obligations and intellectual
property infringement or misappropriation and irrespective of the legal theory asserted; 
 (f) all Liabilities, including
but not limited to any obligation to provide any notices, payments or any other benefits due to any Transferred Employees, if any, and any notices due to any Governmental Authority, if any, which may be required as a result of any “employment
loss” (as defined under the Worker Notification Law), in each case, caused by NewCo’s actions that occur on or after the Closing Date; 

(g) all Liabilities arising after the Closing under the Non-Assignable Assets to the
extent NewCo receives the benefits of such Non-Assignable Asset; and 
 (h) all
Liabilities set forth in Schedule 2.3(h). 
 2.4 Excluded Liabilities. Pfizer and its Affiliates shall retain, and shall
be responsible for paying, performing and discharging when due, and NewCo shall not assume or have any responsibility for, any Liabilities of Pfizer and its Affiliates other than the Assumed Liabilities and except as set forth in
Section 12.2(d), including the following Liabilities (collectively, the “Excluded Liabilities”): 

(a) all Liabilities arising from the Excluded Assets; 

(b) all Liabilities under the Assigned Contracts arising prior to the Closing, including all outstanding accounts payable under
the Assigned Contracts arising prior to the Closing; 
 (c) all Liabilities arising from or relating to any
(i) Pfizer Benefit Plan or the employment, or termination of employment, of any employee of a Pfizer Party including any Prospective Employee or Transferred Employee, in each case arising prior to the Closing Date or (ii) termination of
employment of any Prospective Employee that does not accept an offer of employment from NewCo; 
 (d) all Liabilities
in respect of Excluded Taxes; 

  
 22 

 (e) all Liabilities arising from or relating to the use of Group 2 Pfizer IP
Rights licensed to Pfizer by Pfizer or its sublicensees pursuant to the Patent and Know How License Agreement; 
 (f) all
Liabilities arising from any lawsuits commenced and claims made prior to or after the Closing to the extent resulting from the conduct of the Purchased Programs or the ownership of, or license to, the Purchased Assets prior to the Closing; and 

(g) all Liabilities set forth on Schedule 2.4(g). 

2.5 Non-Assignable Assets. 

(a) Notwithstanding the foregoing, and without limiting Section 11.1, if any Contract that would be
an Assigned Contract, or other asset that would be a Purchased Asset, including the portion of any Shared Contract which is applicable to the Purchased Programs pursuant to Section 2.6, is not assignable or transferable
(each, a “Non-Assignable Asset”) without the consent of, or waiver by, a Third Party or action by a Governmental Authority (each, an “Assignment Consent”), either as a result
of the provisions thereof or applicable Laws, and any such Assignment Consent is not obtained on or prior to the Closing Date, then this Agreement and the related instruments of transfer shall not constitute an assignment or transfer of such Non-Assignable Asset and such Non-Assignable Asset shall not be included in the Purchased Assets. Without limiting the Pfizer Parties’ obligations under
Section 8.4 or Section 9.1, each of the parties hereto, for a period of [***] following the Closing Date, or longer to the extent provided for or contemplated by the Transition Services Agreement
(the “Cooperation Period”), shall use commercially reasonable efforts to obtain all such Assignment Consents; provided, however, that nothing in this Section 2.5(a) shall require any of the
Pfizer Parties or any of their Affiliates to modify any of its respective rights in a manner adverse to any of the Pfizer Parties or any of their Affiliates or to pay any fee or other payment, or incur any Liability, cost or out-of-pocket expense in connection with the efforts set forth in this Section 2.5(a), with any such Liabilities, costs or out-of-pocket expenses to be borne by NewCo. To the extent such Assignment Consents are obtained during the Cooperation Period, the Pfizer Parties shall assign to NewCo or its
designee such Non-Assignable Assets. Following any such assignment, such assets shall be deemed Purchased Assets for purposes of this Agreement. 

(b) During the Cooperation Period, the Pfizer Parties shall cooperate with NewCo in any commercially reasonable arrangement
reasonably designed to provide NewCo or its designee with the net benefits of the Non-Assignable Assets after the Closing as if the appropriate Assignment Consents had been obtained, including by granting
rights and establishing arrangements whereby NewCo or its designee shall undertake the work necessary to perform under Assigned Contracts, provided, however, that none of the Pfizer Parties shall be required to (i) undertake any work
that would constitute a breach of the Assigned Contracts, (ii) modify any of its respective rights in a manner adverse to the Pfizer Parties or (iii) incur any Liability, cost or out-of-pocket expense in connection therewith; provided further, that such benefits shall be calculated net of documented
out-of-pocket additional costs in connection therewith (including Taxes). To the extent the benefits of a 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 23 

 Non-Assignable Asset are made available to NewCo during the
Cooperation Period, NewCo shall perform, at the direction of the applicable Pfizer Party, the obligations of such Pfizer Party under such Non-Assignable Asset and assume all Liabilities related thereto, and
economically bear any out-of-pocket additional costs in connection with such Non-Assignable Asset (including Taxes). After the
Cooperation Period, the Pfizer Parties shall continue to be subject to the obligations set forth in Section 9.2. 
 2.6 Shared
Contracts. Each Pfizer Party shall use reasonable best efforts prior to the Closing to cooperate with NewCo in NewCo’s efforts to enter into a new Contract related to the Purchased Programs with the counterparty to each Shared Contract on
substantially the same terms and conditions as exist under such Shared Contract, in each case as of the Closing; provided, however, that nothing in this Section 2.6 shall require any of the Pfizer Parties or any of
their Affiliates to modify any of its respective rights in a manner adverse to any of the Pfizer Parties or any of their Affiliates or to pay any fee or other payment, or incur any Liability, cost or out-of-pocket expense, in connection with the efforts set forth in this Section 2.6, with any such Liabilities, costs or out-of-pocket expenses to be borne by NewCo. The Pfizer Parties shall keep NewCo reasonably informed and shall consult with NewCo in good faith in connection with any material actions taken with respect to
any Shared Contract in furtherance of this Section 2.6 prior to Closing. Any Shared Contract for which the replacement Contract described in this Section 2.6 could not be entered into prior to the
Closing shall be a Non-Assignable Asset subject to Section 2.5(b). 

ARTICLE 3 
 CONSIDERATION FOR
TRANSFER 
 3.1 Consideration. As consideration for the Pfizer Parties’ sale to NewCo of the Purchased Assets, NewCo shall
(a) issue to Pfizer 3,187,772 shares of Series A-1 Preferred Stock (the “Equity Consideration”); (b) assume at the Closing and subsequently, in due course in accordance with the
terms applicable thereto, timely pay, perform and discharge the Assumed Liabilities and (c) subject to ARTICLE 14, make such payments as are required pursuant to ARTICLE 5 if, as and when due and payable thereunder (collectively, the
“Consideration”). 
 3.2 Withholding Taxes. NewCo (and its agents), the Pfizer Parties (and their agents), and any
other applicable withholding agent shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement such amounts as may be required to be deducted or withheld therefrom under any provision
of federal, state, local or foreign Tax law or under any applicable Law and to request any necessary Tax forms, including Form W-9 or the appropriate series of Form W-8,
as applicable, or any similar information. Prior to withholding any amount, the applicable withholding agent shall provide written notice to the Person to whom such amounts would otherwise have been paid, together with reasonably sufficient details
regarding the nature of the relevant withholding Tax. If any reduction of or exemption from such Tax is available, the withholding agent shall cooperate with the Person to whom such amounts would otherwise have been paid to the extent commercially
reasonable to obtain any such reduction or exemption. To the extent such amounts are so deducted or withheld and properly remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as
having been paid to the Person to whom such amounts would otherwise have been paid. 

  
 24 

 ARTICLE 4 

CLOSING AND CLOSING DELIVERIES 

4.1 Closing; Time and Place. The closing of the Transactions (the “Closing”) shall occur at the offices of
Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, Massachusetts (or, if agreed by the parties, electronically through the exchange of documents), at 10:00 A.M. Eastern time on the date that is two (2) Business Days after
the day on which all of the conditions to closing set forth in ARTICLE 11 are satisfied or waived (other than conditions that are intended to be satisfied at the Closing but subject to the satisfaction or waiver of such conditions), which is
expected to be on or about April 6, 2018 or at such other date, time or place as the parties may agree (the “Closing Date”). 

4.2 Deliveries by Pfizer Parties. At the Closing, Pfizer shall, or shall cause the Pfizer Subsidiaries to, deliver, each of the
following items, duly executed and delivered by the applicable Pfizer Party or Pfizer Parties:  

(a) Contribution, Assignment and Assumption and Bill of Sale. A Contribution, Assignment and Assumption and Bill of Sale
covering all of the applicable Purchased Assets and Assumed Liabilities, substantially in the form attached hereto as Exhibit B (the “General Assignment and Bill of Sale”); 

(b) Intellectual Property Assignments. A patent assignment (the “Patent Assignment”) substantially in
the form attached hereto as Exhibit C, for all of the Patents included in the Pfizer Assigned IP Rights; 
 (c)
Patent and Know-How License Agreement. A patent and know-how license agreement, substantially in the form attached hereto as Exhibit D, pursuant to
which, in part, (i) the Pfizer Parties will grant certain non-exclusive and exclusive licenses to NewCo under the Group 3 Pfizer IP Rights and certain other Intellectual Property Rights of Pfizer, and
(ii) NewCo will grant certain non-exclusive and exclusive licenses to the Pfizer Parties under certain of the Intellectual Property Rights of NewCo (the “Patent and
Know-How License Agreement”); 
 (d) Transition Services Agreement. A
transition services agreement, substantially in the form attached hereto as Exhibit E (the “Transition Services Agreement”), obligating the Pfizer Parties and certain of their Affiliates to provide certain transition services
to NewCo and certain of its Affiliates for the period following the Closing set forth therein; 
 (e)
Investors’ Rights Agreement. A shareholder rights agreement among Pfizer, NewCo and the Other Investors, substantially in the form attached hereto as Exhibit F (the “Investors’ Rights
Agreement”); 
 (f) Preferred Stock Purchase Agreement. A preferred stock purchase agreement among Pfizer,
NewCo, the Other Investors, and the Founders substantially in the form attached hereto as Exhibit H-1, provided that if Gilead Sciences, Inc. or its Affiliate enters into an Equity Commitment Letter
with respect to a funding commitment 

  
 25 

 
of [***] prior to Closing, such preferred stock purchase agreement shall be in the form attached hereto as Exhibit H-2 (in either case, the
“Preferred Stock Purchase Agreement”); 
 (g) Right of First Refusal and
Co-Sale Agreement. A right of first refusal and co-sale agreement among Pfizer, NewCo, the Other Investors and the Founders, substantially in the form attached
hereto as Exhibit I (the “Right of First Refusal and Co-Sale Agreement”). 

(h) Voting Agreement. A voting agreement among Pfizer, NewCo, the Other Investors and the Founders, substantially in the
form attached hereto as Exhibit J (the “Voting Agreement”). 
 (i) Books and Records. The
Books and Records; 
 (j) FIRPTA Documentation. From each of Pfizer and Rinat Neuroscience Corp., a duly
executed certificate of non-foreign status, dated as of the Closing Date, in form and substance reasonably satisfactory to NewCo, and conforming to the requirements of Treasury Regulations Section 1.1445-2(b)(2), stating that each of Pfizer and Rinat Neuroscience Corp. is not a “foreign person” as defined in Section 1445 of the Code; 

(k) Form W-9. From each of Pfizer and Rinat Neuroscience Corp., an
original, properly completed and duly executed IRS Form W-9 (Rev. November 2017) executed on behalf of Pfizer and Rinat Neuroscience Corp., as applicable, by a duly authorized representative; and 

(l) Certificate of Representations and Warranties. A certificate executed on behalf of Pfizer by an officer of Pfizer,
certifying as to the matters in Section 11.1(a). 
 4.3 Deliveries by NewCo. At the Closing, NewCo shall
deliver the following items, duly executed by NewCo as applicable: 
 (a) Consideration. The Equity Consideration;

 (b) General Assignment and Bill of Sale. The General Assignment and Bill of Sale; 

(c) Patent Assignment. The Patent Assignment; 

(d) Patent and Know-How License Agreement. The Patent and Know-How License Agreement; 
 (e) Transition Services Agreement. The Transition
Services Agreement; 
 (f) Investors’ Rights Agreement. The Investors’ Rights Agreement; 

(g) Preferred Stock Purchase Agreement. The Preferred Stock Purchase Agreement; 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 26 

 (h) Right of First Refusal and
Co-Sale Agreement. The Right of First Refusal and Co-Sale Agreement; 

(i) Voting Agreement. The Voting Agreement; and 

(j) Certificate of Representations and Warranties. A certificate executed on behalf of NewCo by an officer of NewCo,
certifying as to the matters in Section 11.2(a). 
 ARTICLE 5 

MILESTONES, ROYALTIES AND OTHER FINANCIAL OBLIGATIONS 

5.1 Post-Closing Financial Obligations.  

(a) Payments Upon Regulatory Approval. Subject to the remainder of this Section 5.1(a), on a
Pfizer Target-by-Pfizer Target basis, NewCo will pay Pfizer the amounts set forth below within [***] days following the first occurrence of the event described in row
(i), (ii), (iii) or (iv) of Table A, as applicable (such event, a “Milestone Event”) that is achieved by NewCo or any of its Affiliates or any Sublicensee (each amount, a “Milestone Payment”). 

Table A: Milestone Events and Payments 
  

							
	 	  	 Event
	  	Milestone Payment	 
	 [***]
	  	[***]	  	 	[***]	 
	 [***]
	  	[***]	  	 	[***]	 
	 [***]
	  	[***]	  	 	[***]	 
	 [***]
	  	[***]	  	 	[***]	 

 Each of the Milestone Payments set forth in Table A above will be payable only once for each applicable Pfizer
Target (if at all), irrespective of how many Products Targeting such 
 [***] = CONFIDENTIAL TREATMENT
REQUESTED 

  
 27 

 Pfizer Target achieve the applicable Milestone Event. For clarity, no payments are due
hereunder for any CD52 Product. 
 (b) Sales Milestone Payments. On a Pfizer Target-by-Pfizer Target basis, other than for Early Stage Targets (i.e., for all Developed Pfizer Targets, the ROR1 Target and the CD19 Target), NewCo will pay Pfizer the following one-time payments (each, a “Sales Milestone Payment”) when aggregate Territory Annual Net Sales of all Products Targeting such Pfizer Target (other than an Early Stage Target), in any Calendar Year
during the Term (the “Total Annual Net Sales”) first reach the respective thresholds indicated below for the [***] such Pfizer Targets for which such threshold is achieved: 

Table B: Sales Milestone Payments 
  

					
	 Total Annual Net Sales
	  	Sales Milestone Payment	 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

 NewCo will make any Sales Milestone Payment payable with respect to a Calendar Year within [***] days
after the end of the applicable Calendar Year, and such payment will be accompanied by a report identifying the applicable Pfizer Target and applicable Products, the Annual Net Sales of such Products, and the amount payable to Pfizer under
this Section 5.1(b). Each of the Sales Milestone Payments set forth in Table B above will be payable one time only for each applicable Pfizer Target, regardless of the number of times the corresponding Total Annual
Net Sales levels are achieved with respect to such Target. In the event more than one of the Total Annual Net Sales levels set forth in Table B above are achieved in the same Calendar Year, each applicable Sales Milestone Payment will become
due and payable to Pfizer. For clarity, no sales based milestone payments will be payable with respect to any Products Targeting any Early Stage Target, or with respect to CD52 Products. 

(c) Royalty Payments. 

(i) Royalties for Products Targeting CD19 and ROR1 Targets. On a Product-by-Product and country-by-country basis, NewCo will pay Pfizer royalties equal to [***] percent ([***]%) of Annual Net
Sales of Products Targeting the CD19 Target or the ROR1 Target during the applicable Royalty Term for each such Product in such country, subject to adjustment as provided under Section 5.1(c)(iv). 

(ii) Royalties for Royalty-Bearing Products. On a Royalty-Bearing Product-by-Royalty-Bearing Product and country-by-country basis, NewCo will pay Pfizer royalties for each Royalty-Bearing
Product (other than Products 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 28 

 Targeting the CD19 Target and the ROR1 Target, which are addressed under subsection
(i) above), on a tiered marginal royalty rate basis as set forth below (the “Marginal Royalty Rates”) based on the annual aggregate Royalty Territory-wide Net Sales of such Royalty-Bearing Product during each Calendar Year of
the applicable Royalty Term for each such Royalty-Bearing Product in such country (each, the “Annual Net Sales”), subject to adjustment as provided under Section 5.1(c)(iv): 

Table C: Marginal Royalty Rates 
  

					
	 Annual Net Sales of a Royalty-Bearing Product
	  	Marginal
Royalty Rate
(% of Annual
Net Sales)	 
	 Annual Net Sales above $[***], up to $[***] million
	  	 	[	***]% 
	 Annual Net Sales including and above $[***], up to $[***]
	  	 	[	***]% 
	 Annual Net Sales including and above $[***]
	  	 	[	***]% 

 Each Marginal Royalty Rate set forth in Table C above will apply only to that portion of the Net Sales
of such Royalty-Bearing Product in the Territory during a given Calendar Year that falls within the indicated range. 
 (iii)
Royalties for Other Royalty-Bearing Products. On an Other Royalty-Bearing Product-by-Other Royalty-Bearing Product and country-by-country basis, NewCo will pay Pfizer royalties equal to [***] percent ([***]%) of Net Sales of Other Royalty-Bearing Products during the applicable Royalty Term for each such Other Royalty-Bearing
Product in such country in the Territory. 
 (iv) Adjustments. 

(A) Third Party Intellectual Property. Except with respect to any amounts payable by NewCo under Section 2.6 of the
Patent and Know-How License Agreement or any amounts payable to Ablexis, LLC, Aliva Biopharmaceuticals, Inc. or any Affiliate thereof pursuant to the Ablexis Agreement or any new agreement entered into with
respect to the Ablexis Antibodies, NewCo shall have the right to offset up to [***] percent ([***]%) of the royalty payments actually paid to a Third Party by NewCo, its Affiliates, or its Sublicensees on the sales of a Royalty-Bearing Product in a
country in the Royalty Territory with respect to any license to intellectual property owned or controlled by such Third Party that is necessary or useful for development, manufacture, use or sale of such Royalty-Bearing Product in such country in
the Royalty Territory against royalties otherwise payable by NewCo to Pfizer under subsection (i) or (ii) above for such Royalty-Bearing Product in such country; provided, however, that the maximum reduction under this subsection (A) in
the amount of royalties otherwise payable hereunder for such Royalty-Bearing Product shall be capped at 
 [***] = CONFIDENTIAL
TREATMENT REQUESTED 

  
 29 

 (B) [***] percent ([***]%), subject to subsection (B) below. If, but
for the proviso in the preceding sentence, the calculation of any deduction hereunder would have the effect of reducing a royalty payment made by NewCo by more than [***] percent ([***]%), then such deduction amount in excess of [***] percent
([***]%) will be applied to one or more subsequent royalty payments until the full amount that NewCo would have been entitled to deduct with respect to such deduction (absent the foregoing limitation) is deducted. Prior to applying any offset under
this Section 5.1(c)(iv)(A), NewCo shall inform Pfizer in advance that amounts paid to a Third Party will be so offset against royalties owed to Pfizer in consideration for a license to intellectual property owned or
controlled by such Third Party for the development, manufacture, use or sale of the applicable Royalty-Bearing Product in the applicable country. 

(C) Non-Exclusive Group 3 Patents, Non-Exclusive Know-How Patents, Non-Exclusive Group 3 Know-How. If a Royalty-Bearing Product is (1) not Covered by a Valid
Claim of any Assigned Patent, Key Assigned Contract Patent, Exclusive Group 3 Patent, Exclusive Know-How Patent or an Arising Patent that is an Arising Patent under clause (b) of the “Arising
Patent” definition in Section 1.1 (with respect to an Assigned Patent or Exclusive Group 3 Patent) and (2) does not incorporate and is not made, discovered, developed or derived from the use of Exclusive Group 3 Know-How, or any Know-How included in the Pfizer Assigned IP Rights, then, notwithstanding Section 5.1(c)(ii), the royalty rate payable by NewCo for
such Product under this Agreement shall be, on a country-by-country basis, equal to [***] percent ([***]%) of Net Sales of such Royalty-Bearing Product during the
applicable Royalty Term in such country. 
 (D) Floor. The royalty rates set forth in Sections 5.1(c)(i) and
(ii) may not be reduced for a given country in the Royalty Territory by application of the adjustments set forth in Section 5.1(c)(iv)(A) in the aggregate to less than the greater of (1) [***] percent ([***]%)
of Net Sales and (2) [***] percent ([***]%) of the applicable royalty rate of Net Sales set forth in Sections 5.1(c)(i) or (ii). 

(v) Third Party Payment Obligations. NewCo will be solely responsible for all obligations (including any milestone,
royalty or other obligations that relate to the Products) under the Assigned Contracts arising as of or after the Closing Date and NewCo’s other existing or future agreements with Third Parties. For the avoidance of doubt, no such
obligations under the Assigned Contracts may be offset pursuant to Section 5.1(c)(iv) against royalties or any other payments owed to Pfizer under this Agreement. 

(d) Reports and Payments. 

(i) Royalty Statements and Payments. Within [***] days of the end of each Calendar Quarter, NewCo will deliver to Pfizer
a report setting forth, for such Calendar Quarter, the following information, on a Product-by-Product, Target-by- Target, country-by-country and Territory-wide basis: (A) Net Sales of each Product for each Target, (B) the type of permitted deductions from 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 30 

 (ii) gross sales to determine Net Sales and the total amount of such
deductions; (C) the calculation of the royalties due to Pfizer for such Calendar Quarter, and (D) the royalty due hereunder for the sale of each such Product. NewCo will remit to Pfizer the total royalty due for the sale of all Products
during the applicable Calendar Quarter at the time each such report is delivered. 
 (iii) Currency. As applicable,
Net Sales that are recorded in local currencies other than United States dollars will be translated into United States dollars in a manner consistent with NewCo’s normal practices used to prepare its audited financial statements for external
reporting purposes, provided that such practices use a widely accepted source of published exchange rates. 
 (iv) Blocked
Currency. If by applicable Law in a country or region, conversion into United States dollars or transfer of funds of a convertible currency to the United States becomes restricted, forbidden or substantially delayed, then NewCo shall promptly
notify Pfizer and, thereafter, amounts accrued in such country or region shall be paid to Pfizer (or its designee) in such country or region in local currency by deposit in a local bank designated by Pfizer and to the credit of Pfizer. 

(v) Method of Payment. Each payment hereunder will be made by electronic transfer in immediately available funds via
either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer’s election, to such bank account as Pfizer will designate in writing to NewCo at least [***] days before the
payment is due. 
 (vi) Late Payments. Interest on any late payment by NewCo shall accrue from the date such payment
was originally due at a rate equal to [***] percent ([***]%) above the prime rate of interest as reported in the Wall Street Journal on the date payment was due. Such interest shall be computed on the basis of a year of 360 days for the actual
number of days payment is delinquent. 
 (vii) Record Keeping. NewCo will keep and will cause its Affiliates,
licensees and Sublicensees to keep, books and accounts of record in connection with the sale of Products in sufficient detail to permit accurate determination of all figures necessary for verification of royalties and Sales Milestone Payments to be
paid hereunder. NewCo and its Affiliates will maintain such records for a period of at least [***] years after the end of the Calendar Quarter in which they were generated, or such longer period as is required by applicable Law. 

(viii) Audits. Upon [***] days prior notice from Pfizer, NewCo will permit, and will cause its Affiliates and
Sublicensees to permit, an independent certified public accounting firm of nationally recognized standing selected by Pfizer and reasonably acceptable to NewCo, to examine, at Pfizer’s sole expense, the relevant books and records of NewCo, its
Affiliates and Sublicensees who are Sellers for the sole purpose of verifying the amounts reported by NewCo in accordance with Section 5.1 and the payment of royalties and Sales Milestone 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 31 

 (ix) Payments hereunder. An audit by Pfizer under this
Section 5.1(d)(viii) will occur not more than once in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] years before the date of the request. The
accounting firm will be provided access to such books and records at the facility(ies) of NewCo, its Affiliates or Sublicensees, as applicable, where such books and records are normally kept and such examination will be conducted during normal
business hours. NewCo or the applicable Sublicensee may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to facilities or
records. Upon completion of the audit, the accounting firm will provide both Pfizer and NewCo a written report disclosing any discrepancies in the reports submitted by NewCo or the royalties or Sales Milestone Payments paid by NewCo, and, in each
case, the specific details concerning any discrepancies. Such accounting firm shall not disclose NewCo’s Confidential Information to Pfizer, except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by
NewCo in accordance with Section 5.1 or the amount of payments by NewCo under this Agreement, in which case Pfizer’s obligations with respect to such Confidential Information shall be subject to
Section 9.6. 
 (x) Underpayments/Overpayments. If such accounting firm concludes that
additional royalties or Sales Milestone Payments were due to Pfizer, then NewCo will pay to Pfizer the additional royalties or Sales Milestone Payments within [***] days of the date NewCo receives such accountant’s written report. Further, if
the amount of such underpayments exceeds more than [***percent ([***]%) of the amount that was properly payable to Pfizer, then NewCo will reimburse Pfizer for Pfizer’s reasonable documented out-of-pocket costs in connection with the audit. If such accounting firm concludes that NewCo overpaid royalties or Sales Milestone Payments to Pfizer, then such overpayments will be credited against future
amounts payable by NewCo to Pfizer under this Section 5.1, or, if no further payments are to be made to Pfizer under this Agreement, Pfizer shall promptly repay such overpayment. 

(xi) Confidentiality. Notwithstanding any provision of this Agreement to the contrary all reports and financial
information of NewCo or its Affiliates’ Sublicensees which are provided to or subject to review by Pfizer under this Section 5.1 will be deemed to be NewCo’s Confidential Information and subject to the provisions
of Section 9.6. 
 5.2 Diligence and Post-Closing Obligations. 

(a) Generally. Subject to Section 5.2(b) below, NewCo will have sole authority over and
control of the development, manufacture, seeking and obtaining Regulatory Approval and commercialization of Products in the Territory and will retain final decision-making authority with respect thereto. 

(b) Diligence. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 32 

 (i) Development and Regulatory Approval. NewCo shall use Commercially
Reasonable Efforts to develop, and to file for and seek to obtain Regulatory Approval for Royalty-Bearing Products in and for the United States and for Royalty-Bearing Products other than the Servier Products, the European Union (including for such
purpose, the United Kingdom), which such obligation shall remain in effect until the tenth anniversary of the Closing Date. 

(ii) Commercialization. On a
Product-by-Product and country-by-country basis, NewCo will use Commercially Reasonable
Efforts to commercialize each Product in each country in the applicable Royalty Territory in which Regulatory Approval for such Product has been obtained. 

(iii) Compliance with Law and Procedures. NewCo will perform all development, Regulatory Approval and commercialization
activities relating to Products in compliance with all applicable Laws. 
 (iv) Diligence Reports. 

 

	 	(A)	 NewCo shall deliver to Pfizer a written report summarizing material development and Regulatory Approval
activities undertaken by or on behalf of NewCo with respect to the Products and Purchased Programs and a reasonably detailed summary of all results and data stemming from such development activities (each, a “Development Update”).
NewCo shall deliver such Development Updates (x) within [***] days of the end of each Calendar Quarter during the period from the Closing Date until [***] anniversary of the Closing Date; and (y) every [***] thereafter until Regulatory
Approval of the first Product, and (z) [***], thereafter, until [***] anniversary of such initial Regulatory Approval. 

  

	 	(B)	 Beginning on or before January 1 of the Calendar Year following the Calendar Year in which Regulatory
Approval of the first Product is received, NewCo shall provide written reports to Pfizer on an annual basis, summarizing material commercial activities undertaken by or on behalf of NewCo with respect to such Product and any other Products.

  

	 	(C)	 Upon at least [***] days’ notice from Pfizer, NewCo shall arrange for representatives of NewCo to meet in
person with Pfizer, no more than [***] per twelve (12) month period and following delivery of any of the above reports, to discuss the contents of such report and any prior report. 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 33 

 ARTICLE 6 

REPRESENTATIONS AND WARRANTIES OF PFIZER 

Subject to the terms of this Agreement and except as set forth in the corresponding sections or subsections of the disclosure schedules
attached hereto, Pfizer represents and warrants to NewCo as of the date of this Agreement as follows: 
 6.1 Organization. Pfizer is a
corporation duly incorporated, validly existing and in good standing under the Laws of the State of Delaware. Each of the other Pfizer Parties is a legal entity duly organized, validly existing and in good standing (where such concept is recognized
under applicable Law) under the Laws of its respective jurisdiction of organization. Each Pfizer Party is duly qualified or licensed, and has, or has a license to, all Governmental Approvals necessary, to do business and is in good standing (where
such concept is recognized under applicable Law) and authorized to do business under the Laws in each jurisdiction in which the property owned, leased or operated by it or the nature of the business conducted by it makes such approvals,
qualification or licensing necessary, except where the failure to be so qualified or licensed or to have such power, authority or approvals or be in good standing has not had, and would not reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect. 
 6.2 Power and Authority Relative to this Agreement. 

(a) Each Pfizer Party has the requisite corporate or limited liability company power and authority to carry out the provisions
of this Agreement and/or the other Transaction Agreements, as applicable. The execution, delivery and performance of this Agreement and the other Transaction Agreements, as applicable, by each Pfizer Party and the consummation of the Transactions
have been duly and validly authorized by each Pfizer Party’s board of directors (or similar governing body). 
 (b) This
Agreement has been duly and validly executed and delivered by Pfizer and is enforceable against Pfizer in accordance with its terms, except as such enforcement may be subject to applicable bankruptcy, reorganization, insolvency, moratorium or other
similar Laws affecting creditors’ rights generally and the availability of equitable relief (the “Enforceability Exceptions”). 

(c) As of the Closing, each of the other Transaction Agreements to which a Pfizer Party is a party will have been duly and
validly executed and delivered by such applicable Pfizer Party and will be enforceable against such Pfizer Party in accordance with its terms, subject to the Enforceability Exceptions. 

6.3 Consents; No Violation. 

(a) Other than as set forth on Schedule 6.3, no authorization, consent, Order, license, permit or approval of, or
registration, declaration, notice or filing with, any Governmental Authority is necessary, under applicable Law, for the consummation by the Pfizer Parties of the Transactions other than such authorizations, consents, Orders, licenses, permits,
approvals, registrations, declarations, notices and filings (i) as have already been 

  
 34 

 
obtained or (ii) the failure of which to be obtained would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

(b) The execution and delivery by the Pfizer Parties of this Agreement and the other Transaction Agreements, as applicable,
does not, and the consummation of the Transactions and compliance with the provisions hereof will not, (i) result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination,
cancellation, first offer, first refusal, modification or acceleration of any obligation or to the loss of a benefit under any Key Assigned Contract or other Assigned Contract binding upon any Pfizer Party by which or to which any of the Purchased
Assets are bound or subject, or result in the creation of Liens, other than Permitted Liens, in each case, upon any of the Purchased Assets or the conduct of the Purchased Programs, (ii) conflict with or result in any violation of any provision
of the respective Organizational Documents of any Pfizer Party or (iii) violate any applicable Laws to which any Pfizer Party is subject, except as, with respect to clause (i) or (iii), would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. 
 6.4 Permits. Schedule 6.4 describes (a) each material Permit
held by a Pfizer Party in connection with such Pfizer Party’s operation of the Purchased Programs (the “Purchased Programs Permits”), and (b) the Governmental Authority responsible for issuing such Purchased Programs
Permit. All Purchased Programs Permits are valid and in full force and effect, and are not subject to any administrative or judicial Proceeding that would reasonably be expected to result in any modification, termination or revocation thereof and,
to the knowledge of the Pfizer Parties, no suspension or cancellation of any such Purchased Programs Permit is threatened by a Governmental Authority in writing. The Pfizer Parties are in compliance in all material respects with the terms and
requirements of all Purchased Programs Permits. 
 6.5 Compliance with Laws. 

(a) The Pfizer Parties are in compliance in all material respects with all Laws, including Regulatory Laws, and Governmental
Approvals applicable to the conduct of the Purchased Programs as conducted as of the date of this Agreement, including the nonclinical and clinical testing, manufacture, storage, distribution, marketing, pricing, packaging, labeling and sale of the
Products in the United States, as applicable. All such Governmental Approvals are valid and in full force and effect without any contingency, restriction or limitation other than which would immaterially impair the conduct of the Purchased Programs.

 (b) The Pfizer Parties are in compliance in all material respects with all Orders of any Governmental Authority to which
they are subject, including any corporate integrity agreement, including all programmatic, operational and reporting requirements, in each case, applicable to the Purchased Programs, the Purchased Assets or the Assumed Liabilities. 

(c) Since January 1, 2016, neither the Pfizer Parties nor, to the knowledge of the Pfizer Parties, any employee or
contractor of the Pfizer Parties, has made any voluntary or self-disclosure to any Governmental Authority regarding any potential non-compliance 

  
 35 

 
in any material respect with any Governmental Approval, Orders of any Governmental Authority, or Law, in each case applicable to the Purchased Programs, the Purchased Assets or the Assumed
Liabilities. 
 (d) Neither Pfizer nor any of its Affiliates, nor any of its or their respective officers or employees
(i) has made an untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Authority responsible for enforcement or oversight with respect to healthcare Laws with respect to the development of any Product,
(ii) has failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Authority responsible for enforcement or oversight with respect to healthcare Laws with respect to the development of any Product, or
(iii) committed an act, made a statement, or failed to make a statement with respect to the development of any Product that, at the time such disclosure was made, would reasonably be expected to provide a basis for the FDA to invoke its policy
respecting “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies outside the United States. 

(e) No Pfizer employee or, to Pfizer’s knowledge, any agent who worked on the development or manufacture of any Product
has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA or any other Governmental Authority to invoke its policy with respect to “Fraud, Untrue Statements of
Material Facts, Bribery, and Illegal Gratuities” set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto. No Pfizer employee or, to Pfizer’s knowledge, any agent who worked on the development or manufacture of any
Product has been convicted of any crime or engaged in any conduct that would reasonably be expected to result, or has resulted, in (i) debarment under 21 U.S.C. Section 335a or any similar state Law, or (ii) exclusion under 42 U.S.C. Section 1320a-7 or any similar state Law. 
 6.6 Absence of Certain Changes. Since
December 31, 2017, (a) no event has occurred or arisen that has had, or would reasonably be expected to have, a Material Adverse Effect, (b) the Purchased Programs have been conducted in the ordinary course of business in all material
respects and (c) except as set forth on the disclosure schedules attached hereto, there has not been any: 
 (i) Sale,
lease or other disposition of any Purchased Asset, other than in the ordinary course of business, or the creation of any Lien on any Purchased Asset, except for Permitted Liens; 

(ii) Termination of any Key Assigned Contract; 

(iii) Increase by the Pfizer Parties of the salaries, bonuses or other compensation to any Prospective Employee, other than in
the ordinary course of business; 

  
 36 

 (iv) Adoption of, amendment to or increase in the payments to or benefits
under any Covered Benefit Plan in which any of the Prospective Employees participates, other than in the ordinary course of business; or 

(v) Contract by Pfizer to do any of the foregoing. 

6.7 Tax Matters. 

(a) Each Pfizer Party has prepared and timely filed (taking into account any valid extension of time within which to file) all
income Tax Returns and all other material Tax Returns required to be filed by it in respect of the Purchased Programs, the Purchased Assets, and the Transferred Employees, and all such Tax Returns are true, complete and accurate in all material
respects. No extension of time within which to file any such Tax Returns that has not been filed has been requested or granted, other than such extensions filed in the ordinary course of business. 

(b) Each Pfizer Party has timely paid all material amounts of all Taxes due, payable and owing by it (whether or not shown on
any Tax Return), except for such Taxes for which adequate reserves have been established, in respect of the Purchased Programs, the Purchased Assets, and the Transferred Employees. 

(c) Each Pfizer Party has complied in all material aspects with all applicable Laws relating to the payment, collection,
withholding and remittance of material amounts of all Taxes (including information reporting requirements in respect thereof) in respect of the Purchased Programs, the Purchased Assets, and the Transferred Employees, including with respect to
payments made to or received from any employee, independent contractor, creditor, customer, stockholder or other Third Party. 

(d) None of the Pfizer Parties has waived or extended any statute of limitations with respect to material amounts of Taxes or
agreed to any extensions of time with respect to a Tax assessment or deficiency which waiver or extension is still in effect, in each case in respect of any Purchased Program, Purchased Asset, or Transferred Employee. 

(e) No deficiencies or proposed assessments for material amounts of Taxes in respect of the Purchased Programs, the Purchased
Assets, or the Transferred Employees have been claimed, proposed or assessed by any Governmental Authority in writing except for deficiencies which have been fully satisfied by payment, settled or withdrawn. 

(f) There are no audits, suits, examinations, investigations or other Proceedings pending or threatened in writing in respect
of material amounts of any Taxes or material Tax matters in respect of any of the Purchased Programs, the Purchased Assets, or the Transferred Employees. None of the Pfizer Parties has received a written ruling from any Tax Authority in respect of
any Purchased Program, Purchased Asset, or Transferred Employee. There are no Liens for Taxes on any of the Purchased Programs or Purchased Assets other than statutory liens for current Taxes not yet due and payable. 

(g) None of the Pfizer Parties (i) is a party to any agreement or arrangement relating to the sharing, indemnification or
allocation of any Tax or Tax asset (other than 

  
 37 

 
(A) an agreement or arrangement solely between or among Pfizer, and/or any other Affiliate of Pfizer and (B) any Tax sharing, indemnification or allocation provisions in agreements entered
into in the ordinary course of business and not primarily relating to Taxes) or (ii) has any Liability for Taxes of any person (other than the Pfizer and/or any other Affiliate of Pfizer) under Treasury Regulations Section 1.1502-6 (or any analogous or similar provision of state, local or foreign Law), as transferee, successor, by contract, or otherwise. 

(h) None of the Pfizer Parties has participated in any “listed transaction” within the meaning of Treasury
Regulations Section 1.6011-4(b)(2) (or any analogous or similar provision of state, local or foreign Law). 

(i) None of the Purchased Assets is a “United States real property interest” within the meaning of
Section 897(c)(1) of the Code and the Treasury Regulations thereunder other than Purchased Assets that are owned and transferred by Pfizer Parties that are not “foreign persons” within the meaning of Section 1445 of the Code (and
each such Pfizer Party has delivered a duly executed non-foreign affidavit in accordance with Section 4.2(j)). 

(j) No claim has been made by a Tax Authority in writing in a jurisdiction where a Pfizer Party does not file Tax Returns in
respect of any Purchased Program, Purchased Asset, or Transferred Employee, that such Pfizer Party is or may subject to taxation by that jurisdiction in respect of such Purchased Program, Purchased Asset, or Transferred Employee. 

(k) Neither the execution of this Agreement nor the consummation of the transactions contemplated hereby, either alone or in
conjunction with any other event (whether contingent or otherwise) will, with respect to any Prospective Employee, result in the payment of any “parachute payment” (within the meaning of Section 280G of the Code) that is subject to
the imposition of an excise Tax under Section 4999 of the Code or that would not be deductible by reason of Section 280G of the Code. 

Notwithstanding any other provision of this Agreement, (i) the representations and warranties contained in this
Section 6.7 constitute the sole and exclusive representations and warranties of the Pfizer Parties in this ARTICLE 6 relating to any Taxes or Tax Returns and (ii) nothing in this Agreement shall be construed as
providing a representation or warranty with respect to the existence, amount, expiration date or limitations on (or availability of) any Tax attribute (including methods of accounting) of the Pfizer Parties for taxable periods (or portions thereof)
beginning after the Closing Date. 
 6.8 Prospective Employees; Employee Benefits. 

(a) The Pfizer Parties have provided to NewCo an accurate and complete list as of the Effective Date of: (i) the job
title, full or part-time status, business unit, base compensation, target bonus percentage, fringe benefits, eligibility for equity, hire date, status as exempt or non-exempt (under applicable overtime
regulations), and location of all current employees who NewCo will be obligated to offer employment to pursuant to 

  
 38 

 
Article 10 (the “Prospective Employees”). As of the Effective Date, no Prospective Employee is on a leave of absence of any kind. As of the date hereof, no Prospective
Employee has given notice to any of the Pfizer Parties of such employee’s termination of employment or request for a leave of absence. To the knowledge of the Pfizer Parties, no Prospective Employee intends to terminate his or her employment
with any of the Pfizer Parties or request or take a leave of absence prior to the Effective Date, or intends to terminate his or her employment with NewCo within six (6) months following the Effective Date. 

(b) The Pfizer Parties are currently, and for the past three (3) years, have been, in material compliance with all
applicable Laws respecting employment, discrimination in employment, terms and conditions of employment, wages, hours and occupational safety and health with respect to the Prospective Employees. There are no Proceedings pending or, to the knowledge
of the Pfizer Parties, threatened, between any of the Pfizer Parties and any of the Prospective Employees before any Governmental Authority. To the knowledge of the Pfizer Parties, no Prospective Employee is in material violation of any
(i) employment, non-disclosure, confidentiality or consulting agreement with any of the Pfizer Parties, or (ii) non-competition agreement, non-solicitation agreement, non-disclosure agreement or similar restrictive covenant with a former employer relating to the right of any such Person to be employed by or
provide services to the Pfizer Parties because of the nature of the business conducted or presently proposed to be conducted by the Pfizer Parties. 

(c) No Prospective Employee is represented by a labor union or other employee representative body, and, to the knowledge of the
Pfizer Parties, there are no activities or proceedings filed by any labor union or other employee representative body as of the date hereof to organize any of the Prospective Employees. 

(d) Schedule 6.8(d) contains an accurate and complete list of all Pfizer Benefit Plans (i)(A) under which any
Prospective Employee or any beneficiary thereof participates and (B) where, pursuant to ARTICLE 10 hereof, NewCo is either agreeing to provide similar benefits under a NewCo benefit plan or assume any costs arising under any such Pfizer Benefit
Plan; or (ii) under which NewCo or any of its Affiliates would reasonably be expected to have any material Liability (each such plan, a “Covered Benefit Plan”). With respect to each Covered Benefit Plan in which any Prospective
Employee currently participates, the Pfizer Parties have made available to NewCo complete and accurate copies of the following: (i) in the case of any Covered Benefit Plan that is a severance plan (including the Pfizer Separation Plan), the
plan document and all amendments thereto; (ii) in the case of any Covered Benefit Plan not identified in clause (i) a summary of the material terms thereof or a copy of the most recent summary plan description; and (iii) if
applicable, the most recent determination or opinion letter received from the IRS. No Covered Benefit Plan is maintained, sponsored, contributed to, or required to be contributed to by the Pfizer Parties primarily for the benefit of employees
outside of the United States. 
 (e) Each Covered Benefit Plan has been maintained, funded and administered in compliance
with its own terms and in compliance in all material respects with the 

  
 39 

 
provisions of applicable Laws, including ERISA and the Code. No Covered Benefit Plan which is a defined benefit plan had, as of the most recent measurement date, an “adjusted funding target
attainment percentage,” as defined in Section 436 of the Code, that was less than 80%. No Covered Benefit Plan has an “accumulated funding deficiency,” whether or not waived, or is subject to a lien for unpaid contributions under
Section 303(k) of ERISA or Section 430(k) of the Code. 
 (f) Each Covered Benefit Plan that is intended to qualify
under Section 401(a) of the Code is subject to a favorable determination or opinion letter from the IRS and, to the knowledge of the Pfizer Parties, no act or omission has occurred that would reasonably be expected to adversely affect the
qualified status of any such Covered Benefit Plan. 
 (g) Other than as set forth on Schedule 6.8(g), no Prospective
Employee participates in any Covered Benefit Plan that is: (i) a “multiemployer plan” within the meaning of Section 3(37) or Section 4001(a)(4) of ERISA; or (ii) a benefit plan that is subject to Title IV of ERISA or
the funding requirements of Section 302 of ERISA or Section 412 of the Code. 
 (h) Other than as set forth on
Schedule 6.8(h) or as provided in ARTICLE 10, neither the execution of this Agreement nor the consummation of the transactions contemplated hereby, either alone or in conjunction with any other event (whether contingent or otherwise) will,
with respect to any Prospective Employee: (i) result in any payment or benefit becoming payable, or required to be provided, by any of the Pfizer Parties to any such individual (other than payment of earned and unpaid wages, accrued vacation or
paid time off in connection with the termination of any Transferred Employee by a Pfizer Party in connection with the Closing); (ii) result in the forgiveness of any indebtedness of any such individual; or (iii) increase the amount of any
benefit or compensation otherwise payable or required to be provided, by any of the Pfizer Parties to any such individual; or (iv) result in the acceleration of the vesting or timing of payment of any compensation or benefits payable by any of
the Pfizer Parties to or in respect of any such individual. 
 (i) Other than the Prospective Employees, there are no
employees of any of the Pfizer Parties, and there are no employees of any of the Pfizer Parties who are employed outside of the United States, who are wholly or mainly assigned to the Purchased Programs or dedicate a material percentage of his or
her services to the Purchased Programs. 
 (j) Notwithstanding any other provision of this Agreement, the representations and
warranties contained in Section 6.6(c)(iv), Section 6.7, this Section 6.8, Section 6.9(k)-(l) and Section 6.13(e)
constitute the sole and exclusive representations and warranties relating to employees and employee benefit plans. 
 6.9 Intellectual
Property. 
 (a) With respect to the Pfizer Assigned IP Rights, Schedule 6.9 sets forth, in each case as of
the date hereof, an accurate and complete list of all U.S. and foreign: (i) Patents including the patent number or application serial number for each jurisdiction in 

  
 40 

 
which the Patent has been filed, the date filed or issued; (ii) applications and registrations for Trademarks, including the application serial number or registration number, for each
country, province and state; (iii) domain names; and (iv) registered Copyrights applications and registrations, including the number and date of registration for each country, province and state, in which a Copyright has been registered
(clauses (i) through (iv), collectively the “Purchased Programs Registered Intellectual Property”). 

(b) No exclusive licenses of any Pfizer Assigned IP Rights, any Group 3 Pfizer IP Rights, or, to Pfizer’s knowledge, no
exclusive licenses of any Key Assigned Contract Patent, are granted by Pfizer Parties to Third Parties. 
 (c) The issued
patents included in the Pfizer Assigned IP Rights and the Group 3 Pfizer IP Rights and to Pfizer’s knowledge, in the Key Assigned Contract Patents, are in effect and subsisting. 

(d) Immediately prior to the Closing Date, the Pfizer Parties will be (i) the sole and exclusive owner of the Pfizer
Assigned IP Rights and the Group 3 Pfizer IP Rights, or (ii) the holder of a valid right or exclusive license to use the Pfizer Assigned IP Rights, which right or license may be assigned to NewCo hereunder without the consent of any Third Party
or, if such consent is required, such consent will have been received prior to the Closing Date. 
 (e) The Pfizer Assigned
IP Rights, the Group 3 Pfizer IP Rights and, to Pfizer’s knowledge, the Key Assigned Contract Patents, are free and clear of any Liens, other than Permitted Liens. 

(f) To Pfizer’s knowledge, no person has infringed or is infringing any Pfizer Assigned IP Rights, Group 3 Pfizer IP
Rights or Key Assigned Contract Patents, or has otherwise misappropriated or is otherwise misappropriating any Know-How within the Pfizer Assigned IP Rights or Group 3 Pfizer IP Rights. 

(g) To Pfizer’s knowledge, there are no claims pending or threatened by the Pfizer Parties against any Person, nor have
the Pfizer Parties sent any written notice to any Person, regarding actual or potential infringement, dilution, misappropriation or other unauthorized use of any Pfizer Assigned IP Rights, Key Assigned Contract Patents or Group 3 Pfizer IP Rights.

 (h) As of the Closing Date, to Pfizer’s knowledge, (i) there are no adverse Third Party actions or claims
pending against the Pfizer Parties by any Person in any court, arbitration or by or before any Governmental Authority or, to Pfizer’s knowledge, any written adverse Third Party allegations, in any such case to the effect that the manufacture,
use, promotion, marketing or sale of the Products constitutes an infringement or misappropriation of the intellectual property rights of such Person, and (ii) none of the Pfizer Assigned IP Rights or Group 3 Pfizer IP Rights or any Key Assigned
Contract Patent is involved in any litigation or inventorship challenge, reissue, interference, reexamination, inter partes review, opposition, cancellation proceeding, or other post-grant proceeding. 

  
 41 

 (i) Each of the Patents within the Pfizer Assigned IP Rights, Key Assigned
Contract Patents, and Group 3 Pfizer IP Rights properly identifies, to Pfizer’s knowledge, each and every inventor of the claims thereof as determined in accordance with the law of the Territory in which such Patents with the Pfizer Assigned IP
Rights, Key Assigned Contract Patents or Group 3 Pfizer IP Rights is issued or pending. 
 (j) To Pfizer’s knowledge,
all material prior art of which the Pfizer Parties were aware during the pendency of any application currently in substantive prosecution relating to any issued patent in the Pfizer Assigned IP Rights, Key Assigned Contract Patents or Group 3 Pfizer
IP Rights owned by a Pfizer Party was properly filed with the patent authorities in the territory in which such application was pending. For all Pfizer Assigned IP Rights, Group 3 Pfizer IP Rights and, to Pfizer’s knowledge, the Key Assigned
Contract Patents, the Pfizer Parties have met their duty of candor as and if required under 37 C.F.R. 1.56 and complied with analogous Law outside the United States requiring disclosure of references. 

(k) Each current and former employee and individual contractor of the Pfizer Parties who is or was involved, to Pfizer’s
knowledge, in the creation or development of any Pfizer Assigned IP Rights or Group 3 Pfizer IP Rights owned by a Pfizer Party has executed and delivered (and to the Pfizer Parties’ knowledge, is in compliance with) an employment or consulting
agreement containing nondisclosure, assignment, and non-solicitation provisions. 

(l) To Pfizer’s knowledge, none of the Prospective Employees is obligated under any agreement, commitment, judgment,
decree or order that would materially conflict with the Purchased Programs as conducted. The Pfizer Parties are not using, and, to Pfizer’s knowledge, it will not be necessary to use, in connection with the Purchased Programs (i) any
inventions of any of their past or present employees or individual contractors made prior to or outside the scope of their employment or consulting agreement by the Pfizer Parties that have not been assigned, licensed or otherwise transferred to a
Pfizer Party or (ii) any confidential information or trade secret of any former employer of any such employee or contractors that has not been assigned, licensed or otherwise transferred to a Pfizer Party. 

6.10 Purchased Assets. 

(a) The Pfizer Parties are the sole and exclusive owners of and have good and valid title to, or valid and subsisting leasehold
interests in, all of the Purchased Assets constituting tangible personal property other than Permitted Liens. The Pfizer Parties have all requisite corporate power and authority to conduct and carry on the Purchased Programs as they are now being
conducted. 
 (b) The Purchased Assets, the Intellectual Property Rights licensed pursuant to the Key Assigned Contracts and
the Group 3 Pfizer IP Rights, together with any of the rights and licenses granted or provided to NewCo pursuant to the Patent and Know-How License Agreement and the services to be provided under the
Transition Services Agreement, as well as the transactions contemplated hereby and thereby, constitute in the 

  
 42 

 
aggregate all the assets necessary to conduct the Purchased Programs in substantially the same manner in all material respects as conducted as of the Effective Date. 

6.11 Investigations; Litigation. Since January 1, 2016 (a) there have been no material Proceedings relating to potential breaches,
misappropriations or other violations of Law pending, alleged or, to the knowledge of Pfizer, threatened with respect to any Pfizer Party and (b) there have been no material Orders of any Governmental Authority imposed upon any Pfizer Party, in
each case with respect to the Purchased Programs or the Transactions. 
 6.12 Inventory. The Purchased Inventory consists of a
quality and quantity usable in the ordinary course of business consistent with past practice except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and (a) are not excessive in light of
the normal operating requirements of the Purchased Programs and (b) are adequate for the conduct of the Purchased Programs in substantially the same manner in all material respects as conducted as of the Effective Date. 

6.13 Assigned Contracts. 

(a) The Pfizer Parties have made available to NewCo prior to the date of this Agreement a complete, legible and correct copy of
each Assigned Contract as in effect on the date of this Agreement. None of the Pfizer Parties is in material breach of or default under the terms of any Assigned Contract and, to the knowledge of the Pfizer Parties, no other party to an Assigned
Contract is in material breach of or default under the terms of any Assigned Contract, and there is no event occurring as a direct or reasonably foreseeable result of any Pfizer Party’s action or inaction or, to the knowledge of any Pfizer
Party, through the action or inaction of any Third Party that with notice or the lapse of time or both would constitute a material breach of or default under the terms of any Assigned Contract. Each Assigned Contract is a legal, valid and binding
obligation of the Pfizer Party that is party thereto and, to the knowledge of the Pfizer Parties, of each other party thereto, and is in full force and effect, subject to the Enforceability Exceptions. 

(b) Except as set forth in Schedule 6.13(b), no approval, consent or waiver of any Person is needed to continue any
Assigned Contract in full force and effect following the consummation of the Transactions. 
 (c) None of the Pfizer Parties
has received written notice from any Person since January 1, 2017 regarding any actual or alleged violation or breach of, or default under, any of the Assigned Contracts or stating that such Person intends to terminate, cancel or make any
material change to any Assigned Contract, in each case that would be material to the conduct of the Purchased Programs taken as a whole. Other than as contemplated herein in connection with the Transactions, there are no pending renegotiations or
amendments of any of the Assigned Contracts that would be material to the conduct of the Purchased Programs taken as a whole. 

(d) The Purchased Programs as conducted by the Pfizer Parties as of the Effective Date do not rely upon or use rights under any
Contract that has expired or been terminated that would be material to the Purchased Programs taken as a whole. 

  
 43 

 (e) The Pfizer Parties are not a party to, bound by or subject to any
Contract exclusively relating to the Purchased Programs or the Purchased Assets that are material to the Purchased Programs taken as a whole, except for (i) the Assigned Contracts, (ii) any Contract for employment of Prospective Employees
or Covered Benefit Plan, (iii) any Contract relating to the use or ownership of any real property and (iv) those Contracts described on Schedule 6.13(e). 

6.14 Finders or Brokers. Other than Centerview Partners LLC, no Pfizer Party has retained any broker or finder or incurred any
Liability for any brokerage fees, commissions or finders fees with respect to this Agreement or the Transactions. 
 6.15 Accredited
Investor. For purposes of the issuance of the Equity Consideration at Closing, Pfizer represents that it is an “accredited investor” as such term is defined in Rule 501 under the Securities Act of 1933. 

6.16 No Other Representations and Warranties. Except for the representations and warranties contained in this ARTICLE 6 (including the
related portions of the disclosure schedules attached hereto), the General Assignment and Bill of Sale, the Patent Assignment and Section 7 of the Patent and Know-How License Agreement, neither Pfizer nor
any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf of Pfizer, including any representation or warranty as to the accuracy or completeness of any information regarding the
Purchased Programs and the Purchased Assets furnished or made available to NewCo and its Representatives or as to the future revenue, profitability or success of the Purchased Programs. 

ARTICLE 7 
 REPRESENTATIONS AND
WARRANTIES OF NEWCO 
 Subject to the terms of this Agreement and except as set forth in the corresponding sections or subsections of the
disclosure schedules attached hereto, NewCo represents and warrants to Pfizer as of the date of this Agreement as follows: 
 7.1
Organization. 
 (a) NewCo is a corporation duly organized, validly existing and in good standing under the Laws of
the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. Except as set forth on Schedule 7.1(a), NewCo is duly qualified to transact business and
is in good standing in each jurisdiction in which the failure to so qualify would have a material adverse effect on NewCo’s ability to consummate the Transactions. 

(b) NewCo has made available to Pfizer prior to the date of this Agreement a true and complete copy of its certificate of
incorporation and bylaws that are currently in effect (together, the “Initial NewCo Organizational Documents”). Prior to the Closing, NewCo shall have filed the Restated Certificate with the Delaware Secretary of State and amended
and restated its bylaws (the “Restated Bylaws”) and at the Closing and immediately after the Closing, the Restated Certificate and the Restated Bylaws (together, 

  
 44 

 
the “Post-Closing NewCo Organizational Documents”) shall be in full force and effect and NewCo shall not be in violation of their provisions. 

7.2 Capitalization. 

(a) Immediately prior to the Closing, the authorized capital of NewCo shall consist, of: 

(i) 20,000,000 shares of Common Stock, 5,000,000 shares of which are issued and outstanding immediately prior to the Closing.
All of the outstanding shares of Common Stock have been duly authorized, are fully paid and non-assessable and were issued in compliance with all applicable federal and state securities laws. NewCo holds no
Common Stock in its treasury. 
 (ii) 11,743,987 shares of Class A Preferred Stock, par value $0.001, of which: (A)
7,557,990 shares have been designated Series A Preferred Stock; and (B) 4,185,997 shares have been designated Series A-1 Preferred Stock, none of which shall be issued and outstanding immediately
prior to the Closing. The rights, privileges and preferences of the Equity Consideration are as stated in the Restated Certificate and as provided by the Delaware General Corporation Law. NewCo holds no Preferred Stock in its treasury. 

(b) NewCo has reserved 1,000,000 shares of Common Stock for issuance to officers, directors, employees and consultants of NewCo
pursuant to its 2017 Equity Incentive Plan duly adopted by NewCo’s board of directors and approved by NewCo’s stockholders (the “Stock Plan”), all of which remain available for issuance to officers, directors, employees
and consultants pursuant to the Stock Plan. NewCo has furnished to Pfizer complete and accurate copies of the Stock Plan and forms of agreements to be used thereunder. Promptly following the Closing, the NewCo’s board of directors shall amend
the Stock Plan to provide for a share reserve equal to 10% of the fully diluted capitalization of NewCo (including the 1,000,000 shares of Common Stock reserved for issuance pursuant to this Section 7.2(b)) as of the
Closing. 
 (c) Schedule 7.2(c) sets forth the capitalization of NewCo immediately following the Closing including the
number of shares of the following, if any: (i) issued and outstanding Common Stock, including, with respect to restricted Common Stock, vesting schedule and repurchase price; (ii) granted stock options, including vesting schedule and
exercise price; (iii) shares of Common Stock reserved for future award grants under the Stock Plan; (iv) each series of Preferred Stock; and (v) warrants or stock purchase rights, if any. Except for (A) the conversion privileges
of the Preferred Stock to be issued under the Preferred Stock Purchase Agreement, (B) the issuance of Preferred Stock pursuant to the Preferred Stock Purchase Agreement, (C) the rights provided in Section 4 of the Investors’
Rights Agreement, and (D) the securities and rights described in Schedule 7.2(c), as of the Closing, there will be no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar
rights) or agreements, orally or in writing, to purchase or acquire from NewCo any shares of Common Stock or Preferred Stock, or any securities convertible into or exchangeable for shares of Common 

  
 45 

 
Stock or Preferred Stock. As of the Closing, all outstanding shares of the Common Stock and all shares of Common Stock underlying outstanding options will be subject to (i) a right of first
refusal in favor of NewCo first, and the holders of the Class A Preferred Stock second, upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market
standoff agreement of not less than 180 days following NewCo’s initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933. 

(d) As of the Closing, none of NewCo’s stock purchase agreements or stock option documents will contain a provision for
acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding upon the occurrence of any event or combination of events, including without limitation in the case
where the Stock Plan is not assumed in an acquisition. NewCo has never adjusted or amended the exercise price of any stock options previously awarded, whether through amendment, cancellation, replacement grant, repricing, or any other means. NewCo
has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock. 
 (e) 409A. NewCo
believes in good faith that any “nonqualified deferred compensation plan” (as such term is defined under Section 409A(d)(1) of the Code and the guidance thereunder) under which NewCo makes, is obligated to make or promises to
make, payments (each, a “409A Plan”) complies in all material respects, in both form and operation, with the requirements of Section 409A of the Code and the guidance thereunder. To the knowledge of NewCo, no payment to be made
under any 409A Plan is, or will be, subject to the penalties of Section 409A(a)(1) of the Code. 
 7.3 Subsidiaries. NewCo does
not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association or other business entity. NewCo is not a participant in any joint venture,
partnership or similar arrangement. 
 7.4 Power and Authority Relative to this Agreement. All corporate action required to be taken
by the NewCo’s Board of Directors and stockholders in order to authorize NewCo to enter into this Agreement and the Transaction Agreements, and to issue the Equity Consideration at the Closing and the Common Stock issuable upon conversion of
the Equity Consideration, has been taken. All action on the part of the officers of the NewCo necessary for the execution and delivery of this Agreement and the Transaction Agreements, the performance of all obligations of NewCo under this Agreement
and the Transaction Agreements to be performed as of the Closing, and the issuance and delivery of the Equity Consideration has been taken. This Agreement and the Transaction Agreements, when executed and delivered by NewCo, shall constitute valid
and legally binding obligations of NewCo, enforceable against NewCo in accordance with their respective terms, except as such enforcement may be subject to the Enforceability Exceptions. 

7.5 No Consent. Other than as set forth on Schedule 7.5, no consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state or local Governmental Authority is required on the part of NewCo in connection with the consummation by NewCo of the Transactions, except for (i) the
filing of the Restated 

  
 46 

 
Certificate, which will have been filed as of the Closing and (ii) filings pursuant to Regulation D of the Securities Act and applicable state securities laws, which will be made in a timely
manner. The execution and delivery by NewCo of this Agreement and the other Transaction Agreements, as applicable, does not, and the consummation of the Transactions and compliance with the provisions hereof will not result in a violation or default
of any provisions of the Initial NewCo Organizational Documents or the Post-Closing NewCo Organizational Documents. 
 7.6
Investigations; Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or to NewCo’s knowledge, currently threatened: (i) against NewCo or any officer, director, Key Employee
or Founder of NewCo; (ii) that questions the validity of this Agreement or the Transaction Agreements or the right of NewCo to enter into them, or to consummate the transactions contemplated by this Agreement or the Transaction Agreements; or
(iii) to NewCo’s knowledge, that would reasonably be expected to have, either individually or in the aggregate, a material adverse effect on NewCo’s ability to consummate the Transactions. Neither NewCo nor, to NewCo’s knowledge,
any of its officers, directors, Key Employees or Founders is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers,
directors, Key Employees or Founders such as would affect NewCo). There is no action, suit, proceeding or investigation by NewCo pending or which NewCo intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or
investigations pending or threatened in writing (or any basis therefor known to NewCo) involving the prior employment of any of the NewCo’s employees, their services provided in connection with NewCo’s business, any information or
techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers. 
 7.7
Finders or Brokers. NewCo has not retained any broker or finder or incurred any Liability for any brokerage fees, commissions or finders fees with respect to this Agreement or the Transactions. 

7.8 Solvency. Immediately after giving effect to the Transactions, NewCo shall be solvent and shall: (a) be able to pay its debts
as they become due; and (b) have adequate capital to carry on its business. No transfer of property is being made and no obligation is being incurred in connection with the transactions contemplated hereby with the intent to hinder, delay or
defraud either present or future creditors of Pfizer or NewCo. In connection with the Transactions, NewCo has not incurred, nor plans to incur, debts beyond its ability to pay as they become absolute and matured. 

7.9 Funding. NewCo hereby represents and warrants that (i) on or before the Effective Date, NewCo shall have entered into the
equity commitment letters with each of the Other Investors, which are attached hereto as Exhibit G (such letters, the “Equity Commitment Letters”), and pursuant to which the Other Investors have collectively committed
to provide an aggregate of two hundred sixty-five million dollars ($265,000,000) of funding to NewCo on the terms and subject to the conditions set forth in the Equity Commitment Letters (the “Financing”), and
(ii) that none of the Equity Commitment Letters has been amended, modified, terminated or withdrawn and that each of the Equity Commitment Letters is in full force and effect. 

  
 47 

 7.10 Valid Issuance of Shares. The Class A Preferred Stock, when issued, sold
and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and non-assessable and free of restrictions on transfer other than
restrictions on transfer under the Restated Certificate, the Restated Bylaws or the Financing Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a purchaser under the Preferred Stock Purchase
Agreement. Assuming the accuracy of the representations of Pfizer in Section 4 of the Preferred Stock Purchase Agreement and subject to the filings described in the Voting Agreement, the Class A Preferred Stock will be issued in compliance
with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Class A Preferred Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Restated Certificate,
will be validly issued, fully paid and non-assessable and free of restrictions on transfer other than restrictions on transfer under the Restated Certificate, the Restated Bylaws or the Financing Agreements,
applicable federal and state securities laws and liens or encumbrances created by or imposed by a purchaser under the Preferred Stock Purchase Agreement. Based in part upon the representations of Pfizer in Section 4 of the Preferred Stock
Purchase Agreement and in the Voting Agreement, the Common Stock issuable upon conversion of the Class A Preferred Stock will be issued in compliance with all applicable federal and state securities laws. 

7.11 Compliance with Other Instruments. NewCo is not in violation or default: (i) of any provisions of the Initial NewCo
Organizational Documents, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to which it is a party or by which it is
bound that is required to be listed on the disclosure schedules attached hereto, or (v) to NewCo’s knowledge, of any provision of federal or state statute, rule or regulation applicable to NewCo. The execution, delivery and
performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving
of notice, either: (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of NewCo or the
suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to NewCo. 
 7.12 Agreements; Actions.

 (a) Except for the Transaction Agreements and this Agreement, there are no agreements, understandings, instruments,
contracts or proposed transactions to which NewCo is a party or by which it is bound that involve: (i) obligations (contingent or otherwise) of, or payments to, NewCo in excess of $50,000, (ii) the license of any patent, copyright,
trademark, trade secret or other proprietary right to or from NewCo, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit NewCo’s exclusive right to develop,
manufacture, assemble, distribute, market or sell its products, (iv) indemnification by NewCo with respect to infringements of proprietary rights, or (v) any other material restriction on the operation of NewCo’s business. 

  
 48 

 (b) NewCo has not: (i) declared or paid any dividends, or authorized or
made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $50,000 or in excess of $100,000 in the
aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary
course of business. For the purposes of (a) and (b) of this Section 7.12, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including
Persons that NewCo has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection. 

(c) NewCo is not a guarantor or indemnitor of any indebtedness of any other Person. 

7.13 Certain Transactions. 

(a) Other than: (i) standard employee benefits generally made available to all employees, (ii) standard director and
officer indemnification agreements approved by NewCo’s board of directors, and (iii) the purchase of shares of NewCo’s capital stock and the issuance of options to purchase shares of NewCo’s Common Stock, in each instance,
approved in the written minutes or written consents of NewCo’s board of directors (previously provided to Pfizer and the Other Investors or their counsel), there are no agreements, understandings or proposed transactions between NewCo and any
of its officers, directors, consultants, Founders or Key Employees, or any Affiliate thereof. 
 (b) NewCo is not indebted,
directly or indirectly, to any of its directors, officers, Founders or employees or to their respective spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the
ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available to all employees. None of NewCo’s directors, officers, Founders or employees, or any members of their immediate
families, or any Affiliate of the foregoing are, directly or indirectly, indebted to NewCo or have any: (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of NewCo’s
customers, suppliers, service providers, joint venture partners, licensees and competitors; (ii) direct or indirect ownership interest in any firm or corporation with which NewCo is affiliated or with which NewCo has a business relationship, or
any firm or corporation which competes with NewCo except that directors, officers, employees or stockholders of NewCo may own stock in (but not exceeding 2% of the outstanding capital stock of) publicly traded companies that may compete with NewCo;
or (iii) financial interest in any contract with NewCo. 
 7.14 Rights of Registration and Voting Rights. Except as provided in
the Investors’ Rights Agreement, to be entered into prior to or at the Closing, NewCo is not under any obligation to register under the Securities Act of 1933 any of its currently outstanding securities or any securities issuable upon exercise
or conversion of its currently outstanding securities. To NewCo’s knowledge, except as contemplated in the Equity Commitment Letters or the Voting Agreement, 

  
 49 

 
to be entered into prior to or at the Closing, no stockholder of NewCo has entered into any agreements with respect to the voting of capital shares of NewCo. 

7.15 Material Liabilities. NewCo has no liability or obligation, absolute or contingent (individually or in the aggregate), except:
(i) obligations and liabilities incurred after the date of incorporation in the ordinary course of business that are not material, individually or in the aggregate, and (ii) obligations under contracts made in the ordinary course of
business that would not be required to be reflected in financial statements prepared in accordance with GAAP. NewCo maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP. 

7.16 Changes. Since the date of incorporation there has not been: 

(a) any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect; 

(b) any waiver or compromise by NewCo of a valuable right or of a material debt owed to it; 

(c) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by NewCo, except in the
ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect; 
 (d) any
material change to a material contract or agreement by which NewCo or any of its assets is bound or subject; 
 (e) any
material change in any compensation arrangement or agreement with any employee, officer, director or stockholder; 
 (f) any
resignation or termination of employment of any officer or Key Employee of NewCo; 
 (g) any mortgage, pledge, transfer of a
security interest in, or lien, created by NewCo, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair
NewCo’s ownership or use of such property or assets; 
 (h) any loans or guarantees made by NewCo to or for the benefit
of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business; 

(i) any declaration, setting aside or payment or other distribution in respect of any of NewCo’s capital stock, or any
direct or indirect redemption, purchase, or other acquisition of any of such stock by NewCo; 
 (j) any sale, assignment or
transfer of any NewCo Intellectual Property that could reasonably be expected to result in a Material Adverse Effect; 

  
 50 

 (k) any other event or condition of any character, other than events
affecting the economy of NewCo’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or 

(l) any arrangement or commitment by NewCo to do any of the things described in this Section 7.16.

 7.17 Employee Matters. 

(a) As of the date hereof, NewCo employs three full-time employees and no part-time employees and engages no consultants or
independent contractors. Schedule 7.17(a) sets forth a detailed description of all compensation, including salary, bonus, severance obligations and deferred compensation paid or payable for each officer, employee, consultant and independent
contractor of NewCo who received annualized compensation in excess of $100,000 for the fiscal year ended December 31, 2017 or is anticipated to receive annualized compensation in excess of that amount for the fiscal year ending
December 31, 2018. 
 (b) None of its employees is obligated under any contract (including licenses, covenants or
commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of NewCo or that would
conflict with NewCo’s business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of NewCo’s business by the employees of NewCo, nor the conduct of NewCo’s business as now conducted and as presently
proposed to be conducted, will, to NewCo’s knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now
obligated. 
 (c) NewCo is not delinquent in payments to any of its employees, consultants, or independent contractors for
any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or independent contractors. NewCo has complied in all
material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification and collective bargaining. NewCo has withheld and
paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of NewCo and is not liable for any arrears of wages, taxes, penalties or other sums for
failure to comply with any of the foregoing. 
 (d) To NewCo’s knowledge, no Key Employee intends to terminate
employment with NewCo or is otherwise likely to become unavailable to continue as a Key Employee. NewCo does not have a present intention to terminate the employment of any of the foregoing. The employment of each employee of NewCo is terminable at
the will of NewCo. Except as set forth in Schedule 7.17(d) or as required by law, upon termination of the employment of any such employees, no severance or other payments will become due. 

  
 51 

 
Except as set forth in Schedule 7.17(d), NewCo has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination of
employment services. 
 (e) NewCo has not made any representations regarding equity incentives to any officer, employee,
director or consultant that are inconsistent with the share amounts and terms set forth in the minutes of meetings of NewCo’s board of directors. 

(f) Schedule 7.17(f) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or
sponsored by NewCo, or which NewCo participates in or contributes to, which is subject to ERISA. NewCo has made all required contributions and has no liability to any such employee benefit plan, other than liability for health plan continuation
coverage described in Part 6 of Title I(B) of ERISA, and has complied in all material respects with all applicable laws for any such employee benefit plan. 

(g) To NewCo’s knowledge, none of the Key Employees, Founders or directors of NewCo has been: (i) subject to
voluntary or involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his or her business or property; (ii) convicted in a criminal
proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (iii) subject to any order, judgment or decree (not subsequently reversed, suspended, or vacated) of any court of
competent jurisdiction permanently or temporarily enjoining him or her from engaging, or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory, banking, insurance, or other type of business or acting
as an officer or director of a public company; or (iv) found by a court of competent jurisdiction in a civil action or by the United States Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any
federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated. 

7.18 Tax Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by NewCo which have not been
timely paid. There are no accrued and unpaid federal, state, county, local or foreign taxes of NewCo which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns or reports by any applicable
federal, state, local or foreign governmental agency. NewCo has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers of applicable statutes of
limitations with respect to taxes for any year. 
 7.19 Insurance. NewCo has in full force and effect insurance policies concerning
such casualties as would be reasonable and customary for companies like NewCo with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed. 

7.20 Employee Agreements. Each current and former employee, consultant and officer of NewCo has executed an agreement with NewCo
regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for Pfizer and the Other 

  
 52 

 
Investors (the “Confidential Information Agreements”). No current or former Key Employee has excluded works or inventions from his or her assignment of inventions pursuant to
such Key Employee’s Confidential Information Agreement. NewCo is not aware that any of its Key Employees is in violation of any agreement covered by this Section 7.20. 

7.21 Permits. Except as set forth on Schedule 7.21, NewCo has all franchises, permits, licenses and any similar authority
necessary for the conduct of its business, the lack of which could reasonably be expected to have a Material Adverse Effect. NewCo is not in default in any material respect under any of such franchises, permits, licenses or other similar authority.

 7.22 Corporate Documents. The Restated Certificate and the Restated Bylaws are in the form provided to Pfizer and the Other
Investors. The copy of the minute books of NewCo provided to Pfizer and the Other Investors contains minutes of all meetings of directors and stockholders and all actions by written consent without a meeting by the directors and stockholders since
the date of incorporation and accurately reflects in all material respects all actions by the directors (and any committee of directors) and stockholders with respect to all transactions referred to in such minutes. 

7.23 Foreign Corrupt Practices Act. Neither NewCo nor any of its directors, officers, employees or agents have, directly or indirectly,
made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
“FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose of: (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such
official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist NewCo or
any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither NewCo nor any of its directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment,
kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. NewCo further represents that it has maintained, and has caused each of its affiliates to maintain, systems of internal
controls (including, but not limited to, accounting systems, purchasing systems and billing systems) and written policies to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law, and to ensure that all books
and records of NewCo accurately and fairly reflect, in reasonable detail, all transactions and dispositions of funds and assets. Neither NewCo nor, to NewCo’s knowledge, any of its officers, directors or employees are the subject of any
allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law. 

7.24 Data Privacy. In connection with its collection, storage, transfer (including, without limitation, any transfer across national
borders) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other third parties (collectively “Personal Information”),
NewCo is and has been in compliance in all material respects with all applicable laws in all relevant jurisdictions, NewCo’s privacy policies and the requirements of any contract or codes of conduct to which NewCo is a party. NewCo has
commercially reasonable physical, technical, organizational and administrative security measures and policies in place to protect all Personal 

  
 53 

 
Information collected by it or on its behalf from and against unauthorized access, use and/or disclosure. To the extent NewCo maintains or transmits protected health information, as defined under
45 C.F.R. § 160.103, NewCo is in compliance with the applicable requirements of the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, including all
rules and regulations promulgated thereunder. NewCo is and has been in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations. 

7.25 Non-Reliance. Except for the representations and warranties contained in ARTICLE 6
of this Agreement (including the related portions of the disclosure schedules attached hereto), the General Assignment and Bill of Sale, the Patent Assignment, and Section 7 of the Patent and Know-How
License Agreement, neither Pfizer nor any of its agents, employees or representatives have made, nor are any of them making any representation or warranty, written or oral, express or implied, in respect of the Purchased Programs and the Purchased
Assets, including any representations and warranties about the accuracy or completeness of any information or documents previously provided, and any such other representations and warranties are hereby expressly disclaimed. NewCo expressly
acknowledges and agrees that neither NewCo nor any of NewCo’s agents, employees or representatives is relying on any other representation or warranty of Pfizer or any of its agents, employees or representatives, including regarding the accuracy
or completeness of any such other representations and warranties or the omission of any material information, whether express or implied. 

ARTICLE 8 
 PRE-CLOSING COVENANTS 
 8.1 Conduct of the Purchased Programs Prior to Closing. 

(a) From the date of this Agreement until the Closing, except as otherwise permitted by this Agreement, set forth in
Schedule 8.1, consented to by NewCo in writing (which consent shall not be unreasonably withheld or delayed) or directed, directly or indirectly, by NewCo, Pfizer agrees to use (and to cause each Pfizer Party to use) commercially reasonable
efforts to: 
 (i) maintain in effect all Pfizer Assigned IP Rights and Governmental Approvals and applications and
registrations included in the Pfizer Assigned IP Rights and Governmental Approvals in the ordinary course of business consistent with past practice; 

(ii) maintain all Purchased Inventory and physical Purchased Assets in its present repair, order and condition in the ordinary
course of business consistent with past practice, except for depletion and ordinary wear and tear; 
 (iii) perform its
obligations in all material respects under the Assigned Contracts; 

  
 54 

 (iv) maintain and perform material obligations under Governmental Approvals
and materially comply with all applicable Laws relating the Purchased Programs and the Purchased Assets; 
 (v) keep in full
force and effect all material rights relating to the Purchased Programs; and 
 (vi) continue to operate, conduct, further
develop and advance the Purchased Programs in the ordinary course of business, consistent with past practices. 
 (b) From
the date of this Agreement until the Closing (or, with respect to clause (ix), the Employee Transfer Date), except as otherwise permitted by this Agreement, set forth in Schedule 8.1, consented to by NewCo in writing (which consent shall not
be unreasonably withheld or delayed) or directed, directly or indirectly, by NewCo, Pfizer will not (and Pfizer will cause each of its Affiliates not to): 

(i) pledge, sell, lease, transfer, license (exclusive or non-exclusive), assign,
impair, dispose of or otherwise make subject to a Lien (other than any Permitted Liens) any Purchased Asset outside of the ordinary course of business consistent with past practice, other than the sale of Purchased Inventory or obsolete, worn-out or excess equipment or assets in the ordinary course of business consistent with past practice; 

(ii) cancel or waive any material claims or rights that relate to the Purchased Assets or commence, settle, or agree to settle
any Proceeding with any Governmental Authority or other Person relating to the Purchased Programs or any Purchased Asset or any Assumed Liability; 

(iii) transfer, assign or grant any license (exclusive or non-exclusive) or sublicense
of any rights under or with respect to any Pfizer Assigned IP Rights or Group 3 Pfizer IP Rights other than non-exclusive licenses in the ordinary course of business consistent with past practice; 

(iv) change, amend or otherwise modify, or waive any material claims or rights under, or terminate any Assigned Contract that
has a value, payment or other obligations in excess of $[***] individually or $[***] in the aggregate; 
 (v) enter into any
Contract in connection with the Purchased Programs with an obligation or value in excess of $[***] individually or $[***] in the aggregate; 

(vi) make any write down in the value of the Purchased Inventory and physical Purchased Assets, except as required by
applicable Law or GAAP; 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 55 

 (vii) abandon or permit the lapse of, as applicable, any Pfizer Assigned IP
Rights to the extent that Pfizer or any of its Affiliates controls prosecution and maintenance of such Pfizer Assigned IP Rights; 

(viii) take any action related to the Purchased Programs which would adversely affect, or impede or impair, the ability of the
parties hereto, to consummate the Transactions; 
 (ix) hire or terminate the employment of any Prospective Employee (other
than for cause), increase any Prospective Employee’s salary or benefits or alter any Prospective Employee’s responsibilities (other than, in each case, (A) annual salary increases in the ordinary course of business or
(B) increases in benefits under any Covered Benefit Plan in the ordinary course of business or (C) increases required by Law or the terms of a Covered Benefit Plan); or 

(x) agree, whether in writing or otherwise, to do any of the foregoing. 

8.2 Access to Information. From the date of this Agreement until the Closing or the earlier termination of this Agreement pursuant to
its terms, Pfizer and its Affiliates shall (a) permit NewCo and its Representatives to have reasonable access to all books, records (including Tax records), contracts and documents exclusively pertaining to the Purchased Programs or the
Purchased Assets and (b) furnish NewCo with all financial, operating and other data and information related exclusively to the Purchased Programs (including copies thereof) as NewCo may reasonably request; provided, however, that Pfizer
shall not be required to permit any inspection or other access, or to disclose any information that in the reasonable judgment of Pfizer would: (i) result in the disclosure of any Trade Secrets, (ii) violate any obligation of Pfizer with
respect to confidentiality entered into prior to the date of this Agreement, (iii) violate or result in the loss or material impairment of any information subject to the attorney-client privilege or the attorney work product doctrine,
(iv) cause competitive harm to any Pfizer Party, (v) violate any Law or (vi) result in disclosure of the Consolidated Returns. Any such access will be provided or conducted during normal business hours upon reasonable advance notice
to Pfizer, under the reasonable supervision of Pfizer’s personnel and in such a manner as not to interfere with the normal operations of Pfizer and its Affiliates. All requests by NewCo for access pursuant to this
Section 8.2 shall be submitted or directed exclusively to such individual or individuals as Pfizer may designate in writing from time to time (including in response to NewCo’s request). Prior to the Closing, without
the prior written consent of Pfizer, which will not be unreasonably withheld or delayed, none of NewCo or any of its Affiliates shall contact any employees of, suppliers to, or any other Person with a material business relationship with Pfizer or
its Affiliates regarding the Purchased Programs. NewCo shall, and shall cause its Affiliates to, abide by the terms of the Confidential Disclosure Agreement with respect to any access or information provided pursuant to this
Section 8.2 or otherwise, in accordance with the terms of such Confidential Disclosure Agreement. 
 8.3
Commercially Reasonable Efforts. Subject to the terms and conditions of this Agreement, from the date of this Agreement to the Closing, or the earlier termination of this Agreement pursuant to its terms, each party hereto shall cooperate with
the other party hereto and use (and shall cause their respective Affiliates to use) their respective commercially reasonable 

  
 56 

 
efforts to promptly take, or cause to be taken, all actions, and do, or cause to be done, all things, necessary, proper or advisable to cause the conditions to Closing set forth in ARTICLE
11 to be satisfied (but not waived) as promptly as practicable. In furtherance and not in limitation of the covenants of the parties contained in this Section 8.3, each of the parties hereto shall use its reasonable
best efforts to resolve such objections, if any, as may be asserted by a Governmental Authority in any jurisdiction in which information on consultation obligations are required by applicable Laws to consummate the Transactions. 

8.4 Consents. Without limiting the provisions of Section 8.3, on or prior to the Closing Date, each of the
Pfizer Parties shall use its respective commercially reasonable efforts to obtain all Consents and make and deliver all filings and notices listed on Schedule 8.4(a), and NewCo shall use commercially reasonable efforts to obtain all Consents
and make and deliver all filings and notices listed on Schedule 8.4(b), provided, however, that nothing in this Section 8.4 shall require any of the Pfizer Parties or any of their Affiliates to modify any of its respective
rights in a manner adverse to any of the Pfizer Parties or any of their Affiliates or to pay any fee or other payment, or incur any Liability, cost or out-of-pocket
expense in connection with the efforts set forth in this Section 8.4, with any such Liabilities, costs or out-of-pocket expenses to be borne by NewCo. 

8.5 Exclusive Dealing.  

(a) From the date of this Agreement until the earlier of (i) the termination of this Agreement pursuant to its terms or
(ii) the Closing, the Pfizer Parties, the Pfizer Parties’ Subsidiaries and their respective Representatives shall not, without the prior written consent of NewCo, directly or indirectly, (x) solicit, knowingly encourage or initiate
any contact concerning the submission of any inquiry, proposal or offer from any entity or person (other than NewCo) or (y) participate in any discussions or negotiations or enter into any agreement with, or provide any additional non-public information to, any entity or person (other than NewCo), in each case relating to a sale of all or any material part of the Purchased Programs or Purchased Assets (whether by way of merger, purchase of
capital stock, purchase of assets, granting of licenses or similar transaction or a sale of a Subsidiary of Pfizer that holds or owns all or any material part of the Purchased Programs or Purchased Assets). 

(b) From the date of this Agreement until the Closing, the Pfizer Parties, their Affiliates and their respective
Representatives shall cease all discussions with any Person (other than NewCo) regarding any of the matters covered by this Section 8.5, including terminating any such Person’s access to the Pfizer Parties’
electronic data room, and shall promptly cause their Representatives to request the return or destruction of all non-public information concerning the Purchased Programs and/or the Purchased Assets that has
been furnished to any person or entity with whom a confidentiality agreement was entered into at any point within the 12-month period immediately prior to the Effective Date. The Pfizer Parties acknowledge and
agree, for itself and each of the persons and entities referred to above, that any remedy at law for breach of the covenants of this Section 8.5 would be inadequate, and in addition to any other relief which may be
available, NewCo will be entitled to temporary and permanent injunctive relief without the necessity of proving actual damages and without regard to the adequacy of any remedy at law. 

  
 57 

 8.6 Financing. 

(a) NewCo and its Affiliates shall use their reasonable best efforts to obtain the Financing, including by using their
reasonable best efforts to deliver all documents and instruments reasonably necessary to satisfy the conditions set forth in the Equity Commitment Letter and otherwise seeking to cause the conditions set forth in the Equity Commitment Letter to be
fulfilled in accordance with its terms. If at any time it becomes likely (as determined in the reasonable judgment of NewCo) that NewCo and its Affiliates will be unable for any reason to consummate the Financing, NewCo and its Affiliates shall use
their reasonable best efforts to seek alternative financing. 
 (b) NewCo and its Affiliates shall not amend, modify or
change any of the conditions in the Equity Commitment Letter in a manner that would reasonably be expected to materially delay or prevent the Closing without the prior written consent of Pfizer, such consent not to be unreasonably withheld,
conditioned or delayed, and, subject to the satisfaction of all the conditions to the Closing set forth in this Agreement, NewCo and its Affiliates shall draw down on the financing referred to in the Equity Commitment Letter when the conditions set
forth in the Equity Commitment Letter are satisfied. 
 8.7 Pre-Closing Cooperation. From the
date of this Agreement until the earlier of Closing or termination of this Agreement pursuant to Section 13.1, each party shall, and shall cause its Affiliates and their respective directors, officers, employees and other
Representatives to, from time to time, at the reasonable request of the other party, cooperate with the other party and use reasonable best efforts to facilitate the transactions contemplated by the Transaction Agreements, provided, however, that
any access or furnishing of information shall be conducted during normal business hours, under the supervision of the other party’s personnel and in such a manner as not unreasonably to interfere with the normal operations of the other party.
Notwithstanding anything to the contrary in this Agreement, the other party shall not be required to disclose any information to the requesting party or its Representatives if such disclosure would, in the other party’s good faith
determination, (i) jeopardize any attorney-client or other legal privilege or (ii) contravene any applicable Laws, fiduciary duty or binding agreement entered into prior to the date hereof. 

8.8 Conduct of NewCo Prior to Closing. From the date of this Agreement until the Closing, except as consented to by Pfizer in
writing, NewCo will not issue any Common Stock, Series A Preferred Stock or any other equity security of NewCo except as expressly contemplated by this Agreement or the Preferred Stock Purchase Agreement or amend or enter into any side letter or
similar agreement with respect to, waive any provision of, or otherwise modify in any respect any of the Equity Commitment Letters. 

ARTICLE 9 
 POST-CLOSING COVENANTS

 9.1 Cooperation. After the Closing, upon the reasonable request of NewCo and at NewCo’s expense for any costs or expense of
Third Parties, Pfizer shall, and shall cause each other Pfizer Party to, (i) use reasonable best efforts during the Cooperation Period following the Closing to (a) execute and deliver any and all further materials, documents and
instruments of conveyance, transfer or assignment as may reasonably be requested by NewCo to effect, record or verify the 

  
 58 

 
transfer to and vesting in NewCo of such Pfizer Party’s right, title and interest in and to the Purchased Assets, free and clear of all Liens other than the Permitted Liens, in accordance
with the terms of this Agreement, (b) deliver physical possession of the Purchased Assets to NewCo, (c) cooperate with reasonable requests from NewCo to assist in an orderly transfer of supplier relationships involving the Purchased
Programs to NewCo, and (ii) use commercially reasonable efforts to perform the post-Closing covenants set forth on Schedule 9.1; provided, however, that nothing in this Section 9.1 shall require
any Pfizer Party or its Affiliates to modify any of its respective rights in a manner adverse to such party or any of their Affiliates or to pay any fee or other payment, or incur any Liability, cost or out-of-pocket expense in connection with the efforts set forth in this Section 9.1, with any such Liabilities, costs or out-of-pocket expenses to be borne by NewCo.    After the Closing, each Pfizer Party shall promptly deliver to NewCo any mail, packages, orders, inquiries and other communications
addressed to such Pfizer Party and to the extent relating to the Purchased Programs. 
 9.2 Return of Assets; Transfer of
Purchased Assets. 
 (a) If, for any reason after the Closing, any asset is ultimately determined to be an
Excluded Asset or NewCo is found to be in possession of any Excluded Asset or subject to an Excluded Liability, (i) NewCo shall return or transfer and convey (without further consideration) to the appropriate Pfizer Party, and such Pfizer Party
shall accept or assume, as applicable, such asset or Excluded Liability; (ii) the appropriate Pfizer Party shall assume (without further consideration) any Liabilities associated with such assets or Excluded Liabilities; and (iii) NewCo
and the appropriate Pfizer Party shall execute such documents or instruments of conveyance or assumption and take such further acts which are reasonably necessary or desirable to effect the transfer of such asset or Excluded Liability back to the
Pfizer Party. 
 (b) In the event that any Purchased Asset or Assumed Liability is discovered by Pfizer or any of its
Affiliates or identified to Pfizer in writing by NewCo at any time after the Closing Date, possession or ownership of which has not been transferred to, or assumed by (without further consideration), either NewCo or its Affiliates at such time, the
Pfizer Parties shall promptly take such steps as may be required to transfer, or cause to be transferred, such Purchased Assets or Assumed Liabilities to NewCo, subject to Section 2.5 and otherwise in accordance with the
terms of this Agreement, at no additional charge to NewCo or its Affiliates, and NewCo or its Affiliates shall accept such Purchased Assets or assume such Assumed Liabilities, as the case may be. 

9.3 Records and Documents. For a period of [***] years after the Closing, at the other party’s request, each party shall provide
the other party and its Representatives with access to and the right to make copies of those records and documents to the extent related to the Purchased Programs (possession of which is retained by a Pfizer Party or transferred to NewCo, as
applicable), as may be reasonably necessary in connection with any Third Party litigation, or the conduct of any audit or investigation by a Governmental Authority. Notwithstanding anything to the contrary in this
Section 9.3, Pfizer or the Pfizer Parties, as applicable, shall provide to NewCo reasonable access to, and the right to make copies of, Tax Returns that relate primarily to the Purchased Programs or the Purchased Assets,
and NewCo shall not have access or the right to 
 [***] = CONFIDENTIAL TREATMENT REQUESTED 

  
 59 

 9.4 make copies of any other Tax Returns provided, that in no event shall Pfizer or
the Pfizer Parties, as applicable, provide access to Consolidated Returns. 
 9.5 Bulk Sales Waiver. NewCo hereby waives compliance
by each Pfizer Party with any applicable bulk sales Laws in connection with the Transactions. 
 9.6 Confidentiality. 

(a) Definitions. “Confidential Information” shall mean: (a) all
non-public or proprietary information (including Know-How) that is disclosed by or on behalf of a party (the “Disclosing Party”) (or any of its
Affiliates) to the other party (the “Receiving Party”, each a “Party” for purposes of this Section 9.5) or any of its Representatives pursuant to or in connection with this Agreement or the
Confidential Disclosure Agreement or the Patent and Know-How License Agreement (including the terms thereof); and (b) all other non-public or proprietary
information (including Know-How) that is expressly deemed in this Agreement or the Patent and Know-How License Agreement to be Confidential Information, whether or not
disclosed by or on behalf of a party (or any of its Affiliates) to the other party, any of its Affiliates or any of their respective employees, agents or contractors, in each case ((a) or (b)), without regard as to whether any of the foregoing is
marked “confidential” or “proprietary,” or in oral, written, graphic or electronic form. The terms of this Agreement shall be deemed to be both parties’ Confidential Information. Pfizer’s Confidential Information shall
include all such information disclosed in connection with NewCo’s due diligence investigation of the Purchased Programs, the Purchased Assets and the evaluation of the Transactions, including pursuant to Section 8.2;
provided that, subject to the Patent and Know-How License Agreement, all Know-How (including unpublished patent applications) included in the Pfizer Assigned IP Rights,
and all Confidential Information contained in or exclusively related to the Assigned Contracts, the Books and Records and the Other Assets shall, as between Pfizer and NewCo, be deemed to be NewCo’s Confidential Information as of the Closing
Date, such that NewCo shall be deemed to be the Disclosing Party with respect thereto, Pfizer shall be deemed to be the Receiving Party with respect thereto, and Section 9.6(b)(i) below shall not apply to such Confidential
Information. 
 (b) Exclusions. Information shall not be deemed to be Confidential Information of the Disclosing Party
to the extent that the Receiving Party can demonstrate: 
 (i) through competent evidence that such information is known by
the Receiving Party at the time of its receipt who is not known by the Receiving Party to be under an obligation of confidentiality, and not through a prior disclosure by the Disclosing Party; 

(ii) that such information is in the public domain before its receipt from the Disclosing Party, or thereafter enters the
public domain through no breach of this Agreement by the Receiving Party; 
 (iii) that such information is subsequently
disclosed to the Receiving Party by a Third Party who is not known by the Receiving Party to be under an obligation of confidentiality to the Disclosing Party; or 
  

  
 60 

 (iv) through competent evidence that such information is discovered or
developed by or on behalf of the Receiving Party independently and without use of or reference to any Confidential Information received from the Disclosing Party. 

(c) Duty of Confidence. Subject to the other provisions of this Section 9.5, for a period of
[***] years after the Closing Date: 
 (i) The Receiving Party shall maintain in confidence and otherwise safeguard the
Disclosing Party’s Confidential Information in the same manner and with the same protections as the Receiving Party maintains its own confidential information, but in any event no less than reasonable efforts; 

(ii) the Receiving Party may only use any such Confidential Information for the purposes of performing its obligations or
exercising its rights under the Transaction Agreements; 
 (iii) the Receiving Party may only disclose the Disclosing
Party’s Confidential Information to its Affiliates (and, in the case of NewCo as the Receiving Party, its licensees and sublicensees) and its and their respective Representatives, in each case to the extent reasonably necessary for the purposes
of performing its obligations or exercising its rights under this Agreement; provided that such Persons are bound by legally enforceable obligations to maintain the confidentiality of the Confidential Information in a manner consistent with the
confidentiality provisions of this Agreement. 
 (d) Authorized Disclosures. Notwithstanding the obligations set forth
in this Section 9.6, the Receiving Party may disclose the Disclosing Party’s Confidential Information to the extent: 

(i) such disclosure is reasonably necessary: (A) to the Receiving Party’s Representatives (including attorneys,
independent accountants or financial advisors) for the sole purpose of enabling such Representatives to provide advice to such Receiving Party, provided that in each such case such recipients are bound by confidentiality and non-use obligations that are at least as restrictive as those contained in this Agreement; or (B) to actual or bona fide potential investors, potential acquirors, licensees or other financial, development or
commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration, provided that in each such case such recipients are bound by confidentiality and
non-use obligations at least as restrictive as those contained in the Agreement; 

(ii) such disclosure is to a Governmental Authority and necessary or desirable (A) to obtain or maintain INDs, Regulatory
Approvals or Price Approval for any product (subject to the limitations of any license grant to the Receiving 
 [***] =
CONFIDENTIAL TREATMENT REQUESTED 
  

  
 61 

 (iii) Party related to the use of such Confidential Information), within the
Territory, or (B) in order to respond to inquiries, requests or investigations by such Governmental Authority relating to Products or this Agreement; 

(iv) such disclosure is required by Law, judicial or administrative process, provided that, except for disclosures governed by
the last two sentences of Section 9.6(e) below, the Receiving Party, to the extent legally permitted, shall promptly inform the Disclosing Party of such required disclosure and provide the Disclosing Party an opportunity to
challenge or limit the disclosure obligations, provided that Confidential Information that is disclosed pursuant to subsection (ii) above or this subsection (iii) shall remain otherwise subject to the confidentiality and non-use provisions of this Section 9.6 (provided that such disclosure is not a public disclosure), and the Receiving Party shall cooperate with and reasonably assist the Disclosing Party if
the Disclosing Party seeks a protective order or other remedy in respect of any such disclosure. In any event, the Receiving Party shall furnish only that portion of the Confidential Information which, in the advice of the Receiving Party’s
legal counsel, is responsive to such requirement or request; 
 (v) such disclosure is reasonably necessary to exercise its
right to prepare, file, prosecute, maintain and extend Patents in a manner consistent with the Patent and Know-How License Agreement, including any obligation to cooperate with the Disclosing Party therein; or

 (vi) necessary in order to enforce its rights under the Agreement; or 

(vii) in the case of Pfizer as the Receiving Party, with respect to Know-How in the
Pfizer Assigned IP Rights which is other than that within the Group 1 Pfizer IP Rights, to the extent useful or necessary to exercise and enjoy the rights in and to such Transferred Pfizer Know-How granted to
Pfizer under the Patent and Know-How License Agreement. 
 (e) SEC Filings and
Other Disclosures. Either Party may disclose the terms of this Agreement and make any other public written disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable advice of such
Party’s legal counsel, to comply with (i) applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commission or (ii) any equivalent Governmental Authority, securities exchange or
securities regulator in any country in the Territory. Before disclosing this Agreement or any of the terms hereof pursuant to this Section 9.6(e), the parties will consult with one another on the terms of this Agreement to
be redacted in making any such disclosure, with the Party making such disclosure providing reasonable advance notice, and giving consideration to the timely comments of the other Party. Further, if a Party discloses this Agreement or any of the
terms hereof in accordance with this Section 9.6(e), such Party will, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms as it reasonably determines, giving
consideration to the comments of the other Party pursuant to the preceding sentence. 

  
 62 

 9.7 Non-Solicitation of Employees. 

(a) For a period of [***] after the Closing Date, without the prior written consent of Pfizer, NewCo shall not, and shall cause
its Affiliates not to, solicit for employment or engagement or hire or engage as a consultant or independent contractor any of the employees, independent contractors or consultants of any Pfizer Party or any Affiliate of any Pfizer Party as of the
Closing Date; provided that NewCo and its Affiliates shall not be restricted by this Section 9.7(a) from making any general solicitation for employees or public advertising of employment opportunities (including
through the use of employment agencies) not specifically directed at any such persons and hiring persons who apply for employment as a direct result of such general solicitation or public advertising. 

(b) For a period of [***] after the Closing Date, without the prior written consent of NewCo, Pfizer shall not, and shall cause
its Affiliates not to, solicit for employment or engagement or hire or engage as a consultant or independent contractor any of the employees, independent contractors or consultants of NewCo as of the Closing Date; provided that Pfizer and its
Affiliates shall not be restricted by this Section 9.7(b) from making any general solicitation for employees or public advertising of employment opportunities (including through the use of employment agencies) not
specifically directed at any such persons and hiring persons who apply for employment as a direct result of such general solicitation or public advertising. 

(c) It is the understanding of the parties that the scope of the covenants contained in Section 9.7
as to time and area covered, are reasonable and necessary to protect the goodwill, confidential information, rights and other legitimate interests of the Pfizer Parties. It is the parties’ intention that these covenants be enforced to the
greatest extent (but to no greater extent) in time, area, and degree of participation as is permitted by applicable Laws. The parties further agree that, in the event that any provision of Section 9.7 shall be determined
judicially to be unenforceable by reason of its being extended over too great a time or too great a range of activities, such provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by Law. The parties
further agree that (i) in addition and not in the alternative to any other remedies available to it, Pfizer shall be entitled to preliminary and permanent injunctive relief against any breach or threatened breach by NewCo or any of its
Affiliates of any such covenants, without having to post bond, together with an award of its reasonable attorneys’ fees incurred in enforcing its rights hereunder, (ii) the restricted period applicable to NewCo and its Affiliates shall be
tolled, and shall not run, during the period of any breach by NewCo or its Affiliates of any such covenants, and (iii) no breach of any provision of this Agreement shall operate to extinguish NewCo’s obligation to comply with this
Section 9.7. 
 9.8 Worker Notification Laws Matters. Without limiting NewCo’s obligations under
Article 10 hereof, NewCo shall not, within ninety (90) days after the Employee Transfer Date, involuntarily or constructively terminate the employment (including by making such adverse changes to terms and conditions of employment that would
constitute either such termination under any applicable Worker Notification Law) of more than forty (40) of the Transferred Employees or any other employees who work in the same facility, office or location as any of the Transferred 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

 

  
 63 

 9.9 Employees. As of the Employee Transfer Date, the Pfizer Parties will provide NewCo with
a list by date and location of the number of employees who work in a facility, office or location where any of the Prospective Employees will be based following the Employee Transfer Date and whose employment was involuntarily terminated by any of
the Pfizer Parties within the ninety (90) days preceding the Employee Transfer Date. 
 9.10 [Reserved]. 

9.11 Reporting of Pfizer Financial Information. From and after the Effective Date, Pfizer shall (a) cooperate with NewCo or its
Affiliates and their respective accountants and auditors by providing access to information, books, and records related to the Purchased Assets and Purchased Programs as NewCo may reasonably request in connection with the preparation by NewCo or its
Affiliates of historical and pro forma financial statements related to the Purchased Assets and Purchased Programs as may be required to be included in any filing made by NewCo or any of its Affiliates under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, and the regulations promulgated thereunder, including Regulation S-X and (b) without limiting the foregoing, shall provide NewCo with such information
as is required for NewCo or its Affiliates to prepare audited “carve out” financial statements related to the Purchased Assets and Purchased Programs, for the two (2) fiscal years prior to the Effective Date (or such shorter
period as agreed to by NewCo) and information requested by NewCo and reasonably necessary to prepare any applicable pro forma financial information required to be filed by NewCo with the United States Securities and Exchange Commission. Such
cooperation shall include, as applicable, (i) the signing of management representation letters to the extent required in connection with any such audit performed by NewCo’s auditors, (ii) providing NewCo or its Affiliates and their
respective accountants and auditors with access to management representation letters (specifically limited to portions thereof that are directly related to the Purchased Assets) and (iii) directing Pfizer’s accountants, auditors, and
counsel to reasonably cooperate with NewCo or its Affiliates and its accountants, auditors, and counsel in connection with the preparation and audit of any financial information to be provided under this Section 9.11
(Reporting of Pfizer Financial Information), provided, however, that nothing herein shall require Pfizer to make available to NewCo or its Affiliates or their respective accountants and auditors (i) management representation letters
provided by Pfizer to Pfizer’s accountants and auditors that do not relate to the Purchased Assets, (ii) any communications between Pfizer and its accountants and auditors, (iii) any information prior to June 17, 2014 or
following the Closing Date, (iv) any information related to valuation analyses performed by Pfizer or its Affiliates or their respective accountants, auditors or consultants or (v) any information other than historical financial
information stored in Pfizer’s electronic financial recording systems in the ordinary course of business. NewCo will be responsible for all costs and expenses incurred by Pfizer or its Affiliates in connection with the generation of financial
information as set forth herein, including personnel-, facility- and equipment-related costs and expenses, professional fees, external “carve out” audit fees, consents, and any other fees or expenses, whether
out-of-pocket or otherwise, associated with amendments and/or revisions required to support NewCo’s or its Affiliates’ United States Securities and Exchange
Commission disclosure obligations. Notwithstanding anything to the contrary in this Agreement, in no event shall Pfizer or the Pfizer Parties, as applicable, provide access to Consolidated Returns. 

  
 64 

 ARTICLE 10 

EMPLOYEES 
 10.1 Employees and
Employee Benefits. 
 (a) Not later than five (5) Business Days prior to the anticipated Employee Transfer Date,
NewCo shall offer, or cause one of its Affiliates to offer, employment to each Prospective Employee who is then employed by a Pfizer Party, including each Prospective Employee who is then on a leave under a Pfizer Party’s short-term or
long-term disability plan or under the U.S. federal Family and Medical Leave Act or leave under any other U.S. federal or state Law or other approved leave of absence (other than an unpaid personal leave) (each, an “Inactive
Employee”), commencing on the Employee Transfer Date (or, in the case of any Inactive Employee, on the date provided below) in accordance with the terms of this Section 10.1, including
Section 10.1(b). NewCo will provide Pfizer with a copy of the form of offer of employment at least five (5) Business Days in advance of its distribution to any Prospective Employee and will consider in good faith any
comments that Pfizer may have on such form. Each Prospective Employee who is offered and accepts employment with NewCo or one of its Affiliates shall be referred to in this Agreement as a “Transferred Employee”. With respect to any
Inactive Employee who accepts an offer of employment, such Inactive Employee shall become a Transferred Employee as of the date such Inactive Employee has been cleared for, and presents himself or herself to NewCo for active employment on or prior
to the six (6) month anniversary of the Employee Transfer Date (or such longer period as required by applicable Law). 

(b) NewCo shall provide, or shall cause an Affiliate of NewCo to provide to each Transferred Employee, and the terms of each
offer of employment shall provide for, for a period of one (1) year following the Employee Transfer Date (the “Continuation Period”) (i) an annual base salary or base wage rate, target annual bonus, commission rate and
severance benefits, in each case, that are no less favorable than the Transferred Employee’s annual base salary or base wage rate, target annual bonus, commission rate and severance benefits (except as provided in the last sentence of
Section 10.1(g) and Section 10.1(i)) as of immediately prior to the Employee Transfer Date and (ii) other employee benefits (excluding equity-based compensation, defined benefits pursuant to
qualified and nonqualified retirement plans, nonqualified deferred compensation plans, retiree medical benefits and other retiree health and welfare arrangements and the “retirement savings contribution” under the Pfizer Savings Plan) that are, in aggregate, materially comparable to those provided under a Covered Benefit Plan disclosed on Schedule 6.8(d) to the Transferred Employee as of immediately prior to the Employee
Transfer Date. 
 (c) For each Prospective Employee that is not a Transferred Employee, the Pfizer Parties may elect to
terminate the employment of each Prospective Employee effective as of the Employee Transfer Date (or in the case of any Prospective Employee who is then on a leave of absence, the date such Prospective Employee returns to active employment), and
shall take all actions reasonably necessary to cause each Prospective Employee to cease active participation under all Pfizer Benefit Plans as of the Employee 

  
 65 

 
Transfer Date (or in the case of any Prospective Employee who is on a leave of absence as contemplated hereby, the date such Prospective Employee returns to active employment), or such other date
as is required under the terms of the relevant Pfizer Benefit Plan or applicable Law. 
 (d) Pfizer shall be solely
responsible for, and shall pay at the time or times due or required by applicable Law, all obligations or Liabilities, including, without limitation, hourly pay, commission, bonus, salary, accrued vacation or paid
time-off, fringe benefits, pension or profit sharing benefits, or severance payments and benefits or other termination pay under the Pfizer Benefit Plans or applicable Law, arising out of or relating to the
termination of the employment of the Prospective Employees by the Pfizer Parties. 
 (e) Pfizer and its Affiliates shall
retain responsibility for and continue to pay all expenses and benefits under the Pfizer Savings Plan and all medical, dental, health, hospital, life insurance and disability expenses and benefits with respect to claims incurred under the Pfizer
Benefit Plans prior to the Closing Date by Prospective Employees and their eligible beneficiaries, as determined under the terms of the applicable Pfizer Benefit Plan. Pfizer and its Affiliates shall remain solely responsible for all workers
compensation claims of any Prospective Employee to the extent arising out of conditions having a date of injury prior to the Closing Date. NewCo shall have responsibility for workers compensation claims of Transferred Employees to the extent arising
out of conditions having a date of injury on or after the Closing Date. Pfizer and its Affiliates also shall be solely responsible for satisfying the continuation coverage requirements of Section 4980B of the Code for all individuals who are
“M&A qualified beneficiaries” as such term is defined in Treasury Regulations Section 54.4980B-9. NewCo shall be responsible for providing such continuation coverage in respect of any
Transferred Employee or qualified beneficiary of a Transferred Employee, in either case, who incurs a qualifying event after the Closing Date. 

(f) On and following the Employee Transfer Date, each employee benefit plan sponsored by NewCo or any Affiliate of NewCo in
which any Transferred Employee is eligible to participate shall credit each such Transferred Employee with his or her service with a Pfizer Party or any Affiliate of a Pfizer Party for all purposes (other than for purposes of equity-based
compensation or benefit accrual under any qualified or nonqualified retirement plan) to the extent such service was credited under the corresponding Pfizer Benefit Plan in which such Transferred Employee participated prior to the Employee Transfer
Date (if there is a comparable NewCo benefit plan); provided that (i) such credit shall be conditioned on receipt by NewCo of evidence of such service (e.g., payroll or plan records), and (ii) such recognition of service shall not
operate to duplicate any benefits with respect to any Transferred Employee. Without limiting the generality of the foregoing, on and following the Employee Transfer Date, with respect to any group health plan under which any Transferred Employee is
eligible to receive benefits from NewCo or any Affiliate of NewCo, NewCo will, or will cause the applicable Affiliate of NewCo to, (x) use commercially reasonable efforts to waive or cause the insurance carrier or professional employer
organization plan sponsor to waive any pre-existing condition or actively-at-work requirements or limitations and eligibility
waiting periods (to the extent such requirements or limitations or waiting periods did not apply to the Transferred 

  
 66 

 
Employee and his or her eligible dependents under a comparable Pfizer Benefit Plan as of immediately prior to the Employee Transfer Date), and (y) give the Transferred Employee credit, for
the plan year in which the Employee Transfer Date occurs, toward any applicable deductibles, co-insurance and annual
out-of-pocket limits for expenses actually incurred during the plan year in which the Employee Transfer Date occurs as if such amounts had been paid under such group
health plan, subject to any restrictions imposed by the professional employer organization plan sponsor. 
 (g) NewCo (or an
Affiliate of NewCo) shall make available to Transferred Employees within a reasonable time following the Employee Transfer Date (but in no event more than ninety (90) days)
participation in a cash or deferred arrangement, as described in Section 401(k) of the Code (the “NewCo 401(k) Plan”), which permits Transferred Employees to roll over their account balances from the Pfizer Savings
Plan, without regard to eligibility and waiting periods. NewCo will use commercially reasonable efforts to cause the third party plan administrator for the NewCo 401(k) Plan to permit Transferred Employees to roll over any outstanding participant
loans into the NewCo 401(k) Plan. In the event that rollover of an outstanding participant loan is not possible prior to the deadline for repayment of the loan, NewCo agrees to provide a Transferred Employee with a bridge loan (subject to similar
loan terms under such Transferred Employee’s existing loan) to the extent necessary to avoid an early distribution penalty tax. Notwithstanding the foregoing, neither Section 10.1(b) nor
Section 10.1(g) shall be interpreted to require NewCo to provide or maintain any specific investment alternative (including the Pfizer stock funds) as an investment alternative in the NewCo 401(k) Plan, or to guarantee any
distribution alternative provided for in the Pfizer Savings Plan. 
 (h) On or within a reasonable time following the
Employee Transfer Date, the Pfizer Parties shall pay to each Transferred Employee a prorated portion of such individual’s annual target bonus for 2018. On or within a reasonable time following December 31, 2018, NewCo shall pay to each
Transferred Employee who remains employed as of December 31, 2018 an annual bonus for 2018, which bonus shall be no less than a prorated portion of such individual’s annual target bonus for 2018. The prorated bonuses described in this
Section 10.1(h) shall be prorated based on the number of days during 2018 during which the Transferred Employee was (i) employed by the Pfizer Parties prior to the Closing Date, for the prorated bonuses payable by the Pfizer Parties or
(ii) for the prorated bonuses payable by NewCo, by the Pfizer Parties and NewCo on and after the Closing Date. 
 (i)
With respect to any Transferred Employee whose employment is terminated during the Continuation Period by NewCo and such termination qualifies as either a “Performance-Related Termination” or “Involuntary Termination” that would
be eligible for severance benefits under Section 3.1 of the Pfizer Separation Plan, NewCo shall provide (i) salary continuation severance benefits to such Transferred Employee which are at least as favorable as those that would have been
payable to such Transferred Employee in respect of a termination of employment under the Pfizer Separation Plan; and (ii) in the case of an Involuntary Termination, company-paid COBRA premiums for the “Severance Pay Duration Period”
(as such term is defined in the Pfizer Separation Plan). 

  
 67 

 (j) The parties shall cooperate with each other to give effect to the
provisions set forth in this Section 10.1. Without limiting the foregoing, in order to secure an orderly and effective transition of the employee benefit arrangements for Transferred Employees and their respective
beneficiaries and dependents, the Pfizer Parties and NewCo shall cooperate, both before and after each of the Closing and the Employee Transfer Date, and subject to applicable Laws, regarding the exchange of information related to the Transferred
Employees, including employment records and benefits information. 
 10.2 No Benefit to Employees Intended. Nothing contained in this
Agreement, express or implied, is intended to confer upon any Person not a party hereto any right, benefit or remedy of any nature whatsoever, including any right to employment or continued employment for any period of time by reason of this
Agreement, or any right to a particular term or condition of employment. Notwithstanding anything to the contrary contained in this Agreement, no provision of this Agreement is intended to, or does, constitute the establishment of, or an amendment
to, any employee benefit plan. 
 ARTICLE 11 

CONDITIONS TO CLOSING 
 11.1
Conditions to NewCo’s Obligation to Close. The obligations of NewCo to consummate the Transactions shall be subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may
be waived by NewCo in writing: 
 (a) Representations, Warranties and Covenants. (i) The representations and
warranties of Pfizer in this Agreement, other than the representations and warranties contained in Section 6.1 (Organization), Section 6.2 (Power and Authority Relative to this Agreement) or
Section 6.14 (Finders or Brokers) (collectively, the “Pfizer Fundamental Representations”) shall be true and correct in all respects as of the Closing Date (or, to the extent such representations and
warranties speak as of a specific date or time, they shall be true in all respects as of such date or time), interpreted without giving effect to the words “Material Adverse Effect,” “materially” or “material” or to any
qualifications based on such terms, except for such inaccuracies under such representations and warranties which, taken together in their entirety, would not reasonably be expected to result in a Material Adverse Effect; (ii) the Pfizer
Fundamental Representations shall be true and correct in all respects as of the Closing (or, to the extent such representations and warranties speak as of a specific date or time, they shall be true in all respects as of such date or time); and
(iii) the Pfizer Parties shall have performed, in all material respects, all covenants and obligations in this Agreement required to be performed by any of the Pfizer Parties on or prior to the Closing. 

(b) No Material Adverse Effect. Since the date of this Agreement, there shall not have occurred and be continuing any
event, change or effect that has had, individually or in the aggregate, a Material Adverse Effect. 

  
 68 

 (c) Consents. All approvals, consents and waivers listed on
Schedule 11.1(c) shall have been received, and executed counterparts thereof shall have been delivered to NewCo at or prior to the Closing. 

(d) Deliveries. The Pfizer Parties shall have delivered to NewCo all of the documents, agreements and other items set
forth in Section 4.2. 
 11.2 Conditions to Pfizer’s Obligation to Close. The
obligations of the Pfizer Parties to consummate the Transactions shall be subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by Pfizer in writing: 

(a) Representations, Warranties and Covenants. (i) The representations and warranties of NewCo in this Agreement,
other than the representations and warranties contained Section 7.1 (Organization), Section 7.2 (Capitalization), Section 7.4 (Power and Authority Relative to this
Agreement) or Section 7.7 (Finders or Brokers) (collectively, the “NewCo Fundamental Representations”) shall be true and correct in all respects as of the Closing Date (or, to the extent such
representations and warranties speak as of a specific date or time, they shall be true in all respects as of such date or time), interpreted without giving effect to the words “Material Adverse Effect,” “materially” or
“material” or to any qualifications based on such terms, except for such inaccuracies under such representations and warranties which, taken together in their entirety, would not reasonably be expected to result in a material adverse
effect on NewCo’s ability to consummate the Transactions; and (ii) the NewCo Fundamental Representations shall be true and correct in all respects as of the Closing (or, to the extent such representations and warranties speak as of a
specific date or time, they shall be true in all respects as of such date or time); and (iii) NewCo and the Other Investors shall have performed, in all material respects, all covenants and obligations in this Agreement required to be performed
by any of NewCo and the Other Investors on or prior to the Closing. 
 (b) Deliveries. NewCo shall have delivered to
Pfizer all of the documents, agreements and other items set forth in Section 4.3. 
 (c) Receipt
of Funds. Simultaneous with the Closing and in accordance with the terms and conditions of the Equity Commitment Letters, NewCo shall receive immediately available funds in the full amount of each Other Investor’s cash portion of the
purchase price due at the Closing (as defined in the Preferred Stock Purchase Agreement) for the shares of Class A Preferred Stock being purchased pursuant to the Preferred Stock Purchase Agreement as set forth opposite such Other
Investor’s name in the “Purchase Price Due at Closing” column on Exhibit A thereto. 
 11.3 Conditions to Obligations of
Each Party to Close. The respective obligations of each party to this Agreement to consummate the Transactions shall be subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, which may be waived by
mutual consent of Pfizer and NewCo, in writing: 

  
 69 

 (a) No Legal Impediments to Closing. There shall not be in effect any
Order issued by any Governmental Authority preventing the consummation of the Transactions or that makes the consummation of the Transactions illegal. 

ARTICLE 12 
 TAX MATTERS 

12.1 Allocation of Consideration. Following the Closing Date, Pfizer shall prepare a proposed allocation of the applicable
Consideration (for Tax purposes) among the Purchased Assets in accordance with Proposed Treasury Regulations Section 1.351-2(b). Pfizer and NewCo shall provide such cooperation and information to each
other as the other may reasonably request to prepare and comment on the proposed allocation. To the extent NewCo disagrees with the proposed allocation, NewCo shall notify Pfizer in writing of any disagreement with the proposed allocation, and NewCo
and Pfizer shall attempt in good faith to resolve the disagreement. If NewCo agrees with the proposed allocation prepared by Pfizer, or if NewCo and Pfizer resolve any disagreement regarding the proposed allocated, the parties shall report, act and
file their respective Tax Returns in accordance with the allocation of Consideration as agreed to pursuant to this Section 12.1 and any adjustments thereto. In the event of any adjustment to Consideration, Pfizer and NewCo
agree to cooperate in good faith to revise and amend the final allocation in accordance with the procedures set forth in this Section 12.1. 

12.2 Intended Tax Treatment; Cooperation; Allocation of Taxes. 

(a) It is intended that the transactions contemplated by this Agreement, taken together with the transactions contemplated by
the Preferred Stock Purchase Agreement, shall be treated as an exchange described in Section 351 of the Code with “boot,” and the parties hereto shall report the Transactions consistent with such Tax treatment on their income Tax
Returns unless otherwise required by Law or pursuant to the good faith resolution of a Tax contest. 
 (b) NewCo and the
Pfizer Parties agree to furnish or cause to be furnished to each other, upon request, as promptly as practicable, such information and assistance relating to the Purchased Programs, Purchased Assets, and the Assumed Liabilities (including reasonable
access to Books and Records) as is reasonably necessary for the filing of all Tax Returns, the making of any election relating to Taxes, the preparation for any audit by any Tax Authority, and the prosecution or defense of any claim or Proceeding
relating to any Tax; provided, however, that nothing in this Agreement shall require the Pfizer Parties to provide or otherwise make available to NewCo a copy of their Consolidated Return. NewCo and the Pfizer Parties agree to cooperate with
each other in the conduct of any audit or other Proceeding relating to Taxes involving the Purchased Programs, the Purchased Assets or the Assumed Liabilities. NewCo agrees to cooperate with and provide the Pfizer Parties with financial information
relating to the Purchased Programs, Purchased Assets, and the Assumed Liabilities at Closing as needed to enable Pfizer Parties to comply with GAAP (including any information necessary for the conduct of a third-party valuation). 

  
 70 

 (c) The applicable Pfizer Party shall be responsible for and shall pay any
Excluded Taxes. In respect of Purchased Assets or in connection with the conduct of the Purchased Programs, NewCo shall be responsible for and shall pay any Taxes arising or resulting from or in connection with the conduct of the Purchased Programs
or the ownership of any of the Purchased Assets, in each case attributable to any Post-Closing Tax Period. Taxes described in the first two sentences of this Section 12.2(c) and Transfer Taxes shall be timely paid, and all
applicable filings, reports and returns shall be filed, as provided by applicable Law. The paying party shall be entitled to reimbursement from the non-paying party in accordance with this
Section 12.2(c) or Section 12.2(e), as applicable. Upon payment of any such Tax, the paying party shall present a statement to the non-paying party setting
forth the amount of reimbursement to which the paying party is entitled under this Section 12.2(c) or Section 12.2(e), as applicable, together with supporting evidence as is reasonably necessary to
calculate the amount to be reimbursed. If within ten (10) calendar days after receipt of such a statement, the non-paying party notifies the paying party in writing that such amount is not reasonable, the
parties will negotiate in good faith to resolve such dispute. If the parties fail to resolve such dispute within thirty (30) calendar days, then within five (5) days after the end of such 30-day
period they shall choose a “big four” independent accounting firm mutually acceptable to NewCo and Pfizer (the “Tax Referee”) and the Tax Referee shall as promptly as practicable determine whether the amount of
reimbursement was reasonable and, if not reasonable, shall appropriately revise it. If the non-paying party does not respond to the statement within ten (10) calendar days, or upon resolution of the
disputed items, the amount of reimbursement (as such may have been adjusted) shall be binding on the paying and non-paying parties. The non-paying party shall make the
reimbursement promptly but in no event later than ten (10) calendar days after the presentation of such statement if undisputed, or if disputed, after final determination by the Tax Referee. Any payment not made within such time shall bear
interest from the due date for such payment until, but excluding, the date of payment at a rate per annum equal to [***]. Such interest shall be payable at the same time as the payment to which it relates and shall be calculated daily on the basis
of a year of 365 days and the actual number of days elapsed, without compounding. 
 (d) All Transfer Taxes incurred in
connection with the Transactions shall be borne by NewCo (provided, for the avoidance of doubt, that the Pfizer Parties shall indirectly bear a share of such Transfer Taxes by reason of their ownership interest in NewCo). The appropriate party will
prepare and file all necessary Tax Returns and other documentation with respect to Transfer Taxes and, if required by applicable Laws, the other party will (and will cause its Affiliates to) join in the execution of any such Tax Returns and other
documentation. To the extent permitted pursuant to applicable Law, the Pfizer Parties and NewCo will use Commercially Reasonable Efforts to minimize or avoid Transfer Taxes, if any, arising out of the transactions contemplated by this Agreement.

 (e) In the case of any Tax period that includes (but does not end on) the Closing Date (a “Straddle
Period”), the amount of Excluded Taxes with respect to the Purchased Programs or the Purchased Assets for a Straddle Period that are, in each case based upon or measured by net income or gain that relate to a
Pre-Closing Tax Period will be 
 [***] = CONFIDENTIAL TREATMENT
REQUESTED 
  

  
 71 

 (f) determined based on an interim closing of the books as of the close of
business on the Closing Date; provided, however, that exemptions, allowances or deductions that are calculated on an annual basis (such as deductions for depreciation and real estate taxes) will be apportioned between the Pre-Closing Tax Period and the Post-Closing Tax Period on a daily basis. The amount of Excluded Taxes with respect to the Purchased Assets or the Purchased Programs for a Straddle Period that are not based upon or
measured by net income or gain (other than Transfer Taxes) that relate to a Pre-Closing Tax Period will be deemed to be the amount of such Tax for the entire taxable period multiplied by a fraction, the
numerator of which is the number of days in the Pre-Closing Tax Period and the denominator of which is the number of days in such Straddle Period. Notwithstanding the forgoing, items attributable to any action
taken by NewCo on the Closing Date after the Closing that is neither expressly contemplated by this Agreement nor in the ordinary course of business will not be attributable to a Pre-Closing Tax Period. 

12.3 Tax Contests. 

(a) NewCo and the Pfizer Parties agree to cooperate and to cause their Subsidiaries to cooperate with each other to the extent
reasonably required after the Closing Date in connection with any Proceedings conducted by Tax Authorities relating to any Taxes with respect to or in relation to any Purchased Asset (each a “Tax Contest”). NewCo and the Pfizer
Parties shall provide timely written notices to each other of any Tax Contest relating to the Purchased Assets for taxable periods for which any other party hereto may have a responsibility under this Agreement, or otherwise; provided that
failure to so notify the other party will not relieve any party of liability that it may have under this Agreement except to the extent the other party is actually prejudiced by such failure. Such notice shall include a copy of the relevant portion
of any correspondence received from the relevant Tax Authority and describe in reasonable detail the nature of such Tax Contest. 

(b) The Pfizer Parties shall, at their expense, have the right to conduct and control in good faith the defense of any Tax
Contest for (i) a Straddle Period with respect to so much of such Tax Contest that could reasonably be expected to affect the Pfizer Parties’ Tax Liability, rights to refunds or indemnification obligations under this Agreement or
(ii) a Pre-Closing Tax Period; provided, however that with respect to any such Tax Contest described in clause (i) that could reasonably be expected to affect NewCo’s Tax
Liability, rights to refunds or indemnification obligations under this Agreement (and that does not relate to a Consolidated Return): (i) NewCo shall have the right to participate in all such Tax Contests, which will include participation in
meetings with Tax Authorities and review and comment on written submissions to Tax Authorities, and (ii) the Pfizer Parties shall not settle such Tax Contest without the prior written consent of NewCo, which consent will not be unreasonably
withheld, conditioned or delayed. For the avoidance of doubt, the Pfizer Parties shall have the exclusive right to control all matters relating to a Consolidated Return. Notwithstanding anything herein to the contrary, no party hereto shall have the
right to conduct and control the defense of, or have participation rights with respect to, any Tax Contest with respect to income Tax Returns of the other party (or its Affiliates). 

  
 72 

 (c) This Section 12.3 shall govern the control of
Tax Contests, rather than Section 14.4. 
 ARTICLE 13 

TERMINATION 
 13.1
Termination of Agreement. This Agreement may be terminated and the Transactions may be abandoned at any time prior to the Closing: 

(a) by the mutual written consent of NewCo and Pfizer; 

(b) by NewCo, if (i) Pfizer is in breach of any provision of this Agreement such that the condition to Closing set forth
in Section 11.1(a) would not be satisfied as of the time of such breach, and such breach shall not have been cured within thirty (30) days of receipt by such party of written notice from NewCo of such breach and
(ii) NewCo is not, on the date of termination, in breach of any provision of this Agreement such that the conditions to Closing set forth in Section 11.2(a) would not be satisfied as of the Closing; 

(c) by Pfizer, if (i) NewCo is in breach of any provision of this Agreement such that the condition to Closing set forth
in Section 11.2(a) would not be satisfied as of the time of such breach, and such breach shall not have been cured within thirty (30) days of receipt by such party of written notice from Pfizer of such breach and
(ii) Pfizer is not, on the date of termination, in breach of any provision of this Agreement such that the conditions to Closing set forth in Section 11.1(a) would not be satisfied as of the Closing; 

(d) by either NewCo or Pfizer, if the Closing has not occurred on or prior to May 1, 2018 (the “Drop-Dead
Date”) for any reason; provided, however, that the rights to terminate this Agreement under this Section 13.1(d) shall not be available to any party whose breach of any covenants or agreements contained in
this Agreement has been the cause of, or resulted in, the failure of the Closing Date to occur on or before the Drop-Dead Date; and 

(e) by either NewCo or Pfizer, if there shall be any final non-appealable Order that
permanently enjoins or otherwise prohibits consummation of the Transactions such that the condition to Closing set forth in Section 11.3(a) would not be satisfied as of the Closing; provided, however, that the rights
to terminate this Agreement under this Section 13.1(e) shall not be available to any party whose breach of any covenants or agreements contained in this Agreement has been the cause of, or resulted in, the Order. 

Any party desiring to terminate this Agreement shall give written notice of such termination to the other parties. 

13.2 Effect of Termination. If this Agreement is terminated in accordance with Section 13.1, all obligations
of the parties hereunder shall terminate, except for the obligations set forth in this ARTICLE 13 (Termination), Sections 9.6 (Confidentiality), 15.1 (Expenses), 15.5 (Governing Law), and 15.6 (Jurisdiction; Waiver
of Jury Trial); provided, however, that nothing herein shall relieve any party from Liability for any willful breach of this Agreement or fraud. 

  
 73 

 ARTICLE 14 

INDEMNIFICATION 
 14.1
Indemnification by Pfizer. Subject to the limitations set forth in this ARTICLE 14, from and after the Closing, Pfizer shall indemnify, defend and hold harmless NewCo and its officers, directors, agents, employees, shareholders
and Affiliates (collectively, the “NewCo Indemnified Persons”) from and against any and all Damages imposed on, or indirectly incurred by, without duplication, such NewCo Indemnified Person (collectively, “NewCo
Damages”) arising out of, relating to or resulting from (a) any breach of or inaccuracy in a representation or warranty of any Pfizer Party contained in this Agreement, as of the Closing Date; (b) any breach of a covenant of a
Pfizer Party contained in this Agreement or breach of the terms and conditions of the Patent and Know-How License Agreement, including any practice of Intellectual Property Rights by Pfizer, its licensees or
sublicensees outside of the scope of the licenses granted to Pfizer under the Patent and Know-How License Agreement; and (c) any Excluded Liability. 

14.2 Indemnification by NewCo. Subject to the limitations set forth in this ARTICLE 14, from and after the Closing, NewCo shall
indemnify, defend and hold harmless the Pfizer Parties and their respective officers, directors, agents, employees and Affiliates (collectively, the “Pfizer Indemnified Persons”) from and against any and all Damages (collectively,
“Pfizer Damages”) arising out of, relating to or resulting from (a) any breach of or inaccuracy in a representation or warranty of NewCo contained in this Agreement; (b) any breach of a covenant of NewCo or any of its
Affiliates contained in this Agreement or breach of the terms and conditions of the Patent and Know-How License Agreement, including any practice of Intellectual Property Rights by NewCo or its Sublicensees
outside of the scope of the licenses granted to NewCo under the Patent and Know-How License Agreement; (c) any Assumed Liability; and (d) Taxes of NewCo for all Post-Closing Tax Periods; provided
that the payment by NewCo shall equal the amount of Pfizer Damages multiplied by the Pfizer Damages Fraction. “Pfizer Damages Fraction” shall mean a fraction whose numerator is one and whose denominator is equal to one minus the
fraction of the shares of Equity Consideration held by the Pfizer Parties and their Affiliates at the time when such Pfizer Damages are due and payable (excluding all shares of Class A Preferred Stock that were purchased by the Pfizer Parties
pursuant to the Preferred Stock Purchase Agreement), calculated assuming the conversion of all outstanding shares Class A Preferred Stock at the then applicable conversion rate. 

14.3 Time for Claims. No claim may be made or suit instituted seeking indemnification pursuant to Sections 14.1(a) or
14.2(a) unless a written notice describing such claim in reasonable detail in light of the circumstances then known to the Indemnitee is provided to the Indemnitor prior to the eighteen (18) month anniversary of the Closing Date;
provided, however, that claims arising out of, relating to or resulting from a breach of or inaccuracy in (a) any of the Pfizer Fundamental Representations or the NewCo Fundamental Representations may be made until the third (3rd)
anniversary of the Closing Date and (b) Section 6.7 (Tax Matters) may be made until thirty (30) days after expiration of applicable statutes of limitations. Claims for indemnification pursuant to any other provision of
Section 14.1 or Section 14.2 are not subject to the limitations set forth in this Section 14.3. 

  
 74 

 14.4 Procedures for Indemnification. Except as otherwise provided in
Section 12.3, promptly after receipt by a party entitled to indemnification under Sections 14.1 or 14.2 or any other provision of this Agreement (the “Indemnitee”) of written notice of the
assertion or the commencement of any Proceeding with respect to any matter referred to in Sections 14.1 or 14.2 or in any other applicable provision of this Agreement, the Indemnitee shall give written notice describing such claim or
Proceeding in reasonable detail in light of the circumstances then known to the Indemnitee to the party obligated to indemnify Indemnitee (the “Indemnitor”), and thereafter shall keep the Indemnitor reasonably informed with respect
thereto; provided, however, that failure of the Indemnitee to keep the Indemnitor reasonably informed as provided herein shall not relieve the Indemnitor of its obligations hereunder except to the extent that the Indemnitor is prejudiced
thereby. If any Proceeding is commenced against any Indemnitee by a Third Party, the Indemnitor shall be entitled to participate in such Proceeding and assume the defense thereof at the Indemnitor’s sole expense; provided, however, that
the Indemnitor shall not have the right to assume the defense of any Proceeding if (a) the Indemnitee shall have one or more legal or equitable defenses available to it which are different from or in addition to those available to the
Indemnitor, and, in the reasonable opinion of outside counsel to the Indemnitee, counsel for the Indemnitor could not adequately represent the interests of the Indemnitee because such interests would be in conflict with those of the Indemnitor;
(b) such Proceeding is reasonably likely to have a material adverse effect on any other matter beyond the scope or limits of the indemnification obligation of the Indemnitor; or (c) the Indemnitor shall not have assumed the defense of the
Proceeding in a timely fashion (but in any event within thirty (30) days of notice of such Proceeding). If the Indemnitor, shall assume the defense of any Proceeding, the Indemnitee shall be entitled to participate in any Proceeding at its
expense, and the Indemnitor shall not settle such Proceeding unless the settlement shall include as an unconditional term thereof the giving by the claimant or the plaintiff of a full and unconditional release of the Indemnitee, from all Liability
with respect to the matters that are subject to such Proceeding, or otherwise shall have been approved by the Indemnitee, such approval not to be unreasonably withheld, conditioned or delayed. 

14.5 Limitations on Indemnification. 

(a) Notwithstanding anything herein to the contrary, Pfizer shall not be obligated to indemnify any NewCo Indemnified Person
under Section 14.1: (i) unless the aggregate of all NewCo Damages exceeds $[***] (the “Deductible”), in which case the NewCo Indemnified Persons shall be entitled to recover all NewCo Damages only to
the extent such NewCo Damages exceed the Deductible or (ii) to the extent that the aggregate of all NewCo Damages exceeds $[***] (the “Cap”); provided, however, the Cap and Deductible shall not apply to nor count towards
any Pfizer indemnification obligation (A) arising out of, relating to or resulting from fraud by any Pfizer Party, or arising out of, relating to or resulting under Sections 14.1(b) or (c) or (B) arising out of, relating
to or resulting from a breach of or inaccuracy in any Pfizer Fundamental Representation. 
 (b) Notwithstanding anything
herein to the contrary, NewCo shall not be obligated to indemnify any Pfizer Indemnified Person under Section 14.2: (i) unless the aggregate of all Pfizer Damages exceeds the Deductible, in which case the Pfizer
Indemnified Persons shall be entitled to recover all Pfizer Damages only to the extent such 
 [***] = CONFIDENTIAL
TREATMENT REQUESTED 
  

  
 75 

 (c) Pfizer Damages exceed the Deductible, which Pfizer Damages shall not be
counted against the Deductible, or (ii) to the extent that the aggregate of all Pfizer Damages exceeds the Cap; provided, however, that the Cap and the Deductible shall not apply to nor count towards any NewCo indemnification obligation
(A) arising out of, relating to or resulting from fraud by NewCo or arising out of, relating to or resulting under Sections 14.2(b), (c) or (d), or (B) arising out of, relating to or resulting from a breach of or
inaccuracy in any NewCo Fundamental Representation. 
 (d) All indemnification payments under this Agreement shall be treated
as adjustments to the Consideration for all Tax purposes unless Laws require otherwise. 
 (e) LIMITATION OF LIABILITY,
DISCLAIMER OF CERTAIN DAMAGES. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY SPECIAL, PUNITIVE, EXEMPLARY OR NOT REASONABLY FORESEEABLE DAMAGES OR ANY LOSS OF REVENUE OR PROFITS OR
DIMINUTION IN VALUE OR SPECULATIVE DAMAGES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR THE PATENT AND KNOW-HOW LICENSE AGREEMENT OR THE PERFORMANCE OR BREACH HEREOF OR THEREOF; PROVIDED,
HOWEVER, THAT THE FOREGOING SHALL NOT BE CONSTRUED TO PRECLUDE RECOVERY IN RESPECT OF ANY LOSS DIRECTLY INCURRED OR SUFFERED FROM THIRD PARTY CLAIMS. 

14.6 Third Party Contributors. The amount of any and all Damages for which indemnification is provided pursuant to this ARTICLE
14 shall be net of any amounts actually received by the Indemnitee with respect to such Damages (i) under insurance policies after giving effect to any deductible, retention or equivalent loss rated premium adjustment and any costs or
expenses incurred in recovering such insurance proceeds and (ii) otherwise from any Third Party (including any Tax Authority). 
 14.7
Duty to Mitigate. Each Indemnitee shall take, and shall cause its Affiliates to take, all reasonable steps to mitigate any Damages upon becoming aware of any event or circumstance that would reasonably be expected to, or does, give rise
thereto, including incurring costs only to the minimum extent necessary to remedy the breach that gives rise to the Damages. 
 14.8
Satisfaction by Equity Consideration; Set-off. Pfizer, at its election (which election can be made in Pfizer’s sole and absolute discretion, subject to Section 14.4),
shall be permitted to satisfy Pfizer’s indemnification obligations for NewCo Damages (a) by the cancellation of shares of Class A Preferred Stock owned by Pfizer (an “Equity Consideration Cancellation”),
with such Equity Consideration Cancellation occurring such that $[***] of indemnified NewCo Damages shall be deemed satisfied for each share of Class A Preferred Stock cancelled; and/or (b) by setting off such amounts due against amounts
payable to Pfizer pursuant to Sections 5.1(a), 5.1(b) or 5.1(c) (each of clauses (a) and (b) of this Section 14.8, the “Set-off”); or
(c) any combination of clause (a) and (b). Notwithstanding anything to the contrary in this Section 14.8, any indemnification obligation of Pfizer for NewCo Damages arising out of, relating to or resulting from
fraud, any Excluded Liability, Section 14.1(b) to the extent of a willful breach or any breach of or inaccuracy in any Pfizer Fundamental Representation shall be satisfied by Pfizer in cash, by 

[***] = CONFIDENTIAL TREATMENT REQUESTED 

 

  
 76 

 14.9 wire transfer of immediately available funds, to the applicable NewCo Indemnified
Persons. Nothing in this Section 14.8 shall be construed to increase Pfizer’s indemnification obligations beyond such indemnification obligations that are otherwise provided for in this ARTICLE 14.

 14.10 Qualifications. For purposes of determining the amount of any Damages that are the subject matter of a claim for
indemnification under this Agreement, each representation and warranty in this Agreement will be read without regard and without giving effect to the term “material,” “Material Adverse Effect” or “material adverse
effect” or similar qualifiers (fully as if any such word or phrase were deleted from such representation and warranty). 
 14.11
Remedies Exclusive. 
 (a) Except as set forth in Section 14.11(b), the parties hereto
expressly agree that from and after the Closing (i) the provisions of this ARTICLE 14 shall be the exclusive remedy for all claims of breach or indemnification pursuant to this Agreement and the Patent and
Know-How License Agreement and (ii) in furtherance of the foregoing, each party hereby waives, to the fullest extent permitted by Law, any and all rights, claims and causes of action for any breach of any
representation, warranty, covenant or agreement set forth herein or otherwise relating to the subject matter of this Agreement it may have against the other party hereto and their Affiliates and each of their respective Representatives arising under
or based upon any Law, except pursuant to the indemnification provisions set forth in this ARTICLE 14. 
 (b) The
limitations set forth in Section 14.11(a) shall not apply to (i) claims of fraud that are proven and upon which a judgment entered in the involved Proceeding is expressly based, (ii) claims brought by NewCo
arising from a Pfizer Party’s willful breach of Section 9.5, (iii) claims brought by a Pfizer Party arising from NewCo’s breach of its payment obligations under Sections 5.1(a), 5.1(b) or
5.1(c), or NewCo’s material breach of any of its obligations under Sections 5.2(b)(i) or 5.2(b)(ii) or (iv) claims to equitable relief to which any Person shall be entitled pursuant to
Section 15.13; provided, that, for the avoidance of doubt, in the case of clauses (i), (ii), (iii) and (iv), the parties hereto shall have all remedies available under this Agreement or otherwise at Law without
giving effect to any of the limitations or waivers contained herein, except, with respect to clause (iii), for the limitations in Section 14.5(d). 

14.12 Remedies Cumulative. The rights of the NewCo Indemnified Persons and Pfizer Indemnified Persons under this ARTICLE 14 are
cumulative, and each NewCo Indemnified Person and Pfizer Indemnified Person will have the right in any particular circumstance, in its sole discretion, to enforce any provision of this ARTICLE 14 without regard to the availability of a remedy
under any other provision of this ARTICLE 14. 
 ARTICLE 15 

MISCELLANEOUS PROVISIONS 

  
 77 

 15.1 Expenses. Whether or not the Transactions are consummated, unless otherwise
indicated expressly herein, each party shall pay its own costs and expenses in connection with this Agreement and the Transactions, including the fees and expenses of its advisers, accountants and legal counsel. 

15.2 Entire Agreement. This Agreement, including the exhibits and disclosure schedules specifically referred to herein, the Transaction
Agreements and the Confidential Disclosure Agreement constitute the entire agreement between and among the parties hereto with regard to the subject matter hereof, and supersede all prior agreements and understandings with regard to such subject
matter. In the event of any inconsistency between the statements in this Agreement and those in the exhibits and disclosure schedules specifically referred to herein or in any other Transaction Agreements or the Confidential Disclosure Agreement
(other than an exception expressly set forth as such in the disclosure schedules) the statements in this Agreement will control. 
 15.3
Amendment, Waivers and Consents. This Agreement shall not be changed or modified, in whole or in part, except by supplemental agreement or amendment signed by the parties. Any party may waive compliance by any other party with any of the
covenants or conditions of this Agreement, but no waiver shall be binding unless executed in writing by the party making the waiver. No waiver of any provision of this Agreement shall be deemed, or shall constitute, a waiver of any other provision,
whether or not similar, nor shall any waiver constitute a continuing waiver. Any consent under this Agreement shall be in writing and shall be effective only to the extent specifically set forth in such writing. 

15.4 Successors and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors
and permitted assigns, provided, however, that no party hereto may assign any right or obligation hereunder without the prior written consent of all other parties hereto. Notwithstanding the foregoing, (a) Pfizer may assign this
Agreement or all of its rights or obligations hereunder to any other Pfizer Party or their wholly owned Affiliates without NewCo’s prior written consent (but with notice to NewCo and provided that no such assignment shall relieve Pfizer of its
obligations hereunder), provided that (i) any such assignment does not impose additional Taxes or costs on NewCo (or its Affiliates) or otherwise materially delay or impede Closing, and (ii) the assignee promptly provides NewCo with
such documentation as may be prescribed by applicable Law or reasonably requested by NewCo to determine NewCo’s Tax withholding and reporting obligations in respect of payments to such assignee under this Agreement; and (b) NewCo may
assign this Agreement to, (i) after Closing, any financing source as collateral, (ii) after Closing, any purchaser or licensor of substantially all of the assets of NewCo; or (iii) after Closing, the surviving entity in any merger,
consolidation, share exchange or reorganization involving NewCo, in each case of clause (i), (ii) or (iii), only to the extent otherwise expressly authorized pursuant to the terms of the Investors’ Rights Agreement and the Restated Certificate.
Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. 
 15.5 Governing Law. The rights
and obligations of the parties shall be governed by, and this Agreement shall be interpreted, construed and enforced in accordance with, the Laws of the State of Delaware, excluding its conflict of laws rules to the extent such rules would apply the
Law of another jurisdiction. 

  
 78 

 15.6 Jurisdiction; Waiver of Jury Trial. 

(a) Any judicial Proceeding brought against any of the parties to this Agreement or any dispute arising out of this Agreement
or related hereto shall be brought in the courts of the State of Delaware, or in the United States District Court for the District of Delaware, and, by execution and delivery of this Agreement, each of the parties to this Agreement accepts the
exclusive jurisdiction of such courts, and irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. The foregoing consents to jurisdiction shall not constitute general consents to service of process in the
State of Delaware for any purpose except as provided above and shall not be deemed to confer rights on any Person other than the parties to this Agreement. Each of the parties to this Agreement agrees that service of any process, summons, notice or
document by U.S. mail to such party’s address for notice hereunder shall be effective service of process for any Proceeding in Delaware with respect to any matters for which it has submitted to jurisdiction pursuant to this
Section 15.6(a). 
 (b) EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY
JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, EQUITY OR OTHERWISE) ARISING OUT OF OR RELATING TO OR IN CONNECTION WITH THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN THE NEGOTIATION, ADMINISTRATION,
PERFORMANCE OR ENFORCEMENT HEREOF OR THEREOF. EACH PARTY HERETO (I) CONSENTS TO TRIAL WITHOUT A JURY OF ANY SUCH PROCEEDINGS, (II) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR
OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (III) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS AND CERTIFICATIONS IN THIS SECTION 15.6(b). 
 15.7 Rules of Construction. The parties acknowledge that each party has
read and negotiated the language used in this Agreement. The parties agree that, because each party participated in negotiating and drafting this Agreement, no rule of construction shall apply to this Agreement which construes ambiguous language in
favor of or against any party by reason of that party’s role in drafting this Agreement. 
 15.8 Severability. If any provision
of this Agreement, as applied to either party or to any circumstance, is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision. 

15.9 Exhibits and Schedules. All exhibits and disclosure schedules attached hereto shall be deemed to be a part of this Agreement and
are fully incorporated in this Agreement by this reference. 

  
 79 

 15.10 Notices. Unless otherwise expressly provided herein, all notices, requests,
demands, claims and other communications required or permitted to be delivered, given or otherwise provided for hereunder shall be in writing. All such written notices shall be sent in the manner indicated below to the applicable address, facsimile
number or electronic mail address, and will be deemed effective as indicated below: 
 (a) if sent by personal delivery or by
courier, upon delivery; 
 (b) if sent by facsimile transmission, upon the sender’s receipt of confirmation of good
transmission; 
 (c) if sent by electronic mail, upon the sender’s receipt of an acknowledgement from the intended
recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement); or 

(d) if sent by certified or registered mail or the equivalent (return receipt requested), upon delivery or attempted delivery;

 provided, however, that in any such case, if delivered later than 5:00 p.m. (New York time) on any Business Day, delivery will be deemed to
occur on the next Business Day. 
 If to NewCo at: 

689 5th Avenue, 12th Floor 
 New
York, NY 10022 
 Attention: Secretary 

Email: 
 Phone: 

Fax: 
 With copies (which
shall not constitute notice) to: 
 Cooley LLP 

3175 Hanover Street 
 Palo Alto,
CA 94304 
 Attention: Barbara Kosacz 

Email: bkosacz@cooley.com 

Fax: 650-849-7400 

If to any of the Pfizer Parties at: 

Pfizer Inc. 
 235 East 42nd Street

 New York, NY 10017 

Attention: Executive Vice President and General Counsel 

Email: 
 With copies (which
shall not constitute notice) to: 

  
 80 

 Ropes & Gray LLP 

Prudential Tower 
 800 Boylston
Street 
 Boston, MA 02199 

Attention: Paul Kinsella 

Email: Paul.Kinsella@ropesgray.com 

Fax: 617-235-0822 

or to such other address, facsimile number or electronic mail address as each party may designate for itself by notice given in accordance with this
paragraph. 
 15.11 Rights of Parties. Nothing in this Agreement, whether express or implied, other than the rights of the NewCo
Indemnified Persons and Pfizer Indemnified Persons pursuant to ARTICLE 14 is intended to confer any rights or remedies under or by reason of this Agreement on any persons other than the parties to it and their respective successors and
permitted assigns, nor is anything in this Agreement intended to relieve or discharge the Liability of any third person to any party to this Agreement, nor shall any provision give any third person any right of subrogation or action over or against
any party to this Agreement. 
 15.12 Public Announcements. No public announcement or disclosure (including any general announcement
to employees, customers or suppliers) will be made by any party with respect to the subject matter of this Agreement, the Transactions or the Transaction Agreements without the prior written consent of Pfizer and NewCo; provided that, the
provisions of this Section 15.12 shall not prohibit (a) NewCo from making public announcements or other disclosures after Closing regarding Products and related programs in the ordinary course of business or to comply
with securities laws, (b) any disclosure required by any applicable Laws (in which case the disclosing party will provide the other parties with the opportunity to review and comment in advance of such disclosure) or (c) any disclosure
made in connection with the enforcement of any right or remedy relating to this Agreement or any Transaction Agreement or the Transactions. NewCo further agrees that it will not, and it will cause each of its Affiliates to, not without the prior
written consent of Pfizer, use in advertising, publicity or otherwise the name of Pfizer or any partner or employee of Pfizer, nor any trade name, trademark, trade device, service mark, symbol or any abbreviation, contraction or simulation thereof
owned by Pfizer or any of its Affiliates. 
 15.13 Specific Performance. Notwithstanding anything in
Section 14.10 to the contrary, the parties hereto agree that irreparable damage would occur and that the parties would not have any adequate remedy at Law in the event that the obligations of the parties to effect, on the
terms and conditions set forth herein, the Closing and the other covenants and agreements set forth in this Agreement, including ARTICLE 3, ARTICLE 4, ARTICLE 5, ARTICLE 8 and ARTICLE 9, were not performed in
accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent such (and only such) actual or threatened breaches of this Agreement and to
enforce specifically (without proof of actual Damages or harm, and not subject to any requirement for the securing or posting of any bond in connection therewith) such terms and provisions of this Agreement, this being in addition to any other
remedy to which they are entitled at law or in equity, including money Damages. 

  
 81 

 15.14 Counterparts. This Agreement may be signed in any number of counterparts,
including electronic scan copies thereof delivered by electronic mail, each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 

[Signature Pages Follow] 

  
 82 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its
behalf by their respective officers thereunto duly authorized all as of the date first written above 
  

			
	PFIZER INC.
		
	By:	 	 /s/ G. Mikael Dolsten

	Name:	 	 G. Mikael Dolsten

	Title:	 	 President, Worldwide, Research & Development

  
 [Signature Page to Asset
Contribution Agreement] 

			
	ALLOGENE THERAPEUTICS, INC.
		
	By:	 	 /s/ Joshua A Kazam

	Name:	 	 Joshua A Kazam

	Title:	 	 President

  
 [Signature Page to Asset
Contribution Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]